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Abstract 
Morphine 1 is metabolised in the liver into its active form, morphine-6-
glucuronide (M6G) 2. When M6G 2 is administered directly to patients it has greater 
analgesic potency than morphine 1 and this stimulated interest in the synthesis of 
M6G 2 as a novel analgesic. We have examined several synthetic routes to the 
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The coupling of a glucose residue to morphine 1 was investigated using both 
chemical and enzymatic approaches. However, selective oxidation at the C6 position 
of morphine- 6-glucoside 4 did not yield the desired metabolite M6G 2. The 
replacement of the glucose residue in scheme 1 by galactose and arabinose gave 
morphine-6-glucoside analogues which are potentially an alternative source of 




reflux 24hrs i. TMSOTf, CH 2CI 21 Ho 	
N (YC, 7 hrs 
I TMSOTf, 	 ii. NaOMe. MeOH, 24 hrs 
A,O BI 
	
CH2Cl2 , N 2 , O .C, 5 hrs 
I ii. NaOMe MeOH 24 hrs 
14 
0)0 - 	 I 




Chemo -Enzymatic Approaches to M6G and Selected Analogues 
Acknowledgements 
Nick Turner, as supervisor for this project, has been a constant source of 
support, encouragement and enthusiasm, for which I am very grateful. In addition, 
the financial support, suggestions and ideas offered by Feo Scheinmann as industrial 
supervisor have been of great benefit to this project while the opportunity to spend 
time in the laboratories of Salford Ultrafine Chemicals is greatly appreciated. Of the 
employees working for Salford Ultrafine Chemicals I would like to thank in 
particular Andrew Stachuiski who provided invaluable practical and technical advise 
for the project. I would also greatly appreciate the help and advise generously given 
by Jayne, Tony and Keith with a warm thanks to Lesley, Lesley Ibbotson, Jonathan, 
Piers, John, Adrian and Steve for providing some very entertaining tea-breaks. 
The first two years of this Ph.D. were spent at the University at Exeter 
chemistry department. Of the many people I met at the department I would like to 
thank, in particular, Rosy and Robin for their invaluable technical assistance and 
Vladimir Sik for the NMR spectral service. I found the atmosphere of the chemistry 
department both friendly and supportive and I thoroughly enjoyed the time I spent 
there, the staff, students and local people I met were warm, generous and great fun 
and have provided me with a wealth of memories to look back on. 
The final two years of my Ph.D. were spent at the University of Edinburgh 
chemistry department. Of the staff and students I met at the department I would like 
to thank in particular John Millar at the department's NMR spectral service, Derek, 
Raymond and Tim in stores, Stuart in the glassblowing workshop and all the staff in 
the electrical and mechanical workshops. Finally I would like to acknowledge all the 
members of the Turner-Flitsch research groups whose research achievements, 
humour, hard work and dedication are a credit to both Nick and Sabine. Thanks to all 
of you and to the postgraduate and undergraduate students I have met in Edinburgh, 
the true value of friendship is an experience to cherish. 
And there's a hand, my trusty fiere, 
And gies 's a hand o 'thine. 
Robert Burns 1759-1796 
Chemo-Enzymatic Approaches to M6G and Selected Analogues 
Abbreviations 
AIDS Acquired Immune Deficiency Syndrome 
Ac Acetate COCH 1 
Bz Benzoyl COCA 
Bn Benzyl CH 2 C6 H 6 
C111 Centimetre 10 2  Meters 
deg Degree 
dm Decimetre 10- ' Meters 
ee. enantiomeric excess 
EtOAc Ethyl acetate 
Et Ethyl CH 3 CH2 
EtOH Ethanol 
Me Methyl CH 1 
MeOH Methanol 
Mins Minutes 
mlvi Milli molar 10 	Moles dm 3 
NaOMe Sodium methoxide 
nm Nanometer 10 9 Meters 
'pr Isopropyl CH(CH 3 ) 7 
PrOH Isopropanol 
Piv Pivaloyl COC(CH,),, 
Py Pyridine 
rt Room temperature 
Tf Trifluromethylsulfonate (triflate) 02 SCF1 
TMS Trimethylsilyl (CH 1 ) 1 Si 
TEMPO 2,2,6,6-Tetramethyl- 1 -piperidenyloxy 
tm Micrometer 10-6 Meters 
pmol Micromole 106 Moles 
UTP Uridine triphosphate 
Chemo -Enzymatic Approaches to M6G and Selected Analogues 
Contents 
Chapter One; Introduction 	 Page 
Section One; Morphine and Monosaccharides 
1.1. Morphine i 
1.1.1. The Biosynthesis of Morphine 2 
1.2. The Pharmacological Effects of Opioids on the Body 4 
1.2.1. Analgesia 4 
1.2.2. Side-Effects Associated With the Use of Opioids 5 
1.2.2.1. Dependence, Tolerance and Addiction 5 
1.3. The Physiological Effects of Opioids on the Body 6 
1.4. Opioid Receptors 8 
1.4.1. The Effect of Opioid Receptors on the Body 8 
1.5. Morphine Metabolites 11 
1.6. The Chemical Synthesis of Morphine Glucuronides 13 
1.7. The Enzymatic Synthesis of M6G 15 
1.8. The Chemo-Enzymatic Synthesis of M6G and M6G Analogues 16 
1.8.1. The Chemo-Enzymatic Synthesis of M6G 16 
1.8.2. The Synthesis of M6G Analogues 19 
Section Two; Modern Methods For Glycoside Synthesis 22 
2.1. Classic Glycosidation Reactions 22 
2.2. Anomeric Leaving Groups 23 
2.2.1. Glycosyl Fluorides 24 
2.2.2. Glycosyl Amines, Phosphonium and Nitrilium Compounds 24 
2.2.3. Glycosyl Acyl Esters 26 
2.2.4. Glycosyl Phosphates 27 
2.2.5. Trialkylsilyl Glycosides 28 
2.2.6. Glycosyl Trichioroacetimidates 29 
2.2.7. Glycosyl 2-Pyridine Carboxylates 30 
2.2.8. Orthoester Derivatives as Glycosides 32 
2.3. The Armed-Disarmed Glycosylation Concept 33 
2.4. The Isopropenyl Glycosyl Donors 35 
2.5. Glycals 36 
2.6. Intramolecular Aglycon Delivery 38 
Chemo-Enzymatic Approaches to M6G and Selected Analogues 
2.7. Latent-Active Glycosidations 	 41 
2.8. Differentially Activated Glycosyl Donors and Acceptors 	 42 
2.9. Glycosidations on Solid Supports 	 43 
Section Three; The Use of Enzymes in Glycosidation Reactions 	 45 
3.1. General Features of Enzymes 	 45 
3.2. Glycosidation Reactions With Glycosyltransferases 	 46 
3.2.1. Glycosidation Reactions With Leloir-Type Glycosyltransferases 	46 
3.2.1. Glycosidation Reactions With Non Leloir-Type Glycosyltransferases 50 
3.3. Glycosidation Reactions With Glycosidases 	 51 
Section Four; Enzyme Catalysed Acylation and Deacylation Reactions 	55 
4.1. Enzyme Catalysed Acylation Reactions 	 56 
4.1.1. Enzyme Catalysed Direct Esterifications 	 56 
4.1.2. Enzyme Catalysed Transesterifications 57 
4.2. Enzyme Catalysed Deacylation Reactions 	 60 
Chapter Two; Results and Discussion 
Section One; Chemo-Enzymatic Approaches to M6G 63 
1. Synthesis of M6G; Synthetic Route One 63 
1.1. 13-Glucosidase Catalysed Transglycosidation Reactions 64 
1.1.1. Model Study 64 
1.1.2. Attempted Synthesis of Morphine-6-glucoside 67 
2. Synthesis of M6G; Synthetic Route Two 68 
2.1. TMSOTf Promoted Couplings 69 
2.1.1. Model Study 69 
2.1.2. Synthesis of 3-0-Pivaloylmorphine Tetravaleryl-j3-D-glucoside 70 
2.2. Lipase Catalysed Deacylations 72 
2.2.1. Model Study 73 
2.2.2. Lipase Catalysed Selective Deacylation of 3-0-Pivaloylmorphine 75 
Tetravaleryl- [3-D-glucoside 
2.3. Oxidations 	 75 
2.3.1. Model Study 	 75 
3. Synthesis of M6G; Synthetic Route Three 	 77 
3.1. Koenigs-Knorr Glycosidations 	 77 
Chemo-Enzymatic Approaches to M6G and Selected Analogues 
3.1. 1. Silver (I) Triflate Promoted Glycosidations 
3.1.2. Silver (I) Carbonate Promoted Glycosidations 
3.2. Zemplén Deprotections 
3.2.1. Deacylations of Some Simple Transglycosidation Products 
3.2.2. Synthesis of Morphine-6-glucoside 
3.3. Oxidations 
3.3.1. TEMPO Catalysed Oxidations 
3.3.1.1. Model Studies 
3.3.1.2. TEMPO Catalysed Oxidation of Morphine-6-glucoside 
3.3.2. Platinum Catalysed Oxidations 
3.3.2.1. Model Study 
3.3.2.2. Platinum Catalysed Oxidation of Morphine-6-glucoside 
3.3.3. Enzyme Catalysed Oxidations 
Section Two; Synthesis of M6G Analogues 
2.1. Synthesis of Morphine-6-Galactoside 
2.1.1. Koenigs-Knorr Couplings 
2.1.1.1. Synthesis of Tetra-o-benzoyl-a-D-galactopyranosyl Bromide and 
Tetra-o-acetyl-a-D-galactopyranosyl Bromide 
2.1.1.2. Synthesis of Morphine Tetraacety1-3-D-galactoside 
2.1.2. TMSOTf Promoted Couplings 
2.1.2.1. Synthesis of Pentaisobutyryl-f3-D-Galactose and Pentabenzoyl- 
3 -D-Galactose 
2.1.2.2. Synthesis of 3-0-Pivaloylmorphine Tetraisobutyryl-3-D-
galactopyranoside and 3-0-Pivaloylmorphine Tetrabenzoyl-3-D-
galactopyranoside 
2.1.2.3. Synthesis of Morphine-6-galactofuranoside 
2.2. Synthesis of Morphine-6-arabinopyranoside 
2.2.1. Attempted Synthesis of Tetrabenzoy1-3-D-Arabinopyranose 
2.2.2. Synthesis of 3 -O-Pivaloylmorphine Tribenzoyl-a-D-
arabinopyranoside 
































Section Three; Summary and Conclusions 	 III 
Chemo-Enzymatic Approaches to M6G and Selected Analogues 
Chapter Three, Experimental 
1.1. General Experimental ii 4 
1.2. Synthesis of Morphine-6-Glucuronicle; Synthetic Route One 118 
1.2.1. Cyclohex-6' -enyl 2,3 ,4,6-tetra-o-acetyl- 3-D-g1ucopyranoside 118 
1.2.2. 2' -Phenethyl 2,3 ,4,6-tetra-o-acetyl--D-glucopyranoside 119 
1.2.3. 2-Cyclohepten-1-ol 120 
1.2.4. Cyclohept-7' -enyl 2,3 ,4,6-tetra-o-acetyl-3-D-g1ucopyranosjde 121 
1.3. Synthesis of Morphine-6-Glucuronide; Synthetic Route Two 123 
1.3.1. Morphine- 3-o-pivaloyl-6-(methyl 2' ,3' ,4' -tri-o-isobutyryl)- 123 
13-D-glucopyranosiduronate 
1.3.2. 3-D-Glucopyranose Pentavalerate 124 
1.3.3. 3-0-Pivaloylmorphine-6-(2' ,3 ' ,4' ,6' -tetra-O-valeryl)- 125 
3-D-g1ucopyranoside 
1.3.4. 	-D-Glucopyranose Pentavalerate 126 
1.3.5. Methyl 2,3 ,4,6-tetra-o-valeryl-cx-D-glucopyranoside 127 
1.3.6. 1,2,3 ,4-Tetra-o-valeryl-cx-D-glucopyranose 128 
1.3.7. Methyl 2,3,4-tri-o-va1ery1-3-D-g1ucopyranoside 129 
1.3.8. Methyl 2,3,4-tri-o-valeryl-(X-D-glucopyranosiduronic acid 130 
1.4. Synthesis of Morphine-6-glucuronide; Synthetic Route Three 131 
1.4.1. a-D-Glucopyranose Pentaacetate 131 
1.4.2. Tetra-o-acetyl-a-D-glucopyranosyl Bromide 132 
1.4.3. n-Butyl 2,3 ,4,6-tetra-o-acetyl- 3-D-glucopyranoside 132 
1.4.4. n-Octyl 2,3,4,6-tetra-0-acetyl- -D-g1ucopyranoside 133 
1.4.5. Cyclohex-6' -enyl 2,3 ,4,6-tetra-o-acetyl- 3-D-g1ucopyranoside 134 
1.4.6. 3-0-Pivaloylmorphine-6-(2' ,3' ,4' ,6' -tetra-O-acetyl)- 135 
-D-glucopyranoside 
1.4.7. n-Butyl 3-D-g1ucopyranoside 	 137 
1.4.8. n-Octyl -D-g1ucopyranoside 137 
1.4.9. Cyclohex-6'-enyl f3-D-glucopyranoside 	 138 
1.4.10. Morphine-6-0-D-glucopyranoside 	 139 
1.4.11. Methyl (n-Butyl-3-D-glucopyranosid)uronate 	 140 
1.4.12. Methyl (1-0-methyl 2,3,4-tri-O-acetyl-(x-D-glucopyrariosjd)uronate 141 
1.4.13. Methyl (1-0-methyl 2,3 ,4-tri-o-acetyl- 3-D-ga1actopyranosid)uronate 142 
1.5. Synthesis of Morphine-6-3-D-glucoside Analogues 	 144 
1.5.1. Tetra-o-acetyl-a-D-galactopyranosyl Bromide 144 
Chemo-Enzymatic Approaches to M6G and Selected Analogues 
1.5.2. 3-0-Pivaloylmorphine-6-(2' ,3' ,4' ,6' -tetra-o-acetyl)- 145 
-D-ga1actopyranoside 
1.5.3. a-D-Galactopyranose Pentaisobutyrate 146 
1.5.4. 3-D-Ga1actopyranose Pentaisobutyrate 147 
1.5.5. 3-0-Pivaloylmorphine-6-(2' ,3' ,4' ,6' -tetra-O-isobutyry1)-3-D- 148 
galactofuranoside 
1.5.6. Morphine- 6-3-D-ga1actofuranoside 149 
1.5.7. c-D-Galactopyranose Pentabenzoate 150 
1.5.8. Tetra-O-benzoyl-a-D-galactopyranosyl Bromide 151 
1.5.9. 3-D-Ga1actopyranose Pentabenzoate 152 
1.5.10. (X-D-Arabinopyranose Tetrabenzoate 153 
1.5.11. 3-0-Pivaloylmorphine-6-(2' ,3' ,4' -tri-O-benzoyl)- 154 
a-D-arabinopyranoside 
1.5.12. Morphine-6-a-D-arabinopyranoside 155 
Appendix 
A.1. Synthesis of 3-0-Pivaloylmorphine and 3-0-Acetylmorphine 157 
A.2. Structure and NMR Spectra of 3-0-Pivaloyl Morphine 157 
A.3. 'H and COSY NMR Spectra of Morphine-6-3-D-g1ucoside 163 
A.4. 'H NMR Spectrum of Morphine- 6-3-D-ga1actofuranoside 165 
A.5. 'H and COSY NMR Spectra of Morphine-6-a—D-arabinopyranoside 166 
A.6. 'H NMR Spectrum of 3-0-Pivaloylmorphine-6-(2' ,3' ,4' ,6' -tetra-O-acetyl) 168 
-3 -D-galactopyrano side 
A.7. 'H NMR Spectrum of 3-0-Pivaloylmorphine-6-(2',3',4',6'- 169 
tetra- O-isobutyryl)-f3-D-galactofuranoside 269 
References 	 170 
General References 	 178 
Chemo-Enzymatic Approaches to M6G and Selected Analogues 
Chapter One; Introduction 
Section One; Morphine and Monosaccharides 
1.1. Morphine 
Before the advent of modern medicine herbalists used the compounds present 
in plants for their healing properties. The naturally occurring substances found in the 
opium poppy have been used for thousands of years to relieve pain; Hippocrates 
mentions the use of opium in ancient Greece. 1 The word morphine 1 is derived from 
the Greek word Morpheus, Ovid's name for the God of dreams 2 and it was first 
isolated from opium in 1803 by the German pharmacist Sterner 3 who gave the 
alkaloid its name. Opium itself is the dried milky residue obtained from the unripe 
seed capsules of the opium poppy Papaver somnferum.i ,4 
Opium is composed of a series of alkaloids which includes morphine 1 and 
also codeine 17, which itself has been in common medical use since the beginning of 
the century. 5  The alkaloids found in opium are called opiates;t the major opiate is 
morphine 1 (approximately 10%) and there are also appreciable amounts of codeine 
17 (approximately 0.5%) and thebaine 14 (approximately 0.2%). 4  Opium alkaloids 
are also called isoquinoline alkaloids as they are derived by oxidation from bases of 
the laudanosine series. 7 Morphine 1 is derived from S-reticuline but has the R 
configuration at C14, this means that the amine group at C9 and the proton at C14 lie 
cis with respect to each other giving a stereoisomer of morphine 1 that is referred to 
as cis morphine (figure 1.1 .).4 
HO 3 















Ste reoisonzers of Morphine 11 
Figure 1.1. 
The stereochemistry of morphine 1 is important in providing the compound 
with its analgesic qualities. Pharmacological studies with trans morphine 2, where 
An opioid is any substance that produces morphine-like effects, an opiate is a morphine-like drug 
with a close structural similarity to morphine. 6 
I 
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the C9 amine and C14 proton have trans stereochemistry have demonstrated that this 
compound is biologically less active than morphine 1 itself (figure 1.1.). 1  Changing 
the stereochemistry of morphine 1 could potentially provide compounds with potent 
analgesic activity. 1 
Certain structural features present in morphine 1 have been found to be 
important where the compound's analgesic potency is concerned. The analgesic 
potency of morphine 1 increases when the C6 hydroxyl group is oxidised or the N-
methyl group is replaced by N-ethylphenyl; 1 '7 acetylation of both C3 and C6 
hydroxyl groups affords heroin 21 which is a more potent analgesic than morphine 
1.8 The analgesic potency of morphine 1 is found to decrease on opening of the 4,5-
oxygen bridge; 1,7  methylation of the phenolic hydroxyl group gives codeine 17 
which is less potent than morphine 1 and is used to treat mild or moderate pain. 8 
By modifying the molecular structure of morphine 1 it was hoped alternative 
analgesics would be provided that did not have the side effects associated with using 
morphine 1, for example, respiratory depression and dependence. However, only 
until the analgesic effects exerted by morphine 1 and similar compounds are 
understood at a molecular level can the structural features that provide these 
compounds with activity be identified and modified. 
1.1.1. The Biosynthesis of Morphine 
The biosynthetic pathway to the opium alkaloids is complex, however, the 
use of radiolabelled compounds in feeding studies has enabled plant biotechnologists 
to identify the main biosynthetic precursors of morphine 1. The common 
biosynthetic intermediate of the opium alkaloids is nor-reticuline 9 which is derived 
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Biosynthetic Pathway of Dopamine 7•4 
Scheme 1.1. 
Tyrosine 3 is converted to the neurotransmitter dopamine 7 (scheme 1. 1 .),4 
whereby 3 is oxidatively deaminated to give p-hydroxyphenylpyruvic acid 4 which is 
2 
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hydroxylated to 3,4-dihydroxyphenylpyruvic acid 5. Reductive amination of 5 gives 
L-dopa 6 (the reverse reaction is very slow) which is decarboxylated to afford 
dopamine 7. 
The next step of the biosynthetic pathway, shown in scheme 1.2., involves 
coupling dopamine 7 and 3,4-dihydroxyphenylpyruvic acid 5 to give a 
benzylisoquinoline intermediate 8 which on decarboxylation and methylation gives 
nor-reticuline 9 . 1,4 
HO 
NH 





















































Biosynthetic Pathway of Morphine 11,4 
Scheme 1.2. 
N-Methylation of nor-reticuline 9 in scheme 1.2. gives reticuline 10 which is 
oxidised to the diketone 11, this undergoes cyclisation followed by reduction to give 
salutaridine 12 which is reduced further to salutaridinol 13. Formation of the 4,5-
oxide bridge by ring closure is followed by dehydration to give thebaine 14 which is 
hydrolysed to noepinone 15. Reduction of 15 gives codinone 16 which is reduced 
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1.2. The Pharmacological Effects of Opioids on the Body 
Besides analgesia opioids produce drowsiness, lethargy, apathy and euphoria 
or disphoria when administered to pain free volunteers. Other less pleasant effects 
are constipation and respiratory depression which is potentially fatal. 9 ' 10 
1.2.1. Analgesia 
Pain is seen as an infliction which affects every individual to some degree 
during their lives and the relief of pain, known as analgesia,' 1  has been a medical 
problem for thousands of years. Opiates (also called narcotic analgesics 5) have been 
used for hundreds of years to relieve the pain and anxiety associated with illness and 
surgery. 9 
Morphine 1 is generally administered orally or parenterally in the form of a 
salt, for example, the acetate 18, hydrochloride 19 or sulfate 20, salts. Heroin 21, the 
diacetyl derivative of morphine has a higher analgesic potency (figure 1.2.). 12 
2504 3H 20 
21 	 20 
Some Morphine Salts and Derivatives. 12 
Figure 1.2. 
Morphine 1 is one of the main drugs used to treat acute and chronic pain 
associated with medical illness. Opioid drugs produce analgesia over a wide range of 
doses and produce an analgesic effect without loss of motor and sensory functions. 8 
ru 
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1.2.2. Side-Effects Associated With the Use of Opioids 
The most common side-effects associated with the use of opioids are 
dependence, respiratory depression, sedation, nausea, constipation, and seizures. 8 
Some side effects can be beneficial, for example, constipation is caused by reducing 
the motility and secretions of the gastrointestinal tract and so opioids can be used for 
the relief of diarrhoea and dysentery. In fact the first recorded use of opium was not 
for the treatment of pain but for the relief of diarrhoea and morphine 1 is the oldest of 
the opioid antidiarrhoeal drugs. 10 
One of the more adverse side effects of opioids is respiratory depression 
which occurs as a result of the action of opioids on the brainstem respiratory centres; 
death from an overdose of opioids is usually as a result of respiratory arrest. CNS 
depression is manifested in other side effects including mental clouding and sedation 
(drowsiness) both of which prevent the patient maintaining their normal working and 
social activities. 8 
The effect of opioids on the peripheral blood vessels and the heart can lead to 
a fall in blood pressure (hypotension) as a result of blood vessel dilation and a 
decrease in the heart rate. 9 Morphine 1 is one of the opioids associated with 
histamine release which can cause or exacerbate hypotension. 9 Other unpleasant side 
effects associated with the use of opioids includes nausea and vomiting which 
appears to vary with the drug, route of administration, and the patient. 8 
1.2.2.1. Dependence, Tolerance and Addiction 
Morphine 1 and heroin 21 produce euphoria where the individual has feelings 
of well-being, relief, contentment, stimulation and freedom of imagination, and ease 
of mental effort. 13  Unfortunately opioids also produce a strong physical dependence 
when regular doses of the drug are required to prevent withdrawal symptoms. 14 
Dependence is expressed as a craving for the drug and the addiction associated with 
the use of opioids has become a major source of crime, poverty, and health problems 
within modern society. 6 Heroin 21, in particular is highly addictive and has become 
the recreational drug of modem society, taken by healthy individuals to experience 
the drug's euphoric effects. 14  However, continued use of opioids leads to tolerance, a 
state in which the individual needs to take increasingly larger doses of the drug to 
achieve the same effect. 14 Tolerance to both the narcotic and toxic effects develops 
rapidly and addicts need to take increasingly larger doses to achieve the desired 
euphoric effects. 13  Tragically addicts cannot measure their degree of tolerance as it 
does not increase consistently and an overdose is a frequent cause of death. 13 
5 
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Opioid addiction hinders the effective use of opioids as clinical analgesics; 
alternative opioid analgesics which are more potent and have fewer side effects are 
of great interest and the search for alternatives to opioids and the development of 
other more effective analgesics may lead to some useful future therapies. 
1.3. The Physiological Effects of Opioids on the Body 
When the human body is physically damaged the sensation of pain is 
experienced. The response to pain primarily involves the nervous system which is 
composed of the central nervous system (CNS) (the brain and spinal chord) and the 
peripheral nervous system (the entire nervous system excluding the CNS).1 5,16 
Both the peripheral nervous system and the CNS are composed of nerve cells 
or neurones which are excitatory cells that can receive and transmit electrical signals. 
Neurones are composed of a cell body which contains the nucleus, and an axon, the 
elongated conducting part of the cell which is covered in myelin, an insulating 
sheath. The junctions between neurones are called synapses which are either 
chemical or electrical. Electrical synapses pass the activity of the pre-synaptic 
neurone directly to the post-synaptic neurone in the form of a flow of electrical 
charge (i.e. a current). In a chemical synapse the stimulation of the pre-synaptic 
neurone by an electrical impulse causes the neurone to release a small chemical 
substance called a neurotransmitter. The neurotransmitter diffuses across the synaptic 
gap to the post-synaptic neurone where it binds to receptors, stimulating a change in 
the neurone's permeability to ions (figure 1.3.). 15,16 
When an injury to the body occurs, the sensation of pain starts at the injury 
site, inflammatory substances such as prostaglandins and serotonin are released 
which sensitise or stimulate the firing of primary afferents (pain nerve fibres) within 
the peripheral nervous system. The pre-synaptic end of the primary afferents are 
found in the spinal chord and when neurotransmitters are released from the pre-
synaptic end of the primary afferents, these bind to excitatory receptors on the spinal 
chord. A signal is then transmitted along the spinal chord to the brain which registers 
a sensation of pain. The spine and brain also contain inhibitory receptors, the brain 
can stimulate the release of endogenous substances which can bind to these receptors 
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The Nervous System's Response to Pain. 3 
Figure 1.3. 
The role of opioids in the body's response to pain has been extensively 
studied. Opioids bind to specialised receptors called opioid receptors which are 
widely distributed throughout the body, particularly within the nervous system, 
where opioid receptors are found in both the CNS and peripheral nervous system. In 
the CNS opioid receptors are found clustered in regions of the brain associated with 
pain regulation. The binding of opioids at these receptors means that they act directly 
on the part of the brain where pain is perceived providing the most effective type of 
analgesia. Opioids are therefore used to treat the pain arising from surgery, serious 
injury, and are particularly valuable for relieving the severe pain associated with 
terminal illness. 3 '5 
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In the peripheral nervous system, opioid receptors are mainly found in the 
pre-synaptic ends of primary afferents and the post-synaptic membranes of nerves in 
the spinal chord. The binding of opioids at these receptors inhibits both the pain 
signal to the brain and the pain signal from the brain (figure 1.3.). When the opioid 
morphine 1 binds to the pre-synaptic end of primary afferents, the resulting 
inhibitory action changes the permeability of the neurone membrane to ions, thus 
changing the membrane potential. The neurone can no longer release 
neurotransmitters and there is a decrease in the pain signals from the peripheral 
nervous system. 3 
1.4. Opioid Receptors 
The natural endogenous ligands of opioid receptors are the peptides 
endorphins, enkephalins, and dynorphins. These peptides are agonists for opioid 
receptors and are released by the body in response to pain, binding to and stimulating 
opioid receptors thus reducing the perception of pain. 17  Opioids are also agonists of 
opioid receptors and mimic the action of the natural endogenous ligands. 3,5,17  Three 
types of opioid receptors have been identified on the basis of their different 
pharmacological and binding characteristics and different anatomical distribution, 
these are referred to as the mu (II),  kappa (K), and delta (ö) receptors. 17 Receptor 
binding studies have shown that morphine 1 is selective for the ji opioid receptor and 
binds at two sites within the receptor which have been classified as t 1 and t2 . 18 
1.4.1. The Effect of Opioid Receptors on the Body 
Receptors, including opioid receptors, normally consist of a recognition site 
to which the drug binds and are part of a transduction pathway which leads to a 
biological response. 19 All known opioid receptors are members of the G protein-
linked receptor group which stimulate a cellular response via a G protein. 20 ' 21 G 
proteins are a family of membrane proteins whose name refers to the protein's ability 
to bind guanine nucleotides and are associated with the adenylate cyclase secondary 
messenger systems, the phosphoinositol secondary messenger system, potassium ion 
channels and the operation of calcium ion channels. 20 ' 22 
Opioid receptors have been found to associate with the adenylate cyclase 
secondary messenger systemvia G proteins and are inhibitory, reducing the activity 
of the enzyme. The adenylate cyclase secondary messenger system involves G and 
G1 proteins which stimulate and inhibit adenylate cyclase respectively. G proteins are 
composed of three subunits, referred to as the a, 13 1 and y subunits. The 13  and ' 
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subunits are identical for the G  protein and G protein, however, the a subunit is 
different and is referred to as a  or a for the stimulatory and inhibitory subunit 
respectively. In an unstimulated (basal) state G proteins bind guanosine diphosphate 
(GDP) at the guanine nucleotide binding site which is located on the larger a 
subunit. 20,22,23 
Binding of a natural ligand or agonist occurs at a specific ligand binding site 
or agonist binding site respectively, on the opioid receptor. 23 The opioid receptor can 
exist in either a low or high-affinity state and either stimulates or inhibits adenylate 
cyclase. The binding of opioids to opioid receptors inhibits adenylate cyclase and 
several models have been proposed for the receptor-mediated inhibition of adenylate 
cyclase including the direct action model shown in figure 1 423 
[Basal Slate] 	 [Stimulated State] 
Opioid receptor 	I 
ligand 	 Inhibitory receptor 	 Opioid ligand bound 
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Figure 1.4. 
In the direct action model the inhibitory receptor (R*)  is initially bound to the 
G protein and the a subunit of the G protein is bound to guanosine diphosphate 
(GDP). When a ligand or agonist binds to the inhibitory receptor (R1*)  in its high 
affinity state it causes a conformation change and the GDP bound to the a,-subunit is 
displaced by guanosine triphosphate (GTP). The G protein dissociates and the a 
subunit-GTP complex associates with adenylate cyclase inhibiting the enzyme. 
Active adenylate cyclase catalyses the conversion of cyclic adenosine triphosphate 
(cATP) to cyclic adenosine monophosphate (cAMP), this in turn activates a number 
We 
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about the association of opioid receptors with cellular processes involved in the 
body's sensory perception and response to pain. 
1.5. Morphine Metabolites 
The metabolic fate of morphine 1 in both animals and humans has been 
studied extensively over a number of years and it has been found to undergo 
metabolism via four different pathways (figure 1.5.) ; 26 
Conjugation; gives morphine-3-glucuronide (M3G) 22, morphine-6-
glucuronide (M6G) 23 and morphine-3,6-diglucuronide 24. 
N-Demethylation; gives normorphine which is then conjugated in the liver. 
o-Methylation; to form codeine 17. 
Oxidation; to form dihydromorphinone. 
It has been known for some years that conjugation was one of the important 
mechanisms for the detoxification of morphine 1 in the body 27 and glucuronidation 
has been confirmed as the primary metabolic route for administered morphine 1.28 
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Figure 1.5. 
With the advent of sensitive modern chromatographic and spectroscopic 
techniques, the identity and quantitative study of morphine metabolites is achievable. 
Yeh29 was one of the first to take advantage of these techniques to identify and 
quantify the presence of a number of morphine metabolites in the urine of subjects 
after the parenteral administration of morphine sulfate 20. In a recent study Yeh and 
co-workers26 reported the presence of M3G 22, M6G 23, morphine-3,6-
diglucuronide 24, morphine-3 -ethereal sulphate, normorphine 25, normorphine-6-
glucuronide, and possibly normorphine-3-glucuronide in the urine of subjects after 
the parenteral administration of morphine sulfate 20. Yeh and co-workers 26 also 
found that 55-64% of morphine sulfate 20 administered parenterally was conjugated 
in the liver where microsomal uridine diphosphate glucuronyl transferases 28 attach 
glucuronide residues to the morphine structure. Yeh and co-workers 26 confirmed that 
the major metabolite of administered morphine sulfate 20 is M3G 22 while the 
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amount of M6G 23 and morphine-3,6-diglucuronide 24 is found in much smaller 
quantities which were estimated by Yeh and co-workers 26 to be 1% of the quantity 
of M3G 22 found. 
The identification of morphine metabolites by Yeh and co-workers 26 
stimulated interest in the possible interactions these metabolites would have with t 
receptors. Two in vitro techniques that have provided valuable information about the 
actions of opioid ligands and the receptors with which they interact are receptor 
binding studies in membrane fragments and bioassays in isolated intact tissues. 19 
Pasternak and co-workers 30 examined the binding affinities of both M6G 23 and 
M3G 22 with t receptors. The experiments demonstrated a high affinity of the minor 
metabolite M6G 23 for t receptors, where as the major metabolite M3G 22 had a 
low affinity. 
There was also interest in the analgesic activity of morphine metabolites with 
relation to the results of the binding studies. Pasternak and co-workers 30 reported 
that in animal studies M6G 23 was 20 times more potent than morphine, while M3G 
22 lacked of any significant analgesic activity. The high potency of M6G 23 as an 
analgesic was confirmed by Osborne and co-workers3 I  who studied the 
pharmacological activity of the metabolite in human subjects and suggested that most 
of the analgesic effect that occurred after treatment with morphine was as a result of 
M6G 23. The analgesic potency of M6G 23 reflects the metabolite's high affinity for 
.t receptors while M3G 22 has little affinity for t receptors and consequently lacks 
analgesic activity. 
After the discovery of M6G's 23 analgesic potency, Osborne and co-
workers 32  went on to examine the pharmacokinetics of the metabolite. After both 
intravenous and oral administration of morphine 1, Osborne and co-workers 32 
discovered an abundance of this metabolite in the plasma which exceeded the levels 
of morphine 1 itself. A recent investigation by Hanna and co-workers 33 of the 
pharmacokinetics and side effects associated with M6G 23 confirmed the presence of 
high levels of M6G 23 in plasma after intravenous administration of morphine 1, the 
side effects were also of a low incidence and a shorter time was required for a full 
recovery. 
M6G 23 has also been found to penetrate the blood-brain barrier as 
effectively as morphine 1. This is unusual for glucuronides and more so for M6G 23 
which, as a result of the large number of hydroxyl groups and the carboxylate group, 
is a highly polar compound. 34 In fact studies have shown that M6G 23 is only 
slightly less lipophilic than morphine which explains how this metabolite is able to 
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penetrate the blood-brain barrier. 34  Consequently, as a result of the lipophilic nature 
of M6G 23 it is able to accumulate in membranes which probably accounts for the 
metabolite's blood-brain penetration and slow urinary excretion. 34  A publication by 
Carrupt and co-workers 34  suggests that M6G 23 is a "molecular chameleon" which 
means that the compound will fold in order to adapt to the polarity of the surrounding 
medium allowing what should be a highly polar hydrophilic compound to be 
lipophilic. 
M6G 23 would appear to be a highly unusual if not a unique compound and 
the greater analgesic potency, longer duration of action and fewer side affects 
associated with this metabolite has stimulated interest in the synthesis of this novel 
analgesic. 
1.6. The Chemical Synthesis of Morphine Glucuronides 
One of the first chemical routes to M6G 23 was reported by Yoshimura and 
co-workers 35 ' 36  who used a classic silver (I) carbonate promoted Koenigs-Knorr 
glycosidation with methyl tri-o-acetyl-a-D-glucosyluronate bromide 26 as the 
glycosyl donor and 3-0-acetylmorphine 27 (for synthesis see appendix A.!.) as the 
acceptor (scheme 1.3.). The glycosidation reaction afforded the adduct 28 in a yield 
of 50%, which was then deprotected to afford M6G 23 in 64% yield. 
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Scheme 1.3. 
M3G 22 is the major metabolite of morphine and both Yoshimura 35 ' 36 and 
Berrang 37  attempted its synthesis using a silver (I) carbonate promoted Koenigs-
Knorr glycosidation under similar conditions used for the synthesis of M6G 23 
(scheme 1.3.). However, the glycosidic bond formed at C3 was readily cleaved under 
the reaction conditions, therefore alternative routes were developed. Yoshimura and 
co-workers 35 ' 36  reported a rather tedious reaction involving the addition of aqueous 
sodium hydroxide to a solution of morphine 1 and methyl tri-O-acetyl-ce-D-
glucosyluronate bromide 26 in acetone over a number of days (scheme 1.4.). A 
quicker synthetic route was reported by Berrang and co-workers 37 who used the 
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lithium salt of morphine 1 and methyl tri-O-acetyl-a-D-glucosyluronate bromide 26 
in a reaction that afforded the desired M3G 22 in a moderate yield of 53% (scheme 
1.4.). 
CO,Me 	 CO, 
HO 	
AcO" ,, 	 -. 	HO ' 
AcO 	 I HO 
CO,Me or iv 	 iii.or v., vi. 
AcO" \ 	
+ 	
22 	 INNIC 
AcO 
H' 	
, 	 HOJIIII 	 HO 
i. Acetone, aq NaOH, 7 days; ii. AcOH; iii. NH 40H; 23 = 0.44 g,  25% (Yoshimura et al) 35 '36 
iv. Li01-1.1420, MeOH, rI, 30 mins; v. L1OH.14 20, H20, rI, 30 mins; 
Vi. Ac011; 23 = 12.2 g, 53% (Berrang et a!)37 
Yoshi,nura 35' 36 and Berrang 's37 Synthesis of M3G 22. 
Scheme 1.4. 
The discovery of M6G's 23 analgesic activity stimulated interest in the 
synthesis of this compound as a novel analgesic. As mentioned earlier the use of a 
silver (I) carbonate promoted Koenigs-Knorr reaction had been successfully reported 
by Yoshimura and co-workers. 35 '36  A variation on this reaction was recently carried 
out by Lacy and Sainsbury 38  who used silver (I) carbonate supported on Celite as the 
promoter for a Koenigs-Knorr glycosidation with 3-0-acetylmorphine 27 as the 
acceptor and methyl tri-O-acetyl-a-D-glucosyluronate bromide 26 as the glycosyl 
donor (scheme 1.5.). 
H 
Toluene, reflux. i.0.IMaqNaOH 
CO,Me Ag2 CO7 on Celite ii. AcOH 
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+ o,'1IIj AcO NM C 	CO,Me NMC 
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HO''' 45% - 
HO 	 .'..,cJ 
AcO HO 85%, 26 27 28 HO 	23 
Lacy and Sainsbur,y's Route to M6G 23.38 
Scheme 1.5. 
Lacy and Sainsbury 38  obtained the adduct 28 in a similar yield to Yoshimura 
and co-workers, 35 '36  but achieved a more efficient deprotection step under alkaline 
conditions to afford M6G 23 in a yield of 85%. However, although the use of barium 
salts was avoided in the deprotection step, contamination of the M6G 23 with silver 
would render the compound unsuitable for use in biological systems. 
The publication of a route devised by Scheinmann and co-workers 39 provides 
a novel and efficient synthesis of M6G 23 that avoids the use of heavy metals. The 
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procedure involves a trimethylsilyl trifluoromethanesulfonate (trimethylsilyl triflate 
or TMSOTf) catalysed coupling of 3-0-acetylmorphine 27 and the isobutyryl 
protected (X-D-glucosyluronate trichloroacetimidate 29 which affords the adduct 30 in 
a good yield of 63%. Deprotection of the adduct 30 under alkaline conditions finally 
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Scheme 1.6. 
The synthesis developed by Scheinmann and co-workers 39 currently provides 
the best chemical synthetic route to M6G 23 and related compounds (for example, 
M6G hapten40). However, there has been recent interest in the application of 
biocatalysis to the synthesis of M6G 23. 
1.7. The Enzymatic Synthesis of M6G 
The conjugation of morphine in the liver is catalysed by hepatic 
glucuronyltransferase enzymes affording a water soluble form of morphine that can 
be efficiently eliminated by the kidneys. 41 '42  Urine samples are commonly used to 
measure the levels of drugs present in the body, however, conjugated forms of many 
drugs, including morphine, are difficult to detect. 41 The hydrolysis of conjugated 
forms of drugs under acidic conditions often completely destroys the conjugate, thus 
enzymatic hydrolysis was developed as an milder alternative. 41 Combie and co-
workers 41  reported the use of 0-glucuronidase from Patella vulgata as an efficient 
catalyst for the hydrolysis of morphine glucuronates in equestrian urine in the early 
1980's. In a recent study by Bertholf and co-workers 42 I3-glucuronidase was used to 
hydrolyse morphine glucuronates present in human urine. However, Bertholf and co-
workers 42  demonstrated that 3-glucuronidase was less able to hydrolyse the 
morphine glucuronates in human urine, than those in equestrian urine. Bertholf and 
co-workers42  also suggested that 0-glucuronidase from Patella vulgata is less 
selective for the major metabolite M3G 22 which contains a phenolic glucuronide, 
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than the minor metabolite M6G 23 which contains an allylic glucuronide, although 
this claim was not substantiated by laboratory studies. 
A recent publication by Brown and co-workers 43 found that 13-glucuronidase 
from Patella vulgata demonstrates selectivity for one of the glucuronide residues of 
morphine-3,6-diglucuronide 24 and catalyses the hydrolysis of the phenolic 
glucuronide at C3 with a selectivity that is 20 times greater than for the C6 
glucuronide. Treatment of morphine-3,6-diglucuronide 24 with 3-glucuronidase from 
Patella vulgata affords M6G 23 in a modest yield of 24%, providing a novel 
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Scheme 1.7. 
The successful synthesis of M6G 23 with 13-glucuronidase from Patella 
vulgata stimulated interest in the use of other enzymes towards the synthesis of this 
novel analgesic. The use of enzymes in the synthesis of M6G 23 offers the advantage 
of using mild and selective conditions and provides attractive alternatives to 
chemical synthetic routes which usually require heavy metals such as silver and 
mercury. 
1.8. The Chemo-Enzymatic Synthesis of M6G and M6G Analogues 
The project was composed of two parts; the main aim of the project was to 
synthesise M6G 23 using a combination of biocatalysis and organic chemistry; the 
second part involved an investigation of the chemical synthesis of selected M6G 
analogues. 
1.8.1. The Chemo-Enzymatic Synthesis of M6G 
Three possible routes towards the synthesis of M6G 23 were considered, 
whereby, two were chemo-enzymatic routes (routes 1 and 2) and one was a chemical 
synthetic route (route 3). The two chemo-enzymatic routes incorporated the use of 
either a J3-glucosidase (route 1) or lipase (route 2) with a selective oxidation at C6' of 
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Scheme 1.8. 
Route 1 in scheme 1.8. involves a transglycosidation catalysed by 13-
glucosidase from almonds which has been previously shown to be useful in 
transglycosidations with a variety of alcohols as substrate acceptors. 44-46 The 
acceptors for the proposed transglycosidation catalysed by f3-glucosidase were a 
protected morphine derivative (3-0-pivaloylmorphine 32) and a morphine salt 
(morphine sulfate 20), with para-nitrophenyl-f3-D-glucose 33 as the glycosyl donor. 
It was then proposed that a selective oxidation at C6' of morphine-6-glucoside 31 
using either platinum or TEMPO as the catalyst would afford M6G 23 with a final 
deprotection step required when 3-0-pivaloylmorphine 32 is used as the acceptor to 
remove the pivaloyl group. 
Route 2 in scheme 1.8. involves a TMSOTf promoted glycosidation of 3-0-
pivaloylmorphine 32 with 13-D-glucose pentavalerate 34 to afford 3-0-
pivaloylmorphine-6-(2',3' ,4',6'-tetra-o-valeryl)-3-D -glucoside 35. A selective 
deacylation at C6' of the morphine-f3-D-glucoside 35 is then required, which can be 
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achieved using lipases. Lipases have proved to be versatile and selective enzymes for 
the acylation and deacylation of a range of compounds 47 including ester protected 
glycosides. 48-50  A non selective ruthenium (VIII) oxide catalysed oxidation at the 
C6' hydroxyl group of 3-0-pivaloylmorphine-6-(2' ,3 ' ,4' -tri-o-valeryl)- 13-D-glucoside 
36 followed by deprotection would then afford the desired M6G 23. 
Route 3 in scheme 1.9. is a chemical route to M6G 23 which involves a 
classic silver (I) carbonate promoted Koenigs-Knorr coupling of 3-0-
pivaloylmorphine 32 and acetobromoglucose 37 to give the morphine-3-D-glucoside 
38 which on deacylation would afford morphine-6-glucoside 31. Thereafter a 
selective TEMPO or platinum catalysed oxidation at the C6' position of morphine-6-
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Scheme 1.9. 
The Koenigs-Knorr glycosidation used in route 3 was established at Salford 
Ultrafine Chemicals. Hopkins 51  reported a silver (I) carbonate promoted Koenigs-
Knorr glycosidation of 3-0-acetylmorphine 27 using acetobromoglucose 37 as the 
glycosyl donor. The reaction afforded 3- 0-acetylmorphine-6-(2' ,3' ,4' ,6' -tetra-0-
acetyl)--D-glucoside 38 in yields that varied between 30% and 60% with a Zemplén 
deprotection of 38 affording the desired morphine-6-glucoside 31 in yields in excess 
of 90%. Recently two new routes to morphine- 6-glucoside 31 were reported by 
Kovác and Rice 52  who carried out either a mercury (II) cyanide or a silver (I) triflate 
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promoted coupling of 3-0-acetylmorphine 27 with either acetobromoglucose 37 or 
tetra-o-benzoyl-cx-D-glucopyranosyl bromide 39 (scheme 1.10.). 
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Kovác and Rice's Synthesis of Morphine-6-glucoside 31.52 
Scheme 1.10. 
The mercury (II) cyanide promoted glycosidation attempted by Kovác and 
Rice52  was slow and afforded the orthoester 40 as the major product and 3-0-
acetylmorphine-6-(2' ,3' ,4',6'-tetra-o-acetyl)-3-D-glucoside 38 as the minor product. 
The silver (I) triflate promoted glycosidation although higher yielding afforded the 
same ratio of the orthoester 40 and the morphine-3-D-glucoside 38. When Kovác and 
Rice52  used tetra-O-benzoyl-a-D-glucopyranosyl bromide 39 in a silver (I) triflate 
promoted glycosidation, a mixture of the morphine- a-D- glue oside 41 and the 
morphine--D-glucoside 42 were found in a combined yield of 91% with only a trace 
of the orthoester 43•52 Although Kovdc and Rice 52 did not attempt to explain this 
difference the most likely explanations are that the orthoester 43 forms more slowly 
as a result of steric hindrance due to the aromatic ring or if the orthoester 43 does 
form it rearranges to give the morphine-f3-D-glucoside 42 much more rapidly than the 
rearrangement of orthoester 40 to the morphine- 3-D-glucoside 38. Isolation and 
Zempldn deprotection of the morphine--D-glucoside 38 afforded morphine-6-
glucoside 31 in a yield of 75%•52 
1.8.2. The Synthesis of M6G Analogues 
The synthesis of morphine-6-glucoside 31, morphine-6-galactoside 44 and 
morphine-6-maltoside 45 has been reported by Hopkins 51 using a silver (I) carbonate 
promoted Koenigs-Knorr glycosidation of 3-0-acetylmorphine 27 with the 
appropriate acyl protected glycoside as the glycosyl donor (figure 1.6.). 
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Morphine-6-glucoside Analogues. 51 
Figure 1.6. 
The best results were achieved with morphine glucosides; the Koenigs-Knorr 
glycosidation using acetobromoglucose 37 as the glycosyl donor gave the morphine-
13-D-glucoside 38 in 32-63% yield which on Zemplén deprotection gave morphine-6-
glucoside 31 in 90% yield. When acetobromogalactose 46 was used as the glycosyl 
donor, the morphine-3-D-galactoside 47 was obtained in much lower yields (9-28%); 
also the reaction was performed on a small scale, hence the isolated morphine-6-
galactoside 44 could not be fully characterised. This was also the case for morphine-
6-maltoside 45 (scheme 1.11.). 5 ' 
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Scheme 1.11. 
There was interest in repeating the synthesis of morphine -6-galactoside 44 
and attempting the synthesis of morphine-6-arabinoside 48 using both silver (I) 
carbonate and TMSOTf promoted couplings of 3-0-pivaloylmorphine 32 and the 
appropriate acyl protected glycosyl bromide or the peracylated sugars respectively, 
as the glycosyl donor (scheme 1.12.). 
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Scheme 1.12. 
The synthesis of these morphine glycosides, if successful, would provide a 
series of 3-glycosides, which, if biologically active, could provide alternative 
analgesics to M6G 23. 
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Section Two; Modern Methods For Glycoside Synthesis 
Interest in glycosidation reactions has grown as a result of an increased 
awareness of the biological significance of glycoconjugates and the biomedical 
potential of these compounds. Glycosidation reactions where a sugar moiety is 
attached to an aglycon is a common reaction in nature and natural glycosides are 
found throughout the plant and animal kingdoms. Glycoconjugates have a variety of 
functions, for example, the attachment of sugar residues to foreign compounds such 
as morphine 1 increases solubilization and so assists excretion via the kidneys. 
Glycoconjugates also play an important role in molecular recognition and sugars can 
be found attached to the proteins embedded in the surface of membranes. 
The isolation and synthesis of natural glycosides such as glycoproteins, for 
example, transmembrane protein anchors found in rat brains 53 ' 54 and 
glycosphingolipids such as the tumour associated antigen, Lewis X 55 has lead to the 
development of a number of new and novel glycosidation procedures. Glycosidation 
reactions were an essential part of the synthetic routes examined for the synthesis of 
M6G 23 and M6G analogues. Both classic and relatively modern methods of 
glycoside synthesis have been studied, for example, the Koenigs-Knorr glycosidation 
and the trichloroacetimidate method respectively. However, these are just two of the 
variety of methods currently available for the synthesis of glycosides. 
2.1. Classic Glycosidation Reactions 
The classic glycosidation reactions for the synthesis of 0-glycosides include; 
the Fischer glycosidation reaction, 56 ' 57  which is the acid catalysed substitution of an 
alcohol with the anomeric hydroxyl group of a free sugar, the reaction normally 
produces a mixture of furanosyl and pyranosyl glycosides as a mixture of (X and 13-
anomers. The Purdie method 58  is a classic synthesis of methyl glycosides by direct 
alkylation of a suitably protected hemiacetal using methyl iodide and silver oxide. 
The Koenigs-Knorr glycosidation 59  involves the displacement of a halide ion from a 
glycosyl halide in the presence of heavy metal salts, either silver or mercury, which 
is followed by glycosyl transfer to a free hydroxyl group on the glycosyl acceptor. 57 
Classic glycosidation reactions have been well documented over the years 
and some recent reviews have been published by Schmidt 60 and Paulsen 61 ' 62 . 
However, classic glycosidation reactions have their limitations, for example, the 
mixture of compounds produced in the Fischer glycosidation reaction can be 
inconvenient. 56  The glycosyl halides used in the Koenigs-Knorr glycosidation have 
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low thermal stability, are sensitive to hydrolysis and are generated under harsh 
conditions, while the heavy metal salts are expensive and can be toxic (mercury) or 
explosive (silver perchlorate). 60 
The limitations of these classic glycosidation reactions led to searches for 
improved glycosidation procedures. A number of alkylating agents are now available 
for the direct alkylation of protected hemiacetals, for example, primary triflates such 
as methyl triflate have been found to give the methyl glycoside in high yields; by 
varying the reaction conditions, e.g., reaction temperature, stereoselectivity can be 
introduced. 60  The development of some reagents has even enabled the alkylation of 
unprotected sugars, for example, 1-0-arylation of D-glucose 49 occurs in the 
presence of sodium hydrogen carbonate using 1-fluoro-2,4-dinitrobenzene to give the 
2,4-dinitrophenyl glucoside 50 (scheme 2 . 1 . ) . 63 
OH 	 OH 






NO, 	 NO, 
49 	 50 	
20% 
Ano,neric O-Ar)'lation of D-Glucose 4963 
Scheme 2.1. 
The original Koenigs-Knorr glycosidation is based on the displacement of a 
good leaving group from the anomeric centre of the glycosyl donor. However the 
limitations of glycosyl halides as glycosyl donors has lead to the development of 
alternative anomeric leaving groups. 
2.2. Anomeric Leaving Groups 
The nucleophilic displacement of an electrophilically activated leaving group 
at the anomeric carbon of sugars is one of the most synthetically useful reactions in 
carbohydrate chemistry and many glycosidation reactions, including the Koenigs-
Knorr glycosidation, are based on this principle. 60 The anomeric leaving group of the 
Koenigs-Knorr glycosidation is generally a chloride or bromide (the glycosyl iodide 
is very reactive and is not commonly used 56). However, as a result of the limitations 
of glycosyl bromides and chlorides attention was turned to the use of glycosyl 
fluorides as donors for glycosidation reactions. 
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2.2.1. Glycosyl Fluorides 
Glycosyl fluorides have high thermal stability and are unreactive towards 
many reagents as a result of the short C-F bond. Until recently there were few good 
synthetic routes towards the preparation of glycosyl fluorides, 56'57 but it is now 
possible to synthesise glycosyl fluorides using a number of procedures, for example, 
from thioglycosides 5664  in scheme 2.2. 
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Scheme 2.2. 
Synthesis of Glycosyl Fluorides and their use as Glycosyl Donors. 64 
In the mid 1980's specific fluorophilic promoters were developed enabling 
the use of glycosyl fluorides as glycosyl donors in glycosidation reactions. 5760 Early 
fluorophilic promoters for glycosidation reactions with glycosyl fluorides were 
strong Lewis acids such as boron trifluoride diethyl etherate (BF 3 .Et,0) 65 , other 
fluorophilic promoters include tin (II) chloride (scheme 2.2.) and lithium perchlorate 
(LiC1O4),66  a mild fluorophilic promoter. Nicolaou and co-workers 64 synthesised the 
silyl protected glucosyl fluoride 51 from the silyl protected thioglucoside 52 using 
diethylaminosulfur trifluoride (DAST) (scheme 2.2.). A glycosidation reaction 
promoted by tin (TI) chloride and silver perchlorate using the thioglycoside 53 as the 
glycosyl acceptor gave the a-disaccharide 54 in good yield. 64 
2.2.2. Glycosyl Amines, Phosphonium and Nitrilium Compounds 
The replacement of the anomeric oxygen of glycosides with other elements 
such as sulfur, nitrogen or phosphorus has allowed the introduction of a range of new 
glycosyl donors. Sulfur, nitrogen or phosphorus based leaving groups allow the 
formation of stabilised carbonium ions which will undergo a glycosidation reaction 
with a suitable glycosyl acceptor. 60  The halide leaving group of glycosyl halides is 
readily replaced by an alkyl-thio or aryl-thio group to afford thioglycosides, such as 
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thioglycoside 55 in scheme 2.3., which on treatment with a suitable promoter (XY) 
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Thioglycosides as Glycosyl Donors in Glycosidation Reactions. 56,67 
Scheme 2.3. 
Early glycosidation promoters of thioglycosides were electrophilic reagents 
such as mercury (II), lead (II), copper (II) and silver (I) salts (X= Hg, Pb, Cu or Ag in 
scheme 2.3.).56 Thioalkyl groups in particular are good leaving groups and in the 
presence of metal salts are readily converted into sulfonium cations which are easily 
displaced by a nucleophile. 56  A number of non-metalic glycosidation promoters are 
now available for thioglycosides, such as TMSOTf with N-iodosuccinimide (NIS) 68 
or N-bromosuccinimjde (NBS), 57 ' 60 bis(trifluoroacetoxy)iodobenzene (BTIB ).67  For 
example, Boons and co-workers 68  used TMSOTf-NIS to promote the glycosidation 
of the thioglucoside 57 with the benzyl protected glucoside 58 affording the J3-D-
disaccharide 59 in 75% yield (scheme 2.4.). 
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[IS = N-Iodosuccinimide] 
Synthesis of /3-D-Glucopyranosyl Disaccharides from Thioglycoside Donors. 68 
Scheme 2.4. 
Sulfonium leaving groups are more reactive than ammonium leaving groups 
which are in turn more reactive than phosphonium leaving groups and so interest has 
mainly concentrated on the use of thioglycosides in glycosidation reactions. 
However, ammonium, phosphonium, and acetonitrile groups at the anomeric centre 
of sugars potentially provide useful glycosyl donors (scheme 2.5 .) •57,60 
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Potential Glycoside Donors for Glycosidation Reactions. 56 
Scheme 2.5. 
Of the investigations with ammonium, phosphonium and nitrile glycosides, 
glycosidation reactions predominately give c-glycosides as the reaction 
products. 57 '60 
2.2.3. Glycosyl Acyl Esters 
Acyl esters are now commonly used in glycosidation reactions, early 
promoters for these reactions were Lewis acids such as zinc (II) chloride and tin (IV) 
chloride. These promoters were then followed by triflates such as TMSOTf which is 
a powerful glycosidation promoter. The use of TMSOTf as a promoter of glycoside 
synthesis was first established in the early 1980's by Ogwa and co-workers 69 who 
used the promoter in the glycosidation of 13-lactose octaacetate 60 using the alcohol 
61 to give the 13-D-disaccharide 62 (scheme 2.6.). 
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First Example of the Use of Trimethylsilyl Triflate as a Glycosidation Promoter. 69 
Scheme 2.6. 
A possible mechanism of TMSOTf promoted glycosidations with glycosyl 
donors which have an acyl ester group at the anomeric centre is shown in scheme 
2.7. whereby co-ordination of the electropositive silyl group to the carbonyl oxygen 
of the anomeric acyl group weakens the ester bond. Loss of the 1-0-acyl group in 
compound 63 gives the oxonium ion 64 and neighbouring group participation from 
the 2-0-acyl group gives the acetoxonium ion 65. As the a-face is blocked the 
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acetoxonium ion 65 undergoes equatorial attack by the alcohol acceptor to give the 
-D-glycoside 66. 0  
- OSO 2CF3 
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0 	R 0 	 RO RO R 
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Mechanism of The Trimethylsil)'l Triflate Promoted Glycosidation. 7° 
Scheme 2.7. 
TMSOTf promoted glycosidations using acylated sugars are most successful 
when the glycosyl donor has a 1,2-trans configuration; the acylated 13-anomer is 
more reactive than the anomerically more favoured and more stable acylated a-
anomer. 62 
2.2.4. Glycosyl Phosphates 
In nature glycosyl transfer generally occurs with a sugar nucleotide 
containing a pyrophosphate linkage or with glycosyl phosphates as glycosyl donors; 
this observation stimulated interest for the use of glycosyl phosphates as glycosyl 
donors for chemical synthesis. 56  Glycopyranosyl phosphoramidates in particular are 
becoming increasingly popular as glycosyl donors, being stable, readily prepared 
from acylated glucopyranoses 71 or glycosyl phosphites 72 and they will couple with 
alcohol acceptors under a range of reaction conditions. For example, the glucosyl 
tetrame thy iphosphoramidate 68, readily prepared from the tetra-O-
benzylglucopyranose 67, will react with the partially protected sugar acceptor tri-O-
benzoyl glucoside 69 in the presence of TMSOTf to give predominately the 13-D-







n-BuLl, THF, -70 C 
HMPA, - 10 C, 
(Me2N) 2P(0)CI 





71 	 P NMe, 
NMe, - 
Chemo-Enzymatic Approaches to M6G and Selected Analogues 





 Bn;O 	 BZ0 	0
0 	' 
68 	 P, 	 69 
'NMe, 	 NMe 
NMe, - We, - 




O Bz \ 70 	
BzO 
86% (a/35:95) 	 BzO 
\ NMe, 
We, - 
Glycopyranosyl Tetramethyiphosphorainidates as Glycosyl Donors. 71 
Scheme 2.8. 
Hashimoto and co-workers have investigated the use of glycopyranosyl 
tetramethyiphosphoramidates to synthesise a variety of compounds including the 
anticancer agents podophyllum lignan glycosides 73  and oligosaccharides. 71 Recently 
Hashimoto and co-workers 71  have extended their investigation into the use of more 
reactive glycosyl donors, such as the glycosyl phosphordiamidothioate 71 in scheme 
2.8. which give predominately a-D-glucosides. 
2.2.5. Trialkylsilyl Glycosides 
Silyl ethers provide another source of glycosyl donor, for example, Nashed 
and co-workers 74  coupled the trimethy1si1yl-3-D-g1ucoside 72 to the silyl protected 
galactoside 73 in the presence of TMSOTf to give the J3-disaccharide 74 in a highly 
stereoselective reaction (scheme 2.9.). 
OAc 	 Ac 9 	OSi(Ph),t-Bu 
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Silyl Ethers as Glycosyl Donors. 74 
Scheme 2.9. 
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2.2.6. Glycosyl Trichioroacetimidates 
Imidates have proved to be very versatile glycosyl donors and are extensively 
used in glycosidation reactions. Glycosyl imidates were first introduced as glycosyl 
donors by Pougny and Sinay 75 who examined the use of glycosyl acetimidates and 
benzylimidates in glycosidation reactions with silver (I) oxide as the promoter. 
Trichioroacetimidates are among the most commonly used glycosyl imidates, they 
are formed from a nucleophilic reaction between the unprotected anomeric hydroxyl 
group (the remaining hydroxyl groups are protected) and trichioroacetonitrile in the 
presence of base (scheme 2.10.). Potassium carbonate is generally used to obtain J3-
glycosyl trichioroacetimidates while a stronger base such as sodium hydride is 
required for a-glycosyl trichioroacetimidates (scheme 2.10.). 56 Glycosyl 
trichioroacetimidates will react with a suitable alcohol acceptor in the presence of 
Lewis acid catalysts such as TMSOTf or BF 3 .Et 2 0 to give the desired glycoside. 57 
For example, the trichloroacetimidate glucoside 76 is readily prepared from the tri-O-
benzyl glucose 75 and will react with an alcohol acceptor (R 1 OH) in the presence of 
BF1 .Et2 0 to give the 1-0-glucoside 77 (scheme 2.10.). 57 
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Synthesis of] -O-Glycosides Using 1 -O-Glycosyl Trichloroacetimidates. 56' 57 
Scheme 2.10. 
When phosphoric acids are used as the acceptor, TMSOTf promoted 
glycosidations with glycosyl trichloroacetimidates afford glycosyl phosphates e.g. 78 
in scheme 2.10. These glycoconjugates are components of biological membranes and 
so their synthesis is of significant interest. 60 The mechanism of glycosidation 
reactions with trichloroacetimidate donors such as 79 in scheme 2.11. involves initial 
co-ordination of a Lewis acid, such as TMSOTf with the nitrogen lone pair of the 
trichioroacetimidate group. Generation of the oxonium ion 80 is brought about by the 
loss of the trichloroacetamide-Lewis acid complex, which will pick up a proton to 
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form trichioroacetamide 83 and regenerate the Lewis acid. Neighbouring group 
participation from the 2-0-acyl group gives the acetoxonium ion 81 which undergoes 
nucleophilic attack by the acceptor to form the 3-g1ycosidic bond of the 13-glycoside 
82. 70 
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Mechanism of the Trimethylsilyl Triflate Promoted Glycosidation with Trichioroacetimidate 
Donors. 70 
Scheme 2.11. 
2.2.7. Glycosyl 2-Pyridine Carboxylates 
Novel glycoside donors are being reported on a regular basis, amongst the 
more unusual glycosyl donors being glycosyl 2-pyridine carboxylates, reported by 
Koide and co-workers 76  which were developed on the basis of the Remote 
Activation Concept. Remote Activation, a term originally introduced by Hanessian 
and co-workers, 77  involves the activation of a suitable group on the anomeric carbon 
of an unprotected sugar producing a leaving group followed by nucleophilic attack to 
give the desired glycoside. For example, the isopropylidine protected galactoside 85 
was coupled with pyridin-2-yl thio-3-glucoside 84 in the presence of mercury (IT) 
nitrate to afford a mixture of a and n-disaccharides 86 in a moderate yield (scheme 
2.12.). 77  
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Formation of Glycosides by Remote Activation. 77 
Scheme 2.12. 
Koide and co-workers76 applied the principle of Remote Activation to 
glycosidation reactions using glycosyl pyridine carboxylates in the presence of a 
range of activators including mild Lewis acids such as copper (II) triflate and tin (TI) 
triflate to give either a or -glycosides with good stereoselectivity (scheme 2.13.).76 
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Glycosyl Pyridine Carboxylates as Glycosyl Donors. 76 
Scheme 2.13. 
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The glycosyl pyridine carboxylates, such 87 in scheme 2.13, were readily 
prepared from the tetra-o-benzyl glucose 68 and picolinyl chloride in the presence of 
triethylamine. Koide and co-workers 76 found that copper (II) triflate promoted 
glycosidations of glycosyl pyridine carboxylates afforded predominately a.- 
glycosides while tin (II) triflate promoted glycosidations gave predominately 3-
glycosides. For example, in scheme 2.14., the tin (II) triflate promoted glycosidation 
of the 1-0-methyl tri-O-benzyl glucoside 88 with benzylglucopyranosyl 2-pyridine 
carboxylate 87 as the glycosyl donor afforded predominantly the 3-D-glucoside 89 
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Influence of Promoter on Remote Activation Based Glycosidations. 76 
Scheme 2.14. 
2.2.8. Orthoester Derivatives as Glycosides 
Other novel glycosyl donors recently reported include orthoesters such as 
compound 91 (scheme 2.15.) In the presence of a Lewis acid such as mercury (II) 
bromide, loss of the alkoxy ion ( -OR') from compound 91 gives carbocation 92 
which will react with an alcohol acceptor (R 2 OH) to give a mixture of a and 3- 
glycosides such as the 1,2-trans-glycoside 93 and the 1,2-cis-glycosides 94 (scheme 
2. 15.).5661 
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Synthesis of 1-0-Glycosides Using 1, 2-Orthoesters. 
Scheme 2.15. 
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With simple orthoesters stereoselectivity is difficult to achieve and the 
alcohol released (R'OH) may compete with the intended glycosyl acceptor (R 2 OH) in 
the glycosidation reaction. To overcome this problem a sterically hindered orthoester 
is used such as tert-butyl orthoester, which will provide steric bulk, and the released 
tert-butyl alcohol will be less reactive than the glycosyl acceptor. 56,61 
An alternative route to glycosides using orthoesters has been recently 
examined by limori and co-workers 78  who examined the reduction of cyclic 
orthoesters with diisobutylaluminium hydride (DIBAH) or lithium aluminium 
hydride (LiA1H4) to obtain disaccharides in excellent yields and selectivity. 
Currently glycosyl fluorides, trichloroacetimidates, and sulfides provide the 
most widely used glycosyl donors for glycosidation reactions. New and novel 
glycosyl donors are constantly appearing in the literature and a more comprehensive 
review on glycosyl donors has been published by Toshima and Tatsuta. 79 In the 
search for new glycosidation procedures one area in particular, namely 
oligosaccharide synthesis, has provided some innovative glycosidation techniques 
including the armed-disarmed glycosylation strategy. 
2.3. The Armed-Disarmed Glycosylation Concept 
The armed-disarmed approach to glycoside synthesis was first introduced by 
Fraser-Reid and co-workers 80  who used the term to describe glycosidation reactions 
incorporating the use of pentenyl glycosides. During glycosidation reactions Fraser-
Reid and co-workers 80  found that the reactivity of glycosyl donors was decreased 
when an ester group was present at C2 (disarmed) and increased when an ether group 
was present at C2 (armed). The pentenyl group provides protection for the anomeric 
centre during protection-deprotection steps involving non-anomeric hydroxyl groups, 
and allows activation of the anomeric centre towards glycosidation reactions. 
The pentenyl group is typically formed by a silver (I) triflate or tin (IV) 
chloride promoted glycosidation using penten-l-ol as the acceptor. Activation of the 
pentenyl group is achieved by the addition of a halogen to the double bond using 
iodonium dicollidine perchlorate (IDCP) or NBS. The armed pentenyl tetra-O-
benzylglucoside 95 in scheme 2.16. is initially activated with IDCP to give the 
activated glucosyl donor 96, the pentenyl group then rearranges to give 2-
halomethylfuran 99 and the oxonium ion 97, nucleophilic attack of the oxonium ion 
97 by the desired alcohol acceptor gives the l-O-glucoside 98.56 
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Synthesis of] -O-Glycosides Using Pentenyl Glycosides. 56 
Scheme 2.16. 
Fraser-Reid and co-workers 80 have used the armed-disarmed approach to 
synthesise a variety of compounds from simple disaccharides such as the a/3 -D- 
disaccharide 101 which was synthesised from the armed pentenyl glucoside 95 and 
disarmed pentenyl glucoside 100 in scheme 2.17.80  to more complex 
heptasaccharides such as that found in the glycosyiphosphatidylinositol (GPI) 
anchor. 81 
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The Armed-Disarmed Approach to Glycoside Synthesis. 80 
Scheme 2.17. 
Pentenyl glycosides provide the opportunity to perform glycosidation 
reactions under mild conditions and provide a valuable tool for the synthesis of 
oligosaccharides. 56  The armed-disarmed strategy provides both versatility and 
selectivity for glycoside synthesis 80  and can be applied to other novel glycosidation 
procedures such as those involving glycals (section 2.5.). 
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2.4. Isopropenyl Glycosyl Donors 
The isopropenyl glycosides are similar to the pentenyl glycosides whereby, 
the propenyl group provides protection at the anomeric centre during hydroxyl group 
manipulations. Isopropenyl glycosides such as the isopropenyl glucoside 103 in 
scheme 2.18. are prepared from glycosyl halides such as the tri-O-
benzylglucopyranosyl chloride 102 with bis(acetonyl)mercury. In the presence of an 
electrophile, such as a proton, the isopropenyl group is activated, the hydroxyl group 
of the acceptor adds to the double bond of the isopropenyl glycosyl donor to give a 
mixed sugar acetal which rearranges to give acetone and the f3-glycoside. For 
example, when a Lewis acid catalyst such as TMSOTf is used, reaction with the 
glycosyl acceptor (R'OH) gives triflic acid which protonates the enol ether 104 to 
produce the carbocation 105 (scheme 2.18.). Nucleophilic attack by the silylated 
glycosyl acceptor (R'OSiMe 3 ) gives a mixed acetal 106 which rearranges with loss of 
acetone to give the oxonium ion 107. Nucleophilic attack of 107 by a second 
molecule of the silylated glycosyl acceptor (R'OSiMe 1 ) finally gives the desired 13-D-
glucoside 108. 56,82,83 
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Synthesis of] -O-Glycosides Using Isopropenyl Glycosides. 83 
Scheme 2.18. 
As observed with pentenyl glycosides, isopropenyl glycosides are a useful 
tool, providing the versatility and selectivity required for oligosaccharide synthesis. 83 
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2.5. Glycals 
Another important glycosidation procedure involves the use of glycals which 
have recently been demonstrated by Danishefsky and co-workers 84 to provide a 
useful route to a and 3-glycosides. Glycals are readily prepared from acylated 
glycosyl halides using zinc and acetic acid and when treated with electrophilic 
species such as PhSe or I from NIS, the electrophile adds across the double bond 
between Cl and C2. 56  If the 1 ,2-iodonium ion intermediate that forms is then treated 
with a nucleophile such as an alcohol, the nucleophile adds to C  to give the a or P_ 
glycosidewhile the electrophilic species adds to C2. The iodide ion influences the 
stereochemistry of the glycoside and is easily removed from the glycoside with, for 
example, nickel (II) chloride and sodium borohydride to give the 2-deoxy sugar. For 
example, the D-glucal 109 forms the iodonium ion on the 13-face of the double bond, 
addition of an alcohol acceptor, this is followed by radical displacement of iodine 
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Synthesis of 2-deoxy Glycosides From G1yca1s. 57,84 
Scheme 2.19. 
Glycals provide useful starting materials for 2-deoxy sugars and are 
extensively used for the synthesis of oligosaccharides. 56 The reaction between two 
glycals is possible using the armed-disarmed approach which allows one of the 
glycals to provide a donor function. This is achieved by protecting the free hydroxyl 
groups with ether functions while the acceptor is protected by ester groups (scheme 
2.20.). 84 
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Scheme 2.20. 
In scheme 2.20 the armed tri-O-benzyl-D-glucal 111 and the disarmed tri-O-
benzoyl-D-glucal 112 couple to afford the a-linked disaccharide 113 in good yield 
and stereoselectivity. 84 
Recently glucals have been shown by Halcomb and Danishefsky 85 to be 
useful precursors of 1,2-anhydro sugars which are potentially good glycosyl donors 
as a result of the strain in the alkoxy epoxide moiety. Glucals are readily epoxidised 
with dimethyldioxirane to afford 1 ,2-anhydro sugars, for example, when the tri-O-
benzyl-D-glucal 111 (scheme 2.20.) is treated with dimethyldioxirane the reaction 
gives the 1,2-anhydroglucoside 114 as predominately the a-anomer in high yield and 
stereo selectivity. When the 1,2-anhydroglucoside 114 is treated with a suitable 
alcohol, such as the di-O-benzyl-D-glucal 115 in the presence of zinc (II) chloride the 
epoxide ring undergoes trans-diaxial opening to afford selectively the 13-linked 
disaccharide 116 (scheme 2.21.). 85 
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Synthesis of /3-D- Glycosides from Glucals. 85 
Scheme 2.21. 
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The high selectivity of the glycosidation reaction is achieved as a result of 
nucleophilic attack on Cl equatorially, Waldern inversion at Cl then gives the 1,2-
trans configuration expected in an S2  reaction. 56 
Unfortunately anhydro sugars are not stable and dimethyldioxirane is difficult 
to use on a large scale and so interest has turned to cyclic sulfites and sulfates as 
epoxide equivalents. Cyclic sulfites such as 117 are readily prepared from glucals via 
the 1 ,2-diol using thionyl chloride or thionyl diimidazole. Oxidation of cyclic sulfites 
with permanganate, ruthenium (III) chloride or periodate affords cyclic sulfates such 
as 118 (scheme 2.22.). 56,86 
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Synthesis of Cyclic Sulfites and Sulfates. 56,86 
Scheme 2.22. 
The treatment of cyclic sulfites with lanthanide (III) triflates as glycosidation 
promoters has recently been reported by Sanders and co-workers, 86 who observed 
the stereoselective glycosidation of glucose 1,2-cyclic sulfites, for example, 119 
which coupled to benzyl alcohol to give the 3-D-glucoside 120 in a good yield 
(scheme 2.23.). 
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Synthesis of], 2-Trans-$-D-glucosides Front Cyclic Sulfites.86 
Scheme 2.23. 
2.6. Intramolecular Aglycon Delivery 
The potential of a functional moiety present on the sugar that provides both 
activation and stereo-control during glycoside formation offers a novel glycosidation 
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procedure that potentially could be of great significance in oligosaccharide synthesis. 
Intramolecular aglycon delivery provides a useful strategy for the synthesis of 1,2-
cis--D-mannopyranoside linkages which are difficult to construct using traditional 
glycosidation reactions such as the Koenigs-Knorr procedure. 56 ' 87 For glycosidation 
to occur a good leaving group, for example, a thiol group, is required at the anomeric 
position, while either a carbon bridge or a silicon bridge is present at C2. 56 Both 
approaches have been successfully used to synthesise f3-D-mannosides, for example, 
the synthesis of the 3-D-mannoside 124 using a carbon bridge by Barresi and 
Hindsgaul87 (scheme 2.24.). 
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The Intramolecular Synthesis of a f3-D-Mannodisaccharjde.87 
Scheme 2.24. 
The carbon bridge is readily prepared by the methylene-de-oxo-bi subs titution 
at the 2-0-acetate group of the 2-0-acetylbenzyl 1-thiomannoside 121 using Tebbe's 
Reagent (a titanium cyclopentadiene complex, Cp 2Ti(CH2)(Cl)AlMe,) 88 to give the 
2-0-isopropyl derivative 122 (scheme 2.24.). Coupling of compound 122 and the I - 
0-methyl tri-0-benzyl glucoside 89 at the isopropenyl group occurs in the presence 
of tosic acid to give the bridged disaccharide 123 (scheme 2.24.). The thio group of 
the bridged disaccharide 123 is activated by NIS (for mechanism see scheme 2.25.). 
Equatorial attack of the anomeric centre from the alkoxy group is followed by loss of 
acetone to afford the f-mannoside 124 exclusively. 56 
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Scheme 2.25. 
The silicon bridge is also readily prepared, for example, by condensation of a 
free alcohol group on the thiomannoside 125 with the chlorosilylether group on C2 
of the thiomannoside 126, activation of the thiol group and equatorial attack again 
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Scheme 2.26. 
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The temporary carbon and silicon connections provide a useful and 
stereoselective synthesis of glycosides particularly the difficult 1 ,2-cis-13-mannoside 
linkages. 89 
2.7. Latent-Active Glycosidations 
Influencing the reactivity of the anomeric centre towards glycosidation is a 
concept that has been examined with the armed-disarmed approach demonstrated 
with pentenyl glycosides. 80 Latent-active glycosidations also affect the level of 
reactivity of the anomeric centre to glycosidation and provide further novel routes to 
glycosides. Roy and co-workers 90 have recently reported the use of a thioglycoside 
which has an electron-withdrawing group on the thioaryl substiuent, rendering the 
thioglycosyl acceptor latent and unreactive towards glycosidation. However, on 
replacing the electron-withdrawing group with an electron-donating group the 
thioglycoside acceptor becomes active, for example, the active thioglucoside donor 
128 was synthesised from acetochioroneuraminic acid 127 using tin (II) chloride 
(scheme 2.27.). 90 
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Conversion of Latent Thioglycosyl Donor into the Active Thioglycosvl Donor. 90 
Scheme 2.27. 
Roy and co-workers90 coupled active thioglycosyl donors such as the 4-
methoxyphenylthio-c-sialy1 donor 129 to glucosyl acceptors such as the galactosyl 
acceptor 130 to give predominately the a-D-glucoside 131 in high yield (scheme 
2.28.). 90 
OAc 	 CO 0 	 NIS-TfOH. CH 1 CN/ 	OAc 	 CO,Mc OH
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.. & OMe+C 2 Cl2 2! NHAC 
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129 130 	O 	
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131 	 0 AO 
Latent-Active Approach to Glycosidation Reactions. 90 
Scheme 2.28. 
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Boons and Isles91 also examined latent-active glycosidations with 3-buten-2-
yl glycosides such as the latent 3-buten-2-yl glycoside 131 which can be isomerised 
with Wilkinson catalyst (chlorotris(triphenylphosphine)rhodium, RhCl(Ph 3 P)3 )88  into 
the active 2-buten-2-yl glycoside 132 which will undergo glycosidation reactions 
with suitable glycosyl acceptors such as the latent tri-O-benzyl glucoside 133 
(scheme 2.29.). 9 ' 
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Latent-Active Glycosidation of 3-Buten-2-3 ,1 glvcosides. 9' 
Scheme 2.29. 
The latent 3-buten-2-yl glycosides are readily prepared from the 
corresponding bromide and are stable during many functional and protecting group 
manipulations, for example, deprotection under Zemplén conditions and benzylation. 
In the presence of TMSOTf the active 2-buten-2-yl glycoside 132 couples with the 
latent 3-buten-2-yl glycoside 133 and predominately forms the 13-D-glucoside 134 in 
excellent yield providing a highly stereoselective alternative to the armed-disarmed 
glycosidation strategy. 91 
2.8. Differentially Activated Glycosyl Donors and Acceptors 
Ley and co-workers 92  have recently reported a novel approach to the 
activation of the anomeric centre involving the use of dispiroketal (dispoke) 
protected glycosides. Dispoke protection, for example in the thio galactoside 135 
(scheme 2.30.), increases the rigidity of the sugar ring and inhibits the formation of 
the flattened oxonium ion intermediate. The thio galactoside 135 may act as an 
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acceptor in the presence of mild activating conditions such as iodonium di-sym-
collidine perchiorate (IDCP), 93 which activates the armed benzyl protected thio 
galactoside 136 to afford the (X-D-galactoside 137 in good yield. Coupling of 
compound 137 and the disarmed thiomannoside 138 in the presence of strong 
activating conditions (NIS-TfOH) affords the trisaccharide 139 in good yield as 
almost exclusively the a-anomer (scheme 2.30.).92 
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Glycoside Synthesis With Dtfferentiall'y Activated Glycoside Donors And Acceptors. 92 
Scheme 2.30. 
The use of differentially activated glycosyl donors and acceptors provides a 
useful preparation of complex oligosaccharides avoiding the numerous functional 
group manipulations that are usually required. 
2.9. Glycosidations on Solid Supports 
A relatively new but rapidly expanding area of glycoside synthesis can be 
found in solid-phase chemistry where oligosaccharides or glycopeptides can be 
synthesised rapidly without the numerous isolation steps required for solution based 
oligosaccharide synthesis. Danishefsky and co-workers 94 have examined the use of 
polymer bound glycals for oligosaccharide synthesis, which have the versatile feature 
of behaving as glycosyl donors or acceptors depending on the protecting group 
present (see the armed-disarmed concept discussed in section 2.3.). The solid support 
used is a copolymer of polystyrene cross-linked with 1% divinylbenzene, and 
functionalised with triphenylsilyl chloride, which requires a simple silylation using 
Hunig's base (ethyldiisopropylamine), a good proton acceptor, 95 to afford glycal 140 
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which on epoxidation gives compound 141. Treatment of the immobilised epoxide 
141 with acceptor 140 and zinc chloride affords disaccharide 142 (scheme 2.31 .).94 





sicl + O=(' 2, 	
a. Hunig's base. CH,CI, 
___________________ 	 0 
b. 0-0 CH7CI, 	 141 Ph 










CH3 CO 2 H THF 
143 
	 nig's base = C2H5 
	
142 




Solid-Phase Oligosaccha ride Synthesis. 94 
Scheme 2.31. 
The synthetic steps epoxidation and glycosidation in scheme 2.31. can be 
repeated a number of times to obtain the oligosaccharide of the desired size, for 
example, the trisaccharide 143 in scheme 2.31., which can be cleaved from the solid 
support with tetrabutylammoniumfluoride (TBAF) and acetic acid. The average yield 
of the coupling cycle (epoxidation and glycosidation) was 70% making solid-phase 
synthesis with glycals an attractive synthetic route for oligosaccharides and 
potentially a useful glycosidation procedure. 94 
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Section Three; The Use of Enzymes in Glycosidation Reactions 
Most of the chemical glycosidations discussed in section 2 rely on the use of 
protected glycosyl donors with a selectively protected acceptor which will couple in 
the presence of a highly reactive and often expensive catalyst or promoter. An 
attractive alternative to the chemical glycosidations currently used are enzyme 
catalysed glycosidations which enable the selective synthesis of glycosides under 
mild reaction conditions and without the need for protection. 
3.1. General Features of Enzymes 
Enzymes are biological catalysts which have three distinguishing 
characteristics; 96 
Enzymes increase the rate of a reaction 
Enzyme activity can be regulated 
Enzymes display substrate selectivity 
All three characteristics are important when considering the use of enzymes 
in synthesis. The ability of enzymes to increase the rate of a reaction has been 
studied in great detail, the kinetics and the mechanisms of enzyme action are major 
fields in their own right and can provide a useful insight into how and why enzymes 
catalyse synthetically useful reactions. 96 The catalytic activity of enzymes can be 
influenced by a number of factors; the concentrations of substrates and products in 
the reaction mixture; the requirement for co-factors such as the reduced co-enzyme 
nicotinamide adenine dinucleotide (NADH); extreme heat, pH and mechanical 
damage which can denature enzymes as they are protein in nature. From a synthetic 
point of view some of the factors that regulate and so control enzyme activity can be 
problematic, for example, if accumulation of a product in the reaction mixture 
inhibits enzyme activity, or if expensive co-factors such as adenosine triphosphate 
(ATP) are required. However, some features that affect enzyme activity can be 
useful, for example, enzyme reactions are often reversible; forcing the reaction in 
one direction can afford the desired product in maximum yield with few side-
products 96 
Enzymes in their natural role display high selectivity for a specific substrate, 
however, when used for synthetic purposes, many enzymes have been found to 
exhibit broad substrate specificity enabling the synthesis of a large range of natural 
products and analogues. 48 
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As the field of biocatalysis has grown, enzymes have become common tools 
for the synthetic chemist. From a synthetic point of view enzymes provide a useful 
alternative to traditional organic chemistry, performing chemically difficult reactions 
under very mild reaction conditions of pH, temperature, and pressure. Enzymes are 
also chiral catalysts and are able to produce optically active molecules that can be 
used as the building blocks or synthons for homochiral compounds. 48 ' 97 An 
increasing number of enzymes are now commercially available and have also 
become more economical to use with the development of techniques such as enzyme 
immobilisation which increases enzyme stability and allows the catalysts to be 
recovered and reused. Enzymes that require co-factors are now cheaper to use as a 
result of the development of regenerating systems which allows catalytic amounts of 
co-factors such as ATP to be used in enzyme catalysed reactions. 98 
Enzymes are used in a wide range of reactions including C-C bond formation, 
oxidations, and glycosidations. The enzymes used in glycosidation reactions are from 
two classes; the glycosyltransferases and glycosidases. 
3.2. Glycosidation Reactions With Glycosyltransferases 
There are two classes of glycosyltransferase dependent on the type of 
glycosyl donor they accept, these are called Leloir-type glycosyltransferases and 
non-Leloir glycosyltransferases. 99 Leloir-type glycosyltransferases are the enzymes 
involved in the Leloir pathway, a biosynthetic route to sugar nucleotides discovered 
by Luis Leloir who examined the role of UDP-glucose in the biosynthesis of 
glycogen. 100 Non-Leloir glycosyltransferases are not involved in the Leloir pathway 
and include some phosphorylase enzymes such as trehalose phosphorylase and 
sucrose phosphorylase. 98 
3.2.1. Glycosidation Reactions With Leloir-Type Glycosyltransferases 
The Leloir pathway' 0 ' involves four stages with four different types of 
enzymes. 48 The first part of the Leloir pathway is the phosphorylation of sugars, this 
is catalysed by kinases such as hexokinase. Phosphoisomerases then remove a 
phosphate residue from the C6 hydroxyl group and attach a phosphate residue to the 
anomeric hydroxyl group. Pyrophosphorylases, which are also called nucleotide 
transferases, then attach nucleoside 5'-monophosphates (also called nucleotides) to 
the phosphorylated sugar producing a sugar nucleotide.' In the final step, 
Nucleotides are phosphate esters of glycosides of all heterocyclic bases, nucleosides are glycosides 
of heterocyclic bases and in particular purines and pyrimidines.22 
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glycosyltransferases transfer a monosaccharide unit from a sugar nucleotide to a 
protein, lipid or non-reducing end of a growing oligosaccharide. 98 For example, the 
Leloir pathway enzymes convert D-galactose 144 into UDP-galactose 145 which is 
used by galactosyl transferase to transfer a galactose residue to N-acetylglucosamine 
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Synthesis of N-Acetyllactosamine 147 Catalysed by Galactosyltransferase. 22 
Scheme 3.1. 
A number of compounds have been synthesised using Leloir-type 
glycosyltransferases, for example, the synthesis of disaccharides using galactosyl 
transferase from bovine milk has been reported by Nishida and co-workers1 02,103 
who used the enzyme to catalyse the transfer of galactose from UDP-galactose 145 to 
the anomeric centre of the thio-gentosamine 149 and the gentosamine 150 to give 13-
D-galactosides 151 and 152 respectively (scheme 3.2.). 
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Synthesis of Disaccharides Using Galactosyltransferase. 102,103 
Scheme 3.2. 
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Leloir-type glycosyltransferases have also been used to synthesise nucleotide 
sugars, for example, UDP-glucose pyrophosphorylase and GDP-mannose 
pyrophosphorylase from brewers yeast were used by Simon and co-workers 104  to 
synthesise nucleoside phosphate sugars. The enzymes were used to synthesise UDP-
glucose 154 and GDP-mannose 156 from cL-D-glucose-1-phosphate 153 and cL-D-
mannose- 1-phosphate 155 respectively (scheme 3.3.). 104 
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Scheme 3.3. 
Many Leloir glycosyltransferase enzymes have been used in oligosaccharide 
synthesis, galactosyl and sialyltransferases are frequently used, others include 
fucosyltransferases, glucosyltransferases and N-acetylglucosaminyltransferases 
which Kaur and co-workers 105 used to synthesise the tetrasaccharide 159 and the 
pentasaccharide 160 from the trimannoside 158 by transferring N-acetylglycosyl 
residues from UDP-N-acetylglucosamine 157 (scheme 3.4.).98 
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The Use of Transferase Enzymes in Oligosacchride Synthesis. 105 
Scheme 3.4. 
Recently the solid-phase synthesis of compounds such as oligosaccharides 
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Scheme 3.5. 
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The synthesis of the sialyl Lewis X glycopeptide 162 in scheme 3.5. has been 
examined by Schuster and co-workers 106 using a silica based solid support to which 
N-acetylglucosamine was linked through a peptide spacer 161 and monosaccharide 
units were added in a stepwise fashion. 
The synthesis of an oligosaccharide, antigen 163 which is used against 
Helicobacter pylori was achieved by Halcomb and co-workers 107  using controlled 
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Scheme 3.6. 
3.2.2. Glycosidation Reactions With Non Leloir-Type Glycosyltransferases 
Non-Leloir glycosyltransferases include trehalose phosphorylase and sucrose 
phosphorylase which have been used to synthesise trehalose and sucrose 
respectively. Nucleoside phosphorylases are non-Leloir glycosyltransferases which 
cleave the glycosidic bond of nucleosides to give the corresponding base and sugar 
phosphate and are of particular interest for the synthesis of unnatural 
nucleosides.98 ' 99 
As a result of the high regio and stereoselectivity of glycosyltransferases, 
they are potentially a valuable tool in both solution and solid-phase synthesis of 
oligosaccharides. 99 Glycosyltransferases provide a useful alternative to the current 
complex, multistep chemical synthesis of oligosaccharides, which involves selective 
protection of the acceptor hydroxyl groups, and for each glycosidation step that 
follows exposure of the hydroxyl group is required for glycosidation, and a final 
deprotection step gives the desired product. 56 In addition to oligosaccharides 
glycosyltransferases have also been demonstrated to be highly useful in the synthesis 
of a wide variety of natural and un-natural products including small saccharides and 
nucleosides. 
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Unfortunately, many glycosyltransferases are unstable and difficult to isolate, 
(especially from mammalian sources as the proteins are found in low concentrations 
and are membrane bound) hence only a small number are available from commercial 
sources. 48 '98 Little is also known about the specificity of many glycosyltransferases, 
however, as more enzymes become available, substrate specificity and their potential 
use in glycosidation reactions can be more thoroughly evaluated. 98 
3.3. Glycosidation Reactions With Glycosidases 
Glycosidases are hydrolases and in their natural role will hydrolyse glycoside 
bonds, for example, -g1ucosidase will hydrolyse the 3-glycosidic bond of the J3-D-
glucoside 164 to give D-glucose 49 and the alcohol R-OH (scheme 3.7.).22 
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The Reaction Catalysed by 13-Glucosidase. 22 
Scheme 3.7. 
The reaction catalysed by -glucosidases exists as an equilibrium and so 
changing the reaction conditions will push the equilibrium in favour of the reactants 
or products. Reverse hydrolysis occurs if the 3-glucoside is removed from the 
reaction, an excess of the starting material is present or the reaction is performed 
with the alcohol acceptor as solvent; this is the thermodynamic approach to glycoside 
synthesis using glycosidases (scheme 3.8.). A transglycosidation reaction occurs if an 
efficient leaving group is present on the anomeric carbon of the 3-glucoside glycosyl 
donor, whereby the enzyme catalyses the transfer of the glycosyl moiety to a suitable 
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Synthesis of Glucosides by Reverse Hydrolysis and Transgl)'cosidation Reactions. 108 
Scheme 3.8. 
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Transglycosidation reactions have been employed for the synthesis of a 
variety of compounds including simple glycosides and oligosaccharides. 108  The 
glycosyl donor requires a good leaving group at the anomeric centre, usually an aryl 
group such as para-nitrophenoxide 98 which can concentrate in the reaction medium 
as para-nitrophenol without poisoning the catalyst. 108  The transglycosidation 
product tends to accumulate rapidly during the reaction and can concentrate in the 
reaction medium without affecting the glycosidation reaction. 108 Glycosidases are 
substrate specific and so 3-galactosidases and -g1ucosidases are required for the 
synthesis of 3-galactosides and 3-glucosides respectively. These enzymes are readily 
available and have been used to attach glucose and galactose residues to a variety of 
alcohol acceptors. The synthesis of glycopeptide analogues and disaccharides was 
recently reported by Baker and co-workers 44 using 3-galactosidases and 13-
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Transglycosidation Reactions With J3-Galactosidase and -G1ucosidase.44 
Scheme 3.9. 
The transglycosidation reaction catalysed by 13-glucosidase with the amino 
acid derivative N-acetylamine ester 166 as the alcohol acceptor and 0-nitrophenyl-J3-
D-glucose 165 as the donor afforded the glycoside 167 and suggests the potential 
application of transglycosidation reactions to the synthesis of glycopeptides. 44 '45 The 
second transglycosidation reaction catalysed by 13  -galactosidase between glycoside 
167 and O-nitrophenyl-13-D-galactose 168 to afford the disaccharide 169 
demonstrates the usefulness of glycosidases for the synthesis of small 
oligosaccharides. 
The enzyme N-acetylhexosaminidase from Aspergillus oryzae has recently 
been shown by Sing and co-workers 109 to be a useful catalyst for transglycosidation 
reactions involving the synthesis of disaccharides. The enzyme N-
acetyihexosaminidase was used in a transglycosidation reaction between N- 
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acetylamine nitrophenyl- -D-glucose 170 and 1-0-methyl N-acetyl- a-D-glucosamide 
171 to afford the disaccharide 172 in a good yield (scheme 3.10.). 109 
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Transglycosidation Reaction Catalysed by N-Acetylhexosaininidase.'° 9 
Scheme 3.10. 
The activated glycosyl donor required for transglycosidation reactions can be 
expensive and side products formed during the transglycosidation are often difficult 
to separate from the intended product.' 10  The use of reverse hydrolysis has recently 
been considered by Vic and co-workers 46 ' 108 ' 1101 ' as a more cost effective 
alternative to trans glycosidation reactions. Reverse hydrolysis catalysed by 13-D-
glucosidase was used to transfer glucose residues onto simple alcohol acceptors in a 
reaction medium that contained tert-butanol as a co-solvent to increase the solubility 
of the alcohol acceptor (scheme 3.11.). 11 
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Glycosidation Reactions Using Reverse Hydrolysis. 111 
Scheme 3.11. 
Water is a necessary requirement for enzyme activity to be maintained 
although many enzymes can tolerate high concentrations of organic solvent.1 I I Vic 
and co-workers 1 11  found that in 80-90% tert-butanol, -D-glucosidase from almonds 
was stable and afforded glucoside 173 in 22% yield. However by using the alcohol as 
the solvent 61% yield of 173 was achieved (scheme 3.12.).''' 
The yields of reverse hydrolysis reactions are often low due to the competing 
hydrolysis reaction. To avoid this problem Mori and co-workers 1 2  have used a two 
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phase aqueous-organic reaction system with lipid coated -galactosidase. This allows 
the enzyme to exist in organic solvents, which would normally cause denaturation of 
the native enzyme. The 3-D-galactopyranoside 175 was prepared in 66% yield by 
reacting lactose 174 and 5-phenyl-l-pentanol in the presence of the lipid coated J3-
galactosidase using 2-propylether and an aqueous buffer as the biphasic solvent 
system. The reaction product 175 remains in the organic layer, therefore preventing 
its hydrolysis by the galactosidase (scheme 3.12.).1 12 
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Reverse Hydrolysis with Lipid Coated f3-Galactosidase." 2 
Scheme 3.12. 
An interesting feature of the use of 3-glucosidase in reverse hydrolysis 
reactions is the broad substrate specificity that this enzyme has been found to exhibit. 
For example, when 2-hydroxybenzyl alcohol is used as the acceptor 3-glucosidase 
catalyses the coupling of both D-glucose 49 and D-galactose 144 to 2-hydroxybenzyl 
alcohol affording 2-hydroxybenzyl-f3-D -galactopyranoside 176 and 2-
hydroxybenzyl-3-D-glucopyranoside 177, respectively, both in 9% yield (scheme 
3.13). 108  
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Example of the Broad Specificity of /3-Glucosidase in Reverse Hydrolysis Glycosidations.'° 8 
Scheme 3.13. 
Other enzymes, for example, lipases and proteases are useful for the synthesis 
of chiral starting materials or to catalyse specific functional group transformations 
(enzyme catalysed acylation and deacylation reactions are discussed in section four) 
further demonstrating the extensive applications of enzyme catalysed reactions in 
carbohydrate chemistry. 99 
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Section Four; Enzyme Catalysed Acylation and Deacylation Reactions 
Glycosidation reactions are only one of a wide range of chemical reactions 
that enzymes can catalyse. Since the mid 1980's there has been an enormous amount 
of research into the use of enzymes and whole cells in organic synthesis; biocatalysis 
is now a well established area within this field. Enzyme catalysed acylation and 
deacylation reactions were used in the synthetic routes examined towards M6G 23, 
and provided a useful alternative to the chemical manipulations currently available. 
In general, regioselective acylations and deacylations under acid or base catalysed 
conditions can only be achieved with the careful choice of protecting group and by 
using reaction conditions which exploit the different labilities and cleavage 
conditions required for protecting groups. The use of enzymes provides the 
opportunity to achieve regioselective acylations and deacylations under mild 
conditions and has become a common feature in the synthesis and manipulation of 
carbohydrates; several reviews on the use of enzymes for selective acylation and 
deacylation reactions in carbohydrate chemistry have been published by 
Drueckhammer et a148 and Bashir and co-workers. 113 
The use of enzymes in synthesis exploits their natural catalytic abilities, 
esterases in particular are attractive for synthetic work being readily available, 
inexpensive, and stable. 96  Esterases are a class of hydrolase enzymes which catalyse 
the hydrolysis of ester bonds to give the alcohol and carboxylic acid (scheme 4.1.).22 
Esterase 
0 	 +H-,O 	0 
II II 	 + 	R'— OH 
R—C— OR' 	-H-,O 	R—C—OH 
The Hydrolysis of Esters Catalysed ky Esterases. 
Scheme 4.1. 
The hydrolysis reaction is reversible and so the removal of water or the 
presence of excess alcohol will force the equilibrium in favour of the acylation 
reaction (reverse hydrolysis), esterases can therefore catalyse the acylation of 
alcohols and the deacylation of esters. A frequently used and versatile class of 
esterase are lipases which are inexpensive, have high stability, and are used in a 
variety of acylation and deacylation reactions. 50,113  The natural substrates of lipases 
are glycolipids, whereby the enzyme hydrolyses ester bonds to release the 
component fatty acids. 22 However, lipases are found to exhibit a lack of substrate 
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specificity and will accept a variety of compounds making these enzymes 
particularly useful for synthetic work. 96 
Proteolytic enzymes or proteases are another class of enzymes that can 
participate in acylation and deacylation reactions. Proteases catalyse the hydrolysis 
of peptide bonds exposing the carboxylic acid group of one peptide and the amine 
group of another (scheme 4.2.).22 
Protease 
	
HO 	Me 	 HO 	 Me  
+I 	II I 	II - 	+H2O 	+ 	I 	II + 	I 	II 	- 
H3N—C—C—N—C—00 - H 3 N— C—C—OH + H 3 N—C — C- 0 
H 	H H 	
-H20 	 H 	 H 
The Hydrolysis of Peptides Catalysed by Proteases.22 
Scheme 4.2. 
The hydrolysis reaction catalysed by proteases is reversible and an amine 
group can be esterified if water is removed or excess acid is present. 
4.1. Enzyme Catalysed Acylation Reactions 
There are two potential routes towards the synthesis of esters with esterases 
and proteases; direct esterification and transesterification. 114 
4.1.1. Enzyme Catalysed Direct Esterifications 
The direct esterification of compounds with esterases and proteases offers 
some practical difficulties; the presence of excess acid is required, which lowers the 
pH of the reaction medium and may inactivate the enzyme, and the ester produced in 
the reaction may be susceptible to hydrolysis. These problems can be overcome by 
conducting the reaction in organic media, for example, Candida cylindracea lipase 
(CCL) will catalyse the esterification of R-acid 178 with butanol in hexane (scheme 
4.3.). 114 
X 	 x 	 x 
CI or Br 	
CCL, hexane 
[ R = Me, Me(CH2)3 or Me(CH - 	
R - C - CO2H - 	 R - C - CO2Bu + R - C - 
I 	 BuOH 	I 
H H 	 H 
178 	 179 	 180 
CCL Catalysed Direct Esterification of Acids. 114 
Scheme 4.3. 
The use of excess alcohol forces the reaction towards esterification with the 
R-acid 178 providing the substrate to give the R-ester 179. The S-acid 180 is not 
used as a substrate by the enzyme and remains in the reaction medium. 
Unfortunately, with direct esterification reactions the product will be hydrolysed by 
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the enzyme back to the acid and the alcohol which explains the low yields observed 
for these reactions. 14 
4.1.2. Enzyme Catalysed Transesterifications 
Transesterifications provide a useful alternative to direct esterifications and 
involve the use of high concentration of the ester (the acyl donor) which is 
transferred to a free hydroxyl group on the acyl acceptor. 48 The use of activated 
esters such as trihaloethyl esters 115  and anhydrides 116  as acyl donors facilitates the 
reaction and makes it kinetically irreversible. 114  Lipases in particular are very useful 
in transesterification reactions demonstrating broad substrate specificity, 
regio selectivity and enantio selectivity. The regioselectivity of lipases has been 
demonstrated by Therisod and Klibanov 115 who found that D-glucose 49 can be 
acylated selectively at C6 using 2,2,2-trichioroethyl butyrate in a reaction catalysed 
by porcine pancreatic lipase to afford the 6-0-butyrylglucose 181 in 50% yield 
(scheme 4.4.).115 





porcine pancreatic lipase HO 	
O\ 
HO-.-L.. OH 	 OH 
HO 	 HO 
50% 
49 	 181 
Acylation of D-Glucose 49 Catalysed by Porcine Pancreatic Lipase. 115 
Scheme 4.4. 
Transesterifications catalysed by lipases will generally occur at the primary 
hydroxyl group as it is the least sterically hindered, however, if the primary hydroxyl 
group is protected selective acylation at the secondary hydroxyl groups C2 and C3 is 
possible. 48 This has been demonstrated by Therisod and Klibanov' 17  who found that 
lipases in particular could discriminate between the four remaining hydroxyl groups 
of a C6 protected sugar (scheme 4.5.).117 
OCOCH 7 
o 	OH THF, porcine pancreatic lipase, 	 0
HO 	 OH 




181 	 182 
The Selectivity of Porcine Pancreatic Lipase with C6 Protected Glucose. 117 
Scheme 4.5. 
When 6-0-butyrylglucose 181 was treated with porcine pancreatic lipase the 
enzyme displayed a strong preference for the C2 position resulting in the formation 
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of 2,6-di-O-butyrylglucose 182 (scheme 4.4.). Of the other enzymes examined. 
Aspergillus niger lipase was found to be selective for the C3 position and catalysed 
the acylation of 181 to give 3,6-di-o-butyrylglucose. 117 
The regioselectivity of lipase catalysed transesterifications has been 
particularly useful for the selective acylation of compounds with multiple hydroxyl 
groups. For example, the acylation of nucleosides was recently reported by Uemura 
and co-workers 116 who used Pseudomonas fluorescence lipase to acylate 2'-
deoxyuridine 183 with hexanoic anhydride in dimethylacetamide (DMA) to give 2'-
deoxy-5-0-hexanoyluricline 184 in 73% yield (scheme 4.6.). 
0 
O 
C 5 H 11 OCO. 
1 	o 
Pseudomonas fluorescence lipase 
(C5H 11 C0) 20, DMA 	OH 
73% 
OH 
183 	 184 
The Selective Acylation of Nucleosides with Lipases." 6 
Scheme 4.6. 
Proteases also have broad substrate specificity, regioselectivity, and 
enantioselectivity; this has been demonstrated by Margolin and co-workers 118 who 
recently reported the use of the protease Subtilisin Carlsberg to acylate the plant 
alkaloid castanospermine 185, a potential anti AIDS drug (scheme 4.7.). 
OH 	OH 	 OHH OCOC3H7 
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82% 
Substilin Carlsberg, Py, 
C3H7CO2CF{ 2 CC1 3 
OH H OCOCH7 
( 
C3H70CC 	
+ 	 HO  
HO" 	 C3 H7 Oc" 
8% 	 20% 
188 	 187 
Regioselective Acylation of Castanospermine with Substilin Carlsberg. 118 
Scheme 4.7. 
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When castanospermine 185 is treated with 2,2,2-trichioroethyl butyrate and 
Subtilisin Carlsberg, the Cl hydroxyl group is selectively acylated to give 1-0-
butyry1castanospermine 186 in 82% yield (scheme 4.7.). Subtilisin Carlsberg was 
also found to display selectivity and when the Cl position was protected would 
acylate primarily at C6 to give 1,6-0-butyrylcastanospermine 187 in 20% yield and 
the 1 ,7-o-butyrylcastanospermine 188 in 8% yield. The enzyme accepted a variety of 
acyl donors as substrates and no multiple acylations of castanospermine 185 were 
observed. The broad substrate specificity and enantioselectivity of Subtilisin 
Carlsberg make this enzyme a potentially useful tool in synthetic organic chemistry. 
One of the main problems with esterase catalysed transesterifications is a 
tendency for the enzyme to hydrolyse the newly formed ester bond which can give 
low yields. A recent development in transesterifications has been the use of unstable 
alcohols as acyl donors, for example, enol esters which allow the reversible acylation 
reaction to become irreversible. When enol esters are used the enol released during 
the transesterification spontaneously toutomerises into an aldehyde or ketone causing 
the reaction to become irreversible. 119 For example, the enol ester vinyl acetate was 
used by Ho11a 120 as the acyl donor for the irreversible acylation of glycals (scheme 
4.8.). 
HO 	 HO 
('I  
H Lipase S-VII, powdered 
OH 	4A sieves, H20 	 OH 
0 	CH,OH 	 OCOCH3 	 0 	CH,OAc 
93% 
189 	 190 
Lipase Catalysed Acylation of G1'cals.'2° 
Scheme 4.8. 
A number of lipases were examined by Holla 120 and lipase S-VII in 
particular was found to catalyse the acylation of D-galactal 189 at the primary 
hydroxyl group to give 6-0-acetyl-D-galactal 190 in excellent yield (scheme 4.8.). 
Glycals are useful synthons in carbohydrate chemistry and enzyme catalysed 
acylations of these compounds are highly useful reactions. 120 
Esterases and proteases are usually used to acylate free hydroxyl groups and 
will accept a variety of substrates. Recently it has been shown by Orsat and co-
workers 119 that these enzymes are also capable of protecting amines when vinyl 
carbonates are used as the donor (scheme 4.9.). 119 
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The Protection of Amines as Carbamates Catalysed by the Protease Subtilisin BPN'. 119 
Scheme 4.9. 
The protection of 2-deoxystreptamine 191 with diallyl carbonate was 
catalysed by subtilisin BPN' to afford the carbamate 192 in good yield and high 
enantioselectivity (99% ee.) (scheme 4.8.). 119 The reactions showed high chemo-
and enantio selectivity and the low cost of homocarbonates makes the protection of 
amines as carbamates an attractive proposition. 
4.2. Enzyme Catalysed Deacylation Reactions 
The hydrolysis reaction catalysed by lipases and esterases provides an 
effective means for the selective cleavage of one or more ester groups in 
polyacylated compounds. The selective deacylation of fully acylated sugars has been 
well studied and lipases in particular have provided a useful alternative to the tedious 
chemical steps required to expose a desired hydroxyl group. In a fully acylated sugar 
the anomeric hydroxyl group is generally the most easily cleaved, 48 this has been 
demonstrated by Hennen and co-workers 50 who have found that porcine pancreatic 
lipase and Aspergillus niger lipase are the most effective enzymes for this reaction. 
For example, porcine pancreatic lipase in 10% dimethylformamide (DMF) cleaved 
the Cl acetate of 3-D-glucose pentaacetate 193 to afford glucose tetraacetate 194 in 
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Lipase Catalysed Selective Deacylation at Cl of a Polyacylated Glycosides. 50 
Scheme 4.10. 
Hennen and co-workers 50 also found that in acetylated methyl glycosides, the 
primary hydroxyl group was selectively cleaved; the lipases catalysing this reaction 
were found to favour ester groups with longer chain lengths. For example, Candida 
cylindracea lipase catalysed the deacylation of the C6 ester in 1-0-methyl -D- 
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glucose tetraoctanoate 196 and 1-0-methyl (-D-glucose tetrapentanoate 195 in good 
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Lipase Catalysed Deacylation at C6 of Acyl Protected Glycosides. 50 
Scheme 4.11. 
Hennen and co-workers 50 observed that the use of organic solvents in lipase 
catalysed deacylation reactions enhanced enzyme selectivity and improved the 
solubility of hydrophobic compounds. 48 In general only a thin layer of water is 
required to retain a catalytically active conformation 121  and lipases have been found 
to operate best at water-organic interfaces. 96 The solvent systems generally used for 
lipase catalysed reactions are monophasic organic solvents, however, the use of co-
solvents, such as t-butanol, acetone, 122 and DMF, 50 in a biphasic (water-organic) 
solvent system have been found to enhance the yields, selectivity, and improve the 
solubility of hydrophobic substrates. 48 ' 50 
Although lipases exhibit a good degree of tolerance to organic media, 
denaturation is still a problem and some recent publications have approached this 
difficulty in various ways, for example, by using lipid coated lipases; reported by 
Okahata and co-workers, 123 dialysis membrane enclosed lipases; reported by 
Bednarski and co-workers, 124 and lipases immobilised on anion exchange resin by 
Ballesteros and co-workers. 49 Immobilisation of enzymes onto an insoluble support 
(e.g. beads or resins) allows easier separation of the enzymes from the reaction 
products and also offers the opportunity to recycle the enzyme which is attractive for 
large scale reactions. 124 
Esterases have also proved useful in selective deacylation reactions of 
polyacylated compounds. For example, Uemura and co-workers 125  have found that 
the protease substilisin from Bacillus subtilis cleaves the primary and secondary acyl 
group of pyrimidine nucleosides such as 3',5'-di-o-hexanoyluridine 197 to give the 
2'-deoxy-3'-o-hexanoyluridine 198 in 31% yield and 2'-deoxyuridine 199 in 45% 
yield (scheme 4.12.). 125 
61 






HO 	 + u 
H 	DMF/phosphate buffer 	
OH OCOCH11 
31% 





Subtilisin Catalysed Deacylation of Pyrimidine Nucleosides. 125 
Scheme 4.12. 
The proteases substilisin in common with lipases is able to tolerate dry 
organic solvents 126 and the use of co-solvents such as DMF enhances selectivity and 
substrate solubility. Unfortunately in the conditions used by Uemura and co-
workers 125  substilisin could not distinguish between the primary and secondary acyl 
group and better selectivity was achieved with Pseudomonas fluorescens lipase 
which cleaved the C3 acyl group affording the 2'-deoxy-5'-O-hexanoyluridine 200 in 
a yield of 71% and 2'-deoxyuridine 199 as the minor product in a yield of 23%. 125 
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Chapter Two; Results and Discussion 
Section One; Chemo -Enzymatic Approaches to M6G 
1. Synthesis of M6G; Synthetic Route One 
Synthetic route 1 incorporates the use of 3-glucosidase to catalyse a 
transglycosidation reaction between a glycosyl donor 33 which has a good leaving 
group, and a morphine derivative (the alcohol acceptor 32 or 20). Thereafter, 
selective oxidation of the C6' hydroxyl group of the resulting 3-0-pivaloylmorphine 
glucoside 201 or morphine-6-glucoside 31, followed by removal of the protecting 
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Proposed Synthesis of M6G 23; Synthetic Route One. 
Scheme 1.1. 
The availability of some starting materials, particularly the morphine 
derivatives, was limited and model studies were used to establish suitable conditions 
for each step of the synthetic routes examined. Some of the model studies gave 
interesting results and are discussed with the reactions involving the morphine 
compounds. 
The first step of route one is a transglycosidation catalysed by 3-g1ucosidase 
from almonds. The enzyme 3-glucosidase is a hydrolase which can be used for 
glycosidation reactions under certain conditions, catalysing either reverse hydrolysis 
or a transglycosidation reaction. 108 A transglycosidation reaction was used as the 
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yields are generally higher than those of reverse hydrolysis, and 3-glucosidase from 
almonds had already been shown to catalyse transglycosidation reactions with a 
number of alcohol acceptors. 44 '45 
1.1. 13 -Glucosidase Catalysed Transglycosidation Reactions 
To establish suitable conditions for a transglycosidation reaction with the 
morphine derivatives available, namely 3-0-pivaloylmorphine 32 (for synthesis see 
appendix A. 1.) and morphine sulphate 20, transglycosidations with simple alcohol 
acceptors were initially examined in a model study. 
1.1.1. Model Study 
The acceptor 2-cyclohexen-1-ol 204 provides a good model for the morphine 
1 structure since it contains an allylic alcohol. A transglycosidation catalysed by 13-
glucosidase from almonds with excess 2-cyclohexen-1-ol 204 and p-nitrophenyl-3-D-
glucose 33 as the glycosyl donor afforded cyclohex-2-enyl 13-D-glucoside 202 in 7% 
crude yield (scheme 1.2.). 
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Ac 	203 	 1 	J 
Synthesis of the Cyclohexenyl Tetraacetyl-f3-D-glucoside 203 via a /3-glucosidase Catalvsed 
Transglvcosidation. 
Scheme 1.2. 
After isolation and purification, the transglycosidation product was acetylated 
to afford the cyclohexenyl tetraacetyl- 13-D-glucoside 203 in 1% overall yield. The 'H 
NMR spectrum of the acetylated transglycosidation product 203 revealed two 
anomeric protons as expected for a mixture of two diastereoisomers, however, the 
relative heights of the two peaks were in a ratio of 3:2. The 13-glucosidase was, 
therefore, displaying stereoselectivity, and this observation stimulated interest in 
examining related alcohols as potential acceptors for this 13-glucosidase. 
A number of allylic alcohols were either purchased or synthesised and used 
as acceptors in a series of 13-glucosidase catalysed transglycosidations (figure 1.1.). 
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The alcohol 2-cycloheptan-1-ol 206 was synthesised in 80% yield using a procedure 
reported by Gemal and Luche 127 which involved the reduction of 2-cycloheptanone 
with sodium borohydride. 
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OH 
OH 
204 	6 iIII1_1 	210 
OH 	
OH 211 205 
HO 	
OH 212 6  206 
OH 






-'OH 	 L-OH 	
215 
Alcohol Acceptors for 3-G1ucosidase from Almonds Catalysed Glycosidatioiis. 
Figure 1.1. 
Among the transglycosidation reactions attempted, the most successful 
alcohol acceptors were phenethyl alcohol 205 and 2-cycloheptan-1-ol 206, where the 
transglycosidation products 216 and 218 were afforded in crude yields of 15% and 
2% respectively. The compounds were isolated as the acylated glycosides, phenethyl 
tetraacetyl-f3-D-glucoside 217 and cycloheptenyl tetraacetyl-3-D-glucoside 219 in 
13% and 1% yield respectively (scheme 1.3.). 
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Synthesis of the Phenethyl Tetraacetyl-/3-D-glucoside 217 and the Cycloheptenvi Tetraacetvl-/3-D- 
glucoside 219. 
Scheme 1.3. 
Comparison of the relative peak heights for the anomeric protons in the 'H 
NMR spectrum of the cycloheptenyl tetraacetyl-f3-D-glucoside 219 revealed a 3:2 
ratio of diastereoisomers. This was also observed with the synthesis of the 
cyclohexenyl tetraacetyl-3-D-glucoside 203 confirming the enzyme has a preference 
for either the R or S isomer of cyclic allylic alcohols. 
The success of alcohol acceptors as substrates for 3-glucosidase depends on 
the ability of the alcohol to enter the active site of the enzyme and associate with the 
glycosyl donor. However, the exact mechanism of the hydrolysis reaction catalysed 
by -glucosidases from almonds is still not fully understood. 128 
The glucosidases obtained from plants are often present in multimolecular 
forms, 3-g1ucosidase from almonds is a mixture of at least two isoenzymic forms 
which have different kinetic properties and so mechanistic studies of this plant 
enzyme are difficult, and there is only a limited amount of basic structural and 
mechanistic information available. 128 
Other 3-glucosidases isolated from bacteria and fungi have been studied more 
thoroughly and mechanisms of reverse hydrolysis and transglycosidation reactions 
have been proposed. 48" 29 The reactions are thought to occur with initial loss of the 
anomeric group (as water or alcohol respectively) from the glycosyl donor within the 
active site of the enzyme. The resulting intermediate is stabilised by carboxyl groups 
attached to amino acid residues (aspartic acid or glutamic acid), if this stabilisation is 
concerted then retention of configuration occurs and nucleophilic attack by the 
M. 
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Proposed Mechanism of Reverse Hydrolysis and Transglycosidation Reactions. 
Scheme 1.4. 
The failure of the transglycosidations with the alcohol acceptors 207 to 215 
was probably as a result of the alcohol acceptors either being too sterically hindered 
to enter the active site, for example, benzhydrol 207, or if small enough to enter 
could either not associate with the glycosyl donor within the active site or if 
glycosidation did occur, the rate of cleavage of the newly formed glycosidic bond 
exceeded the rate of glycosidation. 
The partial success of the model studies with 3-g1ucosidase from almonds 
was followed by an attempt to use the enzyme to catalyse the synthesis of morphine-
6-glucoside 31. 
1.1.2. Attempted Synthesis of Morphine-6-glucoside 
A -glucosidase catalysed transglycosidation with 3 -O-pivaloylmorphine 32 
was examined first; the glycosyl donor 33 was consumed after 15 hours and 3-0-
pivaloylmorphine-6-3-D-glucoside 220 was not detected. It was thought the poor 
solubility of 3-0-pivaloylmorphine 32 in the aqueous reaction medium could be a 
factor in the failure of the reaction so a second transglycosidation reaction was 
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consumed in 4 hours but despite the addition of further glycosyl donor the presence 
of morphine-6-glucoside 31 was not detected and the reaction was terminated after 
36 hours. As morphine sulphate 20 was freely soluble in the reaction medium, 
solubility was not a factor in the failure of the reaction and it was more probable that 
3-0-pivaloylmorphine 32 and morphine sulphate 20 were too bulky to participate as 
substrates for the enzyme. 
As a result of the failure of the 3-glucosidase catalysed transglycosidation 
reactions attempted using morphine compounds as acceptors, the synthesis of M6G 
23 was examined using synthetic route two. 
2. Synthesis of M6G; Synthetic Route Two 
Synthetic route 2 incorporates a TMSOTf promoted glycosidation between an 
acyl protected glycosyl donor such as 3-D-glucose pentavalerate 34 and 3-0-
pivaloylmorphine 32 as the acceptor to afford 3-0-pivaloylmorphine-6-(tetravaleryl)-
f3-D-glucoside 35. Selective deprotection of the primary valeryl group of the 
glucoside 35 via an enzyme catalysed reaction is followed by oxidation of the C6' 
hydroxyl group and deprotection to afford M6G 23 (scheme 1.5.). 
TMSOTf promoted coupling 
Selective deacylation at C6 with lipase 
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Proposed Synthesis of M6G; Synthetic Route Two. 
Scheme 1.5. 
The use of traditional Koenigs-Knorr catalysts in the synthesis of M6G 23 is 
not suitable as any contamination with heavy metal ions means that M6G 23 could 
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not be used as a medical drug. The use of TMSOTf provides an attractive alternative 
as heavy metals are avoided, hence, a TMSOTf promoted coupling was examined as 
the first step of route two. 
2.1. TMSOTf Promoted Couplings 
TMSOTf promoted glycosidations of morphine derivatives with acylated 
glycosyl donors have been examined at Salford Ultrafine Chemicals. 30 The 
conditions developed there were examined in a model study before attempting the 
glycosidation reaction on the morphine compounds of interest. 
2.1.1. Model Study 
A TMSOTf promoted coupling between methyl tetraisobutyry1-3-D-
glucuronate 221 and 3-0-pivaloylmorphine 32 afforded 3-o-pivaloylmorphine 
triisobutyry1-3-D-glucuronate 222 in 48% yield (scheme 1.6.). 
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TMSOTf, 4-5 C, Ar, 32, 
CO,Me 
PrCO 	








221 	 'PrCO, 	 0 	222 
'PrCO, 
Synthesis of 3-0-Pivaloylmorphine Triisobutyryl-13-D-glucuronate 222. 
Scheme 1.6. 
The yield was comparable to that reported previously (55%)130  and although 
the melting point was slightly lower than the reported value of 199-200 °C1 30 
(uncorrected), elemental analysis and spectroscopic data suggested a high degree of 
purity for the isolated compound. 
The 'H NMR spectra of 3-0-pivaloylmorphine triisobutyryl- f3 -D-glucuronate 
222 showed the anomeric proton signal of the sugar residue as a doublet with a 
coupling constant of 8 Hz, typical for 3-glycosides, at a chemical shift of 8 4.95 ppm. 
Of the morphine protons, the CIO equatorial proton appears as a doublet at 6 3.04 
ppm with a large geminal coupling constant of 19 Hz. The unusually large geminal 
coupling for the protons at CIO occurs as a result of the close proximity of the 
aromatic ring allowing an overlap between the C-H bond and the it bond of the ring. 
The C 10 equatorial proton also lies at a dihedral angle of about 90° to the C9 proton 
and so according to the Karplus equation, no coupling exists between these two 
protons and only geminal coupling is observed. The axial proton at CIO is found as a 
EG 
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doublet of doublets at ö 2.30 ppm and has a dihedral angle of approximately 300  to 
the C9 proton enabling coupling between these protons to occur. 
The conditions examined for the TMSOTf promoted coupling did not include 
the presence of an acid scavenger such as 2,4,6-collidine (2,4,6-trimethylpyridine) 
which is sometimes required in order to neutralise the triflic acid that forms during 
the reaction, preventing the acid attacking the newly formed glycosidic bond (for 
mechanism see introduction scheme 2.7.).61131  Recent investigations have shown 
that the presence of 2,4,6-collidine can result in the formation of orthoester side 
products, 52 ' 132 thus, it was not used in any of the TMSOTf promoted glycosidations 
of the morphine derivatives examined. 
Having established the conditions for TMSOTf promoted couplings with 
morphine derivatives the synthesis of 3-0-pivaloylmorphine tetravaleryl-3-D-
glucoside 35 was examined. 
2.1.2. Synthesis of 3-0-Pivaloylmorphine Tetravaleryl- 3-D-glucoside 
The TMSOTf promoted coupling between 3-0-pivaloylmorphine 32 and an 
inseparable mixture of the -D-glucose pentavalerate 34 and the a-D-glucose 
pentavalerate 225 afforded 3 -O-pivaloylmorphine tetravaleryl- 13-D -glucoside 35 in 
14% estimated yield (scheme 1.7.). 
OVal 	 TMSOTf, 4-5 'C, Ar, 32, 
ValO 	
(CH2C1)2, 4 A sieves, 4 h 







Synthesis of 3-0-Pivaloylnzorphine Tetravaleryl-f3-D-glucoside 35. 
Scheme 1.7. 
The yield of the coupling reaction was lower than expected, yields in excess 
of 50% are common for TMSOTf catalysed glycosidations of morphine derivatives 
and glycosyl trichloroacetimidates. 39 '40 ' 130 However, as the quantity of 3-D-glucose 
pentavalerate 34 used in the glycosidation reaction was estimated, the yield of 3-0-
pivaloylmorphine tetravaleryl-f3-D-glucoside 35 could only be approximated. 
The mixture of the f3-D-glucose pentavalerate 34 and a-D-glucose 
pentavalerate 225 (in a 3:1 ratio respectively) used as the glycosyl donor in the 
coupling reaction was obtained from the base catalysed acylation of D-glucose 49 
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with valeryl chloride and pyridine (which supplied both solvent and base catalyst) in 
quantitative yield (scheme 1.8.). 
OH 















ValO 	I ValO 
oval 
225 	 34 
Thermodynamic product 	 Kinetic product 
(minor anomer) 	 (major anomer) 
Quantitative yield 
Synthesis of /3-D-Glucose Pentavalerate 34 and a-D-Glucose Pentavalerate225. 
Scheme 1.8. 
The mixture of 13-D-glucose pentavalerate 34 and a-D-glucose pentavalerate 
225 was isolated in a ratio of 3:1 respectively. The anomeric ratio was estimated 
from the relative peak heights of the anomeric protons in the 'H NMR spectrum and 
is strongly influenced by the anomeric effect. When D-glucose 49 is dissolved in 
pyridine an equilibrium develops between the a and 13 anomers. As a result of the 
repulsion between the lone electron pair of the ring oxygen and the lone electron pair 
of the Cl oxygen (the kinetic anomeric effect), the anomeric hydroxyl group of 13-D-
glucose 224 is more reactive than that of the a-D-glucose 223. This means that the 
acylated 13-anomer, the kinetic product of esterification, forms faster than the 
acetylated a-anomer. However, the anomeric effect also favours an axial 
configuration for electron-withdrawing groups such as esters at C  which means that 
in the presence of acid, anomerisation of the acylated product will occur to give the 
a-anomer exclusively. 56 
Unfortunately the base catalysed acylation of D-glucose 49 did not produce 
the 13-anomer exclusively and the temperature of the acylation reaction needed to be 
increased so that the rate of equilibrium between a-D-glucose 223 and 13-D-glucose 
224 was greater than the rate of acylation of a-D-glucose 223 so that only 13-D-
glucose 224 is acylated affording 13-D-glucose pentavalerate 34 exclusively. 
The anomeric effect is the preference for substituents on the anomeric carbon of sugars to adopt the 
sterically more hindered axial position. 56 
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Alternatively a different base, for example, sodium valerate could be used for the 
acylation reaction. This reaction is a modification of the synthesis of 3-D-glucose 
pentaacetate 193 using D-glucose 49 in hot acetic anhydride which is treated with 



























Synthesis of the AD-Glucose Pentancetate 193•56 
Scheme 1.9. 
A high yield of 3-D-glucose pentaacetate 193 is obtained as a result of 
anomerisation of the acetylated products via the acetoxonium ion 226, therefore, the 
acylated 13-anomer, the kinetic product of acylation, is obtained in excess. However, 
this reaction still gives some (X-D-glucose pentaacetate 227 and this would probably 
occur if the reaction was adapted for the synthesis of 3-D-glucose pentavalerate 34. 
Improving the yields of Koenigs-Knorr glycosidations can be achieved with 
the presence of excess alcohol acceptor, although the presence of excess 3-0-
pivaloylmorphine 32 did not appear to be significantly advantageous in improving 
the yield of the TMSOTf promoted glycosidation reaction examined. 
A sufficient quantity of 3-0-pivaloylmorphine tetravalery1-3-D-glucoside 35 
was available for the second step of synthetic route two, a selective deacylation of 
the C6' valeryl group catalysed by a lipase. 
2.2. Lipase Catalysed Deacylations 
Lipases are now widely used in deacylation reactions and provide the most 
effective means for the selective cleavage of ester groups in polyacylated sugars. 48 
The selective cleavage of ester groups within glycosides has been demonstrated by 
Hennen and co-workers 50 who reported that acylated furanose and pyranose 
derivatives can be selectively deacylated at Cl and C6 with the lipase favouring an 
optimal ester group chain length of five carbons. This stimulated interest in the use of 
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lipases in the synthesis of M6G 23 and a selective deacylation catalysed by a lipase 
was incorporated into synthetic route two. 
In order to establish suitable conditions for the lipase catalysed deacylation of 
the valeryl group at C6' of 3-0-pivaloylmorphine tetravaleryl-3-D-glucoside 35, 
enzyme catalysed deacylations of 1-0-methyl a-D-glucoside tetravalerate 195 and a-
D-glucose pentavalerate 225 were examined using the conditions reported by Hennen 
and co-workers. 50 
2.2.1. Model Study 
The selective removal of the C6 valeryl group of 1-0-methyl tetravaleryl-a-
D-glucoside 195 and a-D-glucose pentavalerate 225 with Candida cylindraceae 
lipase afforded 1-0-methyl trivaleryl-a-D-glucoside 229 in 56% yield and a-D-
glucose tetraavalerate 228 in 45% yield (scheme 1.10.). 
OVal 	i. Ca,,dida cylindreaceae lipase, 10% phosphate 	OH 
ValO 	




OR' 	I Starting Material 	Product 	Yield 1 	OR2 
R'=VaI; 225 	R2=Val; 228 	45% I 
R 1 =Me; 195 	R2=Me; 229 	56% 
Synthesis of] -0-Methyl 2,3,4-Tri-0-valeryl-a-D-glucoside 229 and 2,3,4, 6-TetraO-va/er/-a-D- 
Glucose 228. 
Scheme 1.10. 
Examination of the 'H NMR spectra for the isolated products revealed the 
loss of one valeryl group and a reduction in the chemical shift value of the C6 
protons. The chemical shift values for the C6 protons of a-D-glucose pentavalerate 
225 and 1-0-methyl tetravaleryl-a-D-glucoside 195 were 4.06 and 4.17 ppm, and 
4.14 ppm respectively, the chemical shift values for compounds 228 and 229 were 
3.64 and, 3.60 and 3.80 ppm respectively. This reduction in the chemical shift value 
was expected for the removal of the ester group from the C6 position and confirmed 
the identity of compounds 229 and 228 as 1-0-methyl trivaleryl-a-D-glucoside and 
the a-D-glucose tetraavalerate respectively. 
In agreement with Hennen and co-workers 50 100% regioselectivity was 
observed for the lipase catalysed deacylation although the yield was lower than the 
75%-90% previously reported. 50"22 The reaction time of 6 days was twice as long as 
that reported by Sweers and Wong 122 and the optical rotation of [a] 16  +91.50 (c 
0.41, CHC1 3 ) was lower than the value of [a] 2 +98.2 (c 0.55, CHCJ 1) reported by 
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Sweers and Wong. 122  The Candida cylindraceae lipase used in the deacylation 
reaction was purchased from the same supplier as Hennen and co-workers, 50 
however, the slow reaction time and lower yield of the 1-0-methyl trivaleryl-a-D-
glucoside 229 isolated in scheme 1.10. would suggest the enzyme had lower unit 
activity than the enzyme used by Hennen and co-workers 50 or Sweers and Wong. 22 
Synthesis of 1-0-methyl tetravaleryl-a-D-glucoside 195 and the a-D-glucose 
pentavalerate 225 was achieved by treating methyl a-D-glucoside 230 and D-glucose 
49 respectively, with valeric anhydride and a catalytic amount of perchioric acid 
(scheme 1.11.). The acid catalysed acylation reactions afforded 1-0-methyl 













I Startine Material 	 Product 	 Yield 
I R'=OHIH;R 2 =HIOH;49 R 1 =H;R2 = Mal; 225 	76% 
R 1 = H; R2 = OMe; 230 	R 1 =H:R2 =OMe;195 	51% J 
Synthesis of 1-0-Methyl Tetravaleryl-cc-D-glucoside 195 and a-D-Glucose Pentavalerare 225. 
Scheme 1.11. 
Under the reaction conditions of low temperature (below 10 °C) the 
esterification of D-glucose 49 would be expected to occur faster than anomerisation. 
The product of the acylation reaction will, therefore, be predominantly the 3-anomer, 
however, the presence of perchloric acid causes the acetylated product to anomerise 
and under the influence of the anomeric effect the acylated a-anomer (the 
thermodynamic product of acetylation) is obtained exclusively. 
Acetylations of simple sugars are generally in excess of 80-90% yield and so 
the 51% yield obtained for 1-0-methyl tetravaleryl-ct-D-glucoside 195 was lower 
than expected. The compound should be stable under the acylation conditions and so 
the low yield could be a result of terminating the reaction before all the starting 
material had been consumed. Increasing the reaction time for the acylation of methyl 
a-D-glucoside 230 could, therefore, give an improved yield of 1-0-methyl 
tetravaleryl-cx-D-glucoside 195. 
The model studies with Candida cylindraceae lipase had proved successful 
so an attempt was made to selectively deacylate the C6' valeryl group of 3-0-
pivaloylmorphine tetrava1ery1-3-D-glucoside 35. 
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2.2.2. Lipase Catalysed Selective Deacylation of 3-o-Pivaloylmorphine 
Tetravalery1- -D-glucoside 
Teatment of 3 -o-pivaloylmorphine tetravaleryl-i3-D -glucoside 35 with 
Candida cylindraceae lipase as described above did not result in any deacylation 
reaction. It would appear that the enzyme could not accept 3-0-pivaloylmorphine 
tetravaleryl- -D -glucoside 35 as a substrate, which is probably as result of the 
molecule being too large for the enzyme's active site. 
2.3. Oxidations 
Despite the failure of the lipase catalysed deacylation reactions, it was 
decided to investigate the C6 oxidation reactions. The third step of route two was a 
ruthenium (VIII) oxide catalysed oxidation of the C6' hydroxyl group of 3-0-
pivaloylmorphine trivaleryl-13-D-glucoside 36. Ruthenium (VIII) oxide is a strong 
oxidising reagent first introduced in the 1960's by Beynon and co-workers. 133 
Ruthenium (VIII) oxide provides an efficient oxidant for a number of compounds 
including nucleosides 134,135  and carbohydrates, 136  oxidising isolated secondary 
alcohols and primary alcohols to give the dialdose and uronic acid, respectively. 
Carisen and co-workers 137 have recently developed new rapid and mild conditions 
for ruthenium (VIII) oxide catalysed reactions based on a biphasic reaction mixture, 
avoiding the sluggish reactions previously encountered. These new conditions 
developed by Carlsen and 137 were applied to some simple sugars before 
attempting the oxidation on the morphine glycosides. 
2.3.1. Model Study 
The ruthenium (VIII) oxide catalysed oxidation of the 1-0-methyl trivaleryl-
ct-D-glucoside 229 afforded 1-0-methyl trivaleryl-c-D-glucuronide 231 in 
quantitative yield (scheme 1.12.). 
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Synthesis of the 1-0-Methyl Trivaleryl-a-D-glucuronide 231. 
Scheme 1.12. 
Examining the 'H NMR spectra of the product confirmed the presence of I -
0-methyl  trivaleryl-a-D-glucuronide 231 isolated as an impure red solid. The C6 
protons observed in the 'H NMR spectra of the 1-0-methyl trivaleryl-a-D-glucoside 
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231 were absent and the C5 multiplet at a chemical shift of 8 3.78 ppm had become a 
doublet and moved downfield to 8 4.16 ppm in agreement with the formation of the 
carboxylic acid at C6. 
Several attempts were made to remove the red colour of 1-0-methyl 
trivaleryl--D-g1ucuronide 231 with decolourising charcoal, however the colour 
remained. This suggested contamination with ruthenium which would explain the 
failure to record the [aID value, and potentially could pose a problem in the use of 
ruthenium catalysed oxidations for the synthesis of compounds which are required 
for use in biological systems. 
The ruthenium (VIII) oxide catalysed oxidation was complete after 40 hours, 
which is slow compared to the reaction times of up to 6 hours reported by Carlsen 
and co-workers 137 for some simple olefins. A quicker ruthenium (VIII) oxide 
catalysed oxidation (30 mins to 3 hours) for some acyl protected sugars has been 
reported by Smejkal and Kalvoda, 136 however, the catalyst used is much harsher 
than that used by Carisen and co-workers 137  and involves fusing a mixture of 
powdered ruthenium, sodium hydroxide and sodium nitrate with heat and adding the 
melt to sodium periodate in water. 
The mechanism of ruthenium (VIII) oxide catalysed oxidations is not well 
understood and could be similar to that reported for chromium (VI) oxide (scheme 
1.13.). 138  The reaction probably involves initial oxidation of either ruthenium (III) 
chloride or ruthenium (IV) oxide with periodate to ruthenium (VIII) oxide, which on 
oxidising the alcohol to the carboxylic acid is reduced to ruthenium (IV) . 133 
	
Ru02.2H 20 + 2NaI04 	RuO + 2NaI03 + 2H 2( 









Ruthenium (VIII) Oxide Catalysed Oxidation of Alcohols. 
Scheme 1.13. 
Unfortunately the failure to synthesise 3-0-pivaloylmorphine triva1eryl-3-D- 
glucoside 36 did not allow the opportunity to attempt the ruthenium (VIII) oxide 
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catalysed oxidation on this compound which was demonstrated in the model study to 
be a useful reagent for the oxidation of simple sugars. 
3. Synthesis of M6G; Synthetic Route Three 
Synthetic route 3 is a chemical synthesis of M6G 23 incorporating three 
steps; firstly, a silver (I) carbonate promoted Koenigs-Knorr glycosidation between 
acetobromoglucose 37 and 3-0-pivaloylmorphine 32; secondly, a Zemplén 
deprotection of 3 -0-pivaloylmorphine-6-(tetraacetyl)- 3-D-g1ucoside 38; thirdly, a 
selective oxidation of the C6' hydroxyl group of morphine- 6-glucoside 31 using 
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A92CO 3 promoted Koenigs-Knorr glycosidation 
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Selective oxidation catalysed by PtJC or TEMPO 





H 1 	I 
Ho I 
23 	I 
HO 	 I 
Proposed Synthesis of M6G 23, Synthetic Route Three. 
Scheme 1.14. 
The silver (I) promoted Koenigs-Knorr glycosidation of 3-0-
pivaloylmorphine 32 with acetobromoglucose 37 was initially examined. 
3.1. Koenigs-Knorr Glycosidations 
The original promoters employed by Koenigs and Knorr 59 for glycosidation 
reactions were silver (I) oxide and silver (I) carbonate. These promoters still prove 
valuable in the synthesis of the four basic structural types of glycosides, a-mannose, 
3-glucose/galactose, a-glucose/galactose, and 13-mannose which are progressively 
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more difficult to synthesise as a result of the anomeric effect and potential 
participation of the C2 neighbouring group (figure 1 .2.). 56  
V~-- 0 	 0 
0 	 0 
	
0 	 0 
1,2-trans a-Manno 	1,2-trans 3-Gluco/galacto 	1,2-cis cz-Gluco/galacto 	1,2-cis 3-Manno 
The Four Structural Types of] -O-Glycopyranosides. 
Figure 1.2. 
The silver (I) carbonate promoted Koenigs-Knorr synthesis of morphine 
glucosides still provides a useful route to these compounds. However, interest has 
turned to the use of silver (I) triflate as a highly reactive glycosidation promoter for 
the synthesis of a variety of 3-glycosides including morphine glucosides, 52  1-
disacchides, 131 ' 139 and the more difficult 13-mannodisaccharides.' 4° 
3.1.1. Silver (I) Triflate Promoted Glycosidations 
The Koenigs-Knorr glycosidation of a variety of simple alcohol acceptors 
using acetobromoglucose 37 as the donor was examined. The glycosyl donor 37 is 
commercially available although it is readily synthesised from D-glucose 49 using an 
acid catalysed acetylation with perchloric acid and acetic anhydride to give a-D-
glucose pentaacetate 227 followed by bromination with a 45% solution of hydrogen 
bromide in glacial acetic acid to afford acetobromoglucose 37 in 88% yield (scheme 
1.15.). 
OAc 	 OAc OH 
 o 	Ac20,HC10 	 0 
OH 	 AcO 	
AcOH,HBr,2h 	AcO 0 'C to it overnight 	AcO 
CO HO 	 AO 
49 	 227 
OAc 	 88% 	
37 	
Br 
Synthesis of Acetobronioglucose 37. 
Scheme 1.15. 
Glycosyl bromides were the preferred glycosyl halide to use for the 
glycosidation reactions as the bromides generally have greater reactivity towards 
glycosidation than the chlorides or fluorides. 61 
The silver (I) triflate promoted glycosidation of two primary alcohols, n-
butanol, n-octanol and the secondary alcohol, 2-cyclohexen-1-ol 204 with 
acetobromoglucose 37 was examined using the conditions described by Hanessian 
and Banoub 131 who used equimolar quantities of the promoter (in common with 
most Koenigs-Knorr promoters 57) with respect to the glycosyl donor. The highly 
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reactive nature of the promoter requires the use of anhydrous conditions and low 
temperatures (a lower temperature of -30 °C 141 was used in preference to the 
reported temperature of 0 °C) (scheme 1.16.). 
OAc 	
AgOTf, -30 C, N 2 , ROH, 	
OAc 
AcO 	
4 A sieves, CH 2Cl 2 , 30 mins 
ORAcO 
AcO I 	 AcO 
Br 
	
ROH 	 R 	 Product 	iki 
' 1BuOH 	 "Bu 	 232 	40% 




Synthesis of the n-Butyl Tetraacetyl-f3-D-glucoside 232, the n-Octyl Tetraacelyl-f3-D-glucoside 233 
and the Cyclohexenyl Tetraacet'1-f3-D-g1ucoside 203. 
Scheme 1.16. 
The initial reactions carried out used equimolar amounts of the promoter, 
glycosyl donor, and alcohol acceptor, however, the transglycosidation products were 
isolated in low yield (less than 20%). The quantity of the alcohol acceptor was 
increased to 10 molar equivalents and a significant increase in yield was observed 
with the glycosidation reactions affording the n-butyl tetraacetyl--D-glucoside 232 
in 40% yield, the n-octyl tetraacetyl-3-D-glucoside 233 in 63% yield, and the 
cyclohexenyl tetraacetyl- 3-D-glucoside 203 as a 1:1 ratio of diastereoisomers in 28% 
yield. 
The use of 2-cyclohexen-1-ol 204 as an acceptor was of interest as it contains 
an allylic alcohol group which is also present in the morphine structure. 2-
Cyclohexen-l-ol 204 is a secondary alcohol and when used as the acceptor, the 
transglycosidation product is isolated in a lower yield compared to the primary 
alcohols, n-butanol and n-octanol. This was expected as secondary alcohols are more 
sterically hindered. 
Two diastereoisomers of cyclohexenyl tetraacetyl--D-glucoside 203 were 
observed in the 'H NMR spectrum. The anomeric protons were easily identified as 
two doublets with chemical shifts of 8 4.60 and 4.64 ppm, as expected the coupling 
constant of the anomeric proton had increased from 4 Hz to 8 Hz indicating the 
anomeric proton has changed from an axial position in the acetobromoglucose 37 to 
a equatorial position in the cyclohexenyl tetraacetyl-f3-D-glucoside 203. 
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The mechanism of silver (I) triflate promoted Koenigs-Knorr glycosidations 
involves initial halogen abstraction from the glycosyl donor 234 by the silver ion 
affording the oxonium ion 235 (scheme 1.17.). Neighbouring group participation 
gives the acetoxonium ion 236 which is attacked by the alcohol equatorially, 

























Mechanism of the Silver Triflate Catalysed Koenigs-Knorr Gl)'cosidation. 
Scheme 1.17. 
Triflic acid is formed as a by-product of the reaction, this can be removed by 
the inclusion of an acid scavenger which neutralises the acid and prevents attack of 
the newly formed glycosidic bond. 6131 
3.1.2. Silver (I) Carbonate Promoted Glycosidations 
Conditions for this reaction have been reported by Hopkins and co-workers 51 
who used of a large excess of the glycosyl donor 37 and catalyst which were heated 
under reflux in benzene for approximately 24 hours. The exact quantities of donor, 
acceptor and catalyst were not given and so the initial reaction examined used 
equimolar quantities of silver (I) carbonate, 3-0-pivaloylmorphine 32 and 
acetobromoglucose 37 to afford 3 -O-pivaloylmorphine tetraacetyl- 3-D-glucoside 38 
in 10% yield. Despite being one of the more thermally stable glycosyl bromides, 
decomposition of acetobromoglucose 37 under the reaction conditions occurred and 
only by increasing the quantities of both the glycosyl donor 37 and catalyst to 5 
molar equivalents was 3-0-pivaloylmorphine tetraacety1-3-D-glucoside 38 isolated in 
an improved yield of 36% (scheme 1.18.). 
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Synthesis of 3-0-Pivaloylmorphine Tetraacetyl-/3-D-glucoside 38. 
Scheme 1.18. 
Hopkins and co-workers 51 obtained 3 -O-pivaloylmorphine tetraacetyl- 13-D-
glucoside 38 in 32-63% yield, demonstrating how difficult it is to achieve 
consistently high yields for this reaction. 
Silver (I) carbonate promoted glycosidations are thought to occur at the 
surface of the catalyst where the halide of the glycosyl halide associates with a silver 
ion (scheme 1.19.).142  The alcohol approaches the surface bound glycosyl halide 
equatorially and an 5N2  reaction allows cleavage of the carbon-halide bond and 


























Proposed Mechanism of the Koenigs-Knorr Glycosidation with the Promoters Silver (I) Oxide or 
Silver (1) Carbonate. 
Scheme 1.19. 
The reaction between protons, released from the alcohol, and carbonate ions 
released from the catalyst, produces small amounts of water during silver (I) 
carbonate promoted Koenigs-Knorr glycosidations. 142 Although the use of Dean-
Stark conditions removes any water present in the reaction medium, this might not 
have been done efficiently enough during the coupling reaction to prevent hydrolysis 
of the glycosyl halide and the new glycosidic bond. Improved yields for the synthesis 
of 3-0-pivaloylmorphine tetraacetyl--D-glucoside 38 by silver (I) carbonate 
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promoted Koenigs-Knorr glycosidations might be achieved by the use of a drying 
agent such as Drierite and dry benzene. 
Alternative Koenigs-Knorr catalysts which avoid the creation of water during 
the glycosidation reactions have been used for the synthesis of morphine glycosides. 
For example, silver (I) triflate is a highly reactive, soluble Koenigs-Knorr catalyst 
which has been used by Kovác and Rice. 52 The soluble nature of the promoter means 
that the anomeric effect and neighbouring group participation have more influence 
over the reaction mechanism than occurs with the insoluble heterogenous catalysts. 
However, the formation of orthoesters has been associated with the use of silver (I) 
triflate, 52 one advantage of the silver (I) carbonate promoted Koenigs-Knorr 
glycosidations is the absence of side-products such as transacylation products and 
orthoesters. 
3.2. Zemplén Deprotections 
The cleavage of ester protecting groups of monosaccharides can be achieved 
under basic or acidic conditions or with lipases which provide mild and selective 
deprotection conditions. A common basic deacylation procedure for ester protecting 
groups, particularly acetates, is the Zemplén deprotection which involves the use of 
catalytic amounts of sodium methoxide in methanol. 56 
Esters can be cleaved with a variety of other reagents, for example, barium 
hydroxide and amines such as dimethylamine and triethylamine which are relatively 
mild reagents. If base labile groups are present, hydrochloric acid in methanol can be 
used. 56 ' 143 The Zempldn procedure is rapid and has been used for the deacylation of 
morphine glycosides and glucuronides, however, contamination of the morphine 
glycosides or glucuronide with sodium acetate has been a problem. 51 
3.2.1. Deacylations of Some Simple Transglycosidation Products 
A Zemplén deprotection was attempted with the n-butyl tetraacetyl-13-D-
glucoside 232, the n-octyl tetraacetyl-3-D-g1ucoside 233, and the cyclohexenyl 
tetraacetyl-f3-D-glucoside 203 to afford n-butyl f3-D-glucoside 238, n-octyl 13-D-
glucoside 239, and cyclohexenyl 3-D-glucoside 202 respectively, in quantitative 
yields (scheme 1.20.). 
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AcO 	 HO 
R' Startine Material 	R2 	Product % Yield 
C4H9 232 	C4H9 	238 Quantitative 
C8H 17 233 	C8H, 7 	239 Quantitative 
203 	 202 Quantitative 
Synthesis of n-Butyl /3-D-glucoside 238, n-Octyl 13-D-glucoside 239 and Cyclohexenyl /3-D-glucoside 
202. 
Scheme 1.20. 
The mechanism of Zemplén deprotections involves nucleophilic attack of the 
methoxide ion on the carbonyl group generating the methyl ester and regenerating 
the methoxide ion from methanol to give the alcohol (scheme 1.21 .).56 
Me0 
oy ) 	 OMe 
0 	 '-0 
0 
MeOH 	 0 
+ ROMe 
OH 	 0- 
+ Me0 
The Zemplén Deprotection. 
Scheme 1.21. 
Sodium acetate is sometimes produced as a side product of the Zemplén 
deprotection, however, n-butyl 3-D-glucoside 238, n-octyl 3-D-glucoside 239 and 
cyclohexenyl 3-D-g1ucoside 202 were formed rapidly in excellent yield without the 
formation any side products. A Zemplén deprotection was therefore used for the 
synthesis of morphine-6-glucoside 31. 
3.2.2. Synthesis of Morphine-6-glucoside 
The Zemplén deprotection of 3-0-pivaloylmorphine tetraacetyl-3-D-g1ucoside 
38 afforded morphine-6-glucoside 31 in 94% yield (scheme 1.22.). 
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Synthesis of Morphine-6-glucoside 31. 
Scheme 1.22. 
The formation of morphine -6-glucoside 31 was confirmed by 'H NMR 
spectroscopy (for NMR spectra see appendix A.3.), however, the removal of the 
acetate groups created a highly polar compound which was difficult to assign as a 
result of extensive overlapping of the spectral peaks. The deacylation reactions are 
typically slow for acylated morphine glucosides and glucuronides (20-72 hours) 39 ' 51 
particularly with the presence of the pivaloyl group which is more difficult to cleave 
than acetate protecting groups. 
Both the 'H NMR spectra and HPLC trace of morphine -6-glucoside 31 
(figure 1.2.) indicated a good degree of purity, unfortunately, this was not confirmed 
by elemental analysis. Attempts were made to purify morphine-6-glucoside 31 by 
crystallisation using a range of solvents including isopropanol-water and methanol-
ether, however, they were unsuccessful. Purification of morphine- 6-glucoside 31 
using size exclusion chromatography was also unsuccessful as the eluent contained 
sodium chloride which could not be removed. Alternatively morphine-6-glucoside 31 
could be purified with preparative HPLC, however the eluent used contained 
phosphate salts which would have also contaminated morphine-6-glucoside 31 and 
this procedure was not attempted. 
The contamination of morphine- 6-glucoside 31 was only slight and the 
contaminants, possibly sodium acetate and sodium pivaloate from the deprotection 
reaction, were unlikely to affect further reactions and so an attempt was made to 
oxidise morphine-6-glucoside 31 to M6G 23. 
3.3. Oxidations 
The selective oxidation of morphine-6-glucoside 31 to M6G 23 has not been 
previously attempted although a number of mild reagents have been developed for 
the selective oxidation of unprotected and partially protected carbohydrates, these 
include platinum, TEMPO, and more recently enzymes and whole cells. 
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3.3.1. TEMPO Catalysed Oxidations 
The use of nitroxyl radicals (a recent review has been published by de Nooy 
et a1 144 ) as mild oxidising agents has been known since the latter part of the last 
century. TEMPO in particular has received much attention and the development of a 
useful procedure for the selective oxidation of primary alcohols in the presence of 
secondary alcohols has been of particular significance. 145,146  Recently the use of 
TEMPO for the synthesis of uronic acids was reported by Davis and Flitsch 147 and 
this has led to the establishment of TEMPO as a useful oxidising agent in 
carbohydrate chemistry. 144,148 
Before attempting a TEMPO catalysed oxidation on morphine-6-glucoside 31 
the reaction was examined with a simple glycoside using the conditions reported by 
Davis and Flitsch. 147 
3.3.1.1. Model Studies 
The oxidation of n-butyl 3-D-glucoside 238 under biphasic alkaline 
conditions afforded the crude uronic acid in 52% yield which on methylation gave 
the desired methyl (n-butyl 3-D-g1ucopyranosid)uronate 240 in 20% yield (scheme 
1.23.). 
OH 	 I. TEMPO, CH 2Cl2 , NaOCI, 	 CO,Me 
HO 	
BuNC1, KBr, NaHCO 3, 17 h 
 
HO 	 ii. MeOH, Dowex, 21 h 	 HO 
238 	 240 20% 
Synthesis of Methyl (n-Butyl /3-D-glucopyranosid)uronate 240. 
Scheme 1.23. 
Examination of the isolated compound by 'H NMR spectroscopy revealed a 
loss of the C6 protons and the presence of a methyl ester group thereby confirming 
the formation of methyl (n-butyl 3-D-glucopyranosid)uronate 240. Yields foi 
TEMPO catalysed oxidations of simple sugars in the presence of hypochiorite-
bromide are generally good. A related glycoside n-octyl 3-D-glucoside 238 was 
readily oxidised and methylated by Davis and Flitsch 147 to afford the methyl urOnate 
240 in 67% yield. The yield of the methyl (n-butyl -D-glucopyranosid)uronate 240 
was lower than expected, the crude yield of the isolated uronate was moderate and so 
the methylation procedure could be the yield limiting step. 
The TEMPO catalysed oxidation of carbohydrates commonly requires the 
glycoside to be stirred at low temperature with a catalytic amount of TEMPO and 
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mixture can be monophasic (aqueous) or biphasic (aqueous-organic) with a phase 
transfer catalyst such as tetrabutylammonium chloride (Bu 4NC1) required for 
biphasic reaction mixtures. The conditions can be alkaline or acidic using sodium 
hydrogen carbonate or aqueous hydrochloric acid respectively, with the uronic acid 
isolated as the sodium salt. 149  TEMPO oxidations can be carried out with or without 
the presence of a secondary oxidant depending on the presence of a catalytic or 
stoichiometric amount of TEMPO respectively. 
The primary oxidant of TEMPO catalysed oxidations has been identified as 
the oxoammonium salt 243 which is obtained by oxidation of the nitroxyl radical 242 
which can also be reduced to the hydroxylamine 241 (scheme 1.24.).149 
Oxidation/Reduction Cycle  of TEMPO. 
Scheme 1.24. 
The exact mechanism of the TEMPO catalysed oxidation of alcohols is still 
unclear and a number of possible routes have been proposed.  150,151  The pH of the 
reaction has been found to be important and different mechanisms are observed in 
acidic and alkaline conditions. 149 The TEMPO oxidation of glycosides often occurs 
under alkaline conditions, under these conditions a sterically confined reaction 


















Proposed Mechanism for the TEMPO catalysed Oxidation of Alcohols in Alkaline Conditions. 
Scheme 1.25. 
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The sterically confining reaction mechanism involves initial abstraction of an 
electron from the nitroxyl radical 242 by the secondary oxidant hypobromite, which 
is a more active oxidant than hypochlorite, to generate the oxoammonium salt 243. 
Compound 243 is then attacked by the alcohol to give the adduct 244 which 
rearranges to release the aldehyde and the hydroxylamine 241. The aldehyde is 
thought to be oxidised in its hydrated form to the carboxylic acid using the same 
mechanism as the oxidation of the alcohol. 149  TEMPO catalysed reactions with 
hypochlorite -bromide are usually very rapid with the rate limiting step being 
regeneration of the oxoammonium salt 243. 149 
As a result of the successful TEMPO catalysed oxidation of n-butyl 13-D-
glucoside 238 to methyl (n-butyl f3-D-glucopyranosid)uronate 240, the TEMPO 
catalysed oxidation of morphine-6-glucoside 31 was examined. 
3.3.1.2. TEMPO Catalysed Oxidation of Morphine-6-glucoside 
Before the oxidation of morphine-6-glucoside 31 could be attempted a 
suitable assay had to be established which would allow the reaction to be monitored 
accurately. The progress of the oxidation was followed by HPLC using a Cl 8 reverse 
phase column with acetonitrile-pH 6.5, 5 mlvI phosphate buffer as the eluent, which 
was set up as a gradient from 10% to 90% acetonitrile (see general experimental 
table 1.1.). Using this eluent the more polar M6G 23 had a considerably shorter 
retention time (4.45 mins) than morphine-6-glucoside 31 (16.20 mins) as 








HPLC Trace of Morphine-6-glucoside 31 (retention time 16.20 mins). 
Figure 1.3. 
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HPLC Trace of M6G 23 (retention time of 4.45 mins). 
Figure 1.4. 
Unfortunately, when the TEMPO oxidation was attempted with the 
morphine-6-glucoside 31 the reaction conditions appeared to completely destroy the 
morphine skeleton as none of the relevant peaks on the HPLC trace were observed. 
The destruction of the starting material was confirmed by 'H NMR spectroscopy, no 
trace of morphine-6-glucoside 31 or desired the M6G 23 was observed. Although the 
reaction medium contains a number of components, the morphine-6-glucoside 31 
was probably destroyed by the sodium hypochiorite which is a powerful oxidising 
agent in its own right. Milder oxidising conditions were required and a platinum 
catalysed oxidation was examined. 
3.3.2. Platinum Catalysed Oxidations 
The use of platinum as a catalyst for the oxidation of primary and secondary 
alcohols was established in the last century and can be used as a mild and selective 
catalyst for the oxidation of carbohydrates. 152  The oxidation of a number of sugar 
derivatives has been achieved using platinum catalysts, for example, the synthesis of 
the aldonic acid 1,6-anhydro-3-D-xylo-hexopyranos-3-uJose 246 from 1,6-anhydro-
3-D-galactopyranoside 245152  and sodium methyl a-D-glucopyranosiduronate 247 
from methyl a-D-glucoside 230153  (scheme  1.26.).56 
W. 







Pi02 , 02, H20, 35 C, I h 
5% Pt/C,  0, H20, NaHCO3 , 











Platinum Oxidation of], 6-Anhydro- 13-D-galactopyranose 245 and Methyl a-D-Glucoside 230. 
Scheme 1.26. 
A variety of conditions have been developed for platinum catalysed 
oxidations. Adams catalyst (platinum (IV) oxide) and 5-10% Pt/C are frequently 
used and oxygen or air is usually bubbled through the reaction mixture which is 
maintained at a temperature of between 20-100 °C depending on the substrate 
reactivity. 152  The solvent is usually water, although a variety of other solvents are 
also suitable including acetone 154  and n-heptane.' 55 The acid that is produced during 
the oxidation reaction lowers the pH of the reaction medium, and the addition of 
sodium hydrogen carbonate is required to maintain neutrality; the reaction affords the 
sodium salt of the acid, in often excellent yields. 153 Platinum catalysts readily 
oxidise the anomeric carbon of aldoses to give aldonic acids, thus, anomeric 
protection is required for oxidations at non-anomeric carbons. 56 As the oxidation of 
morphine glycosides was of interest the sensitivity of the anomeric carbon to 
oxidation did not have to be considered. 
The conditions used by Fabre and co-workers 153 and Heyns and 
Blazejewicz' 55 were of particular interest. Fabre and co-workers 153  prepared uronic 
acids in high yields with Pt/C catalysed oxidations while Heyns and Blazejewicz 155 
successfully oxidised some simple alcohols with platinum (IV) oxide in n-heptane, 
this reaction was examined first. 
3.3.2.1. Model Study 
The oxidation of n-butyl -D-glucoside 238 under the conditions reported by 
Heyns and Blazejewicz 155 afforded the crude uronic acid in 37% yield, which was 
isolated as the methyl (n-butyl 3-D-glucopyranosid)uronate 240 in 10% yield 
(scheme 1.27.). 
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OH 	 I. Pt02, heptane, 	CO,Me 
	
He 	 0 	
60C,O2,42h 
HO o  
HO ii. CH2N2, Et20, 	 HO 
0-C, 1 h 10% 
2 238 	 40 
Synthesis of Methyl (n-Butyl /3-D-glucopyranosid)uronate 240. 
Scheme 1.27. 
'H NMR spectroscopy of the isolated material revealed the loss of the C6 
protons and the presence of a methyl ester as expected for the oxidation of a 
glycoside to its uronic acid confirming the formation of methyl (n-butyl 13-D-
glucopyranosid)uronate 240. 
Although both primary and secondary alcohol groups are present in n-butyl 
3-D-g1ucoside 238, primary alcohols in pyranoid rings are generally oxidised more 
readily than the secondary alcohols, 56 essentially none of the secondary alcohol 
groups present in compound 238 were oxidised. 
A proposed mechanism for platinum catalysed oxidations is shown in scheme 
1.28. and possibly involves an exchange of hydrogen atoms for oxygen atoms at 
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Proposed Mechanism of Platinum Catalysed Oxidations. 
Scheme 1.28. 
The poor yield of methyl (n-butyl P -D -glucopyranosid)uron ate 240 was 
discouraging, therefore, the platinum (IV) oxide catalysed oxidation of morphine-6-
glucoside 31 was not attempted as the conditions were considered unfavourable and 
the reaction not likely to be successful. 
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Attention turned to the platinum catalysed oxidation reported by Fabre and 
co-workers. 153 The oxidation of methyl a-D-glucoside 230 and methyl J3-D-
galactoside 249 afforded the crude sodium glucuronate and galacturonate 
respectively, in quantitative yields. Methylation followed by acetylation gave methyl 
(methyl 2,3 ,4-tri- O-acetyl-(t-D-glucopyranosid)uronate 248 in 40% yield and methyl 
(methyl 2,3,4-tri-O-acetyl-3-D-galactopyranosjd)uronate 250 in 21% yield (scheme 
1.29.). 
OH 
5% Pt/C, 02, 55 'C, pH 6-7,48 h 	
CO,Me 
MeOH, Amberlyte resin, rt, 3 days
40 
 HO 	
HO 	iii. Ac70, DMAP, Py, N 7 , ii, 1 h 
230 	OMe 	 40% 	248 	OMe 




1 5° Pt/C, 02, 55 'C, pH 6-7,48 h 
OH 
ii. MeOH, Amberlyte resin, rt, 5 days 	
OMe 
HO 
OMe 	 21% 
iii. Ac20, DMAP, Py, N 7 , rt, 4 h 	 AcO 
249 	 250 
Synthesis of Methyl (Methyl 2,3,4-tri-O-acetyl- a-D-glucopyranosid)uronate 248 and Met/n'! (Met/n! 
2,3, 4-tri-O-acetyl-J3-D-galactop)'ranoSjd)uronate 250. 
Scheme 1.29. 
Examination of the 'H NMR spectra for methyl (methyl 2,3,4-tri-O-acetyl-ct-
D -glucopyranosid)uronate 248 and methyl (methyl 2,3,4-tri-O-acetyl-3-D-
galactopyranosid)uronate 250 revealed the loss of the C6 proton signals as expected 
and the presence of two strong singlets for the OMe group and the CO 2 Me group. 
The formation of the crude glucuronate and galacturonate in quantitative 
yields were comparable to the 80-90% yields of the sodium glucuronate 247 isolated 
by Fabre and co-workers. 153 However, derivatisation of the crude glucuronate 248 
and galacturonate 250 to give compounds that were easier to handle and charaterise 
significantly reduced the overall yield of the isolated uronates. Although the use of 
methanol and Amberlyte resin provided the mild methylation conditions desired, the 
reactions were slow and afforded the methylated uronic acids in crude yields of less 
than 50%. The low yields of the methylation were probably as a result of the 
equilibrium that develops between the free uronic acid and the methyl ester. This 
equilibrium occurs as the water produced in the methylation reaction can attack the 
methyl ester to give the uronic acid. The removal of water from the reaction medium 
by a drying agent such as Drierite would have pushed the equilibrium in favour of 
the methylated uronate, possibly reducing the reaction time and increasing the yield 
of the methylated uronic acids. 
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Other methylation procedures for uronic acids include the use diazomethane 
and acidified methanol, 156 attempts to use the former procedure resulted in 
disappointingly low yields of the uronic acid methyl ester, and the latter conditions 
were considered too harsh to be examined. 
3.3.2.2. Platinum Catalysed Oxidation of Morphine-6-glucoside 
After the successful oxidation of methyl a-D-glucoside 230 and methyl 13-D-
galactoside 249 with 5% Pt/C the reaction was attempted with the morphine-6-
glucoside 31 using the conditions reported by Fabre and co-workers. 153  The progress 
of the reaction was followed by reverse phase tic using 20% methanol in 0.5 M aq 
sodium chloride and HPLC. However, the reaction conditions again appeared to 
harsh for morphine-6-glucoside 31 which was completely destroyed. 
3.3.3. Enzyme Catalysed Oxidations 
The failure of the TEMPO and platinum catalysed oxidations of morphine-6-
glucoside 31 was disappointing. Other possible routes to M6G 23 exist, and one of 
these may be the use of enzyme catalysed oxidations. A number of isolated enzymes 
and whole cells are currently available for the mild and selective oxidation of a 
variety of compounds including carbohydrates. One such organism is the bacterium 
Acetobacter suboxydans which is isolated from stale beer and is well established as 
an oxidant for a variety of alcohols 157 and carbohydrates. 56 The organism has 
dehydrogenase activity, these are enzymes that catalyse the oxidation of a substrate 
by removing hydrogen, usually with the presence of the co-enzyme nicotinamide 
adenine dinucleotide (NAD) which transfers hydrogen during the oxidation 
reaction. 16  The bacterium Acetobacter suboxydans readily oxidises free aldoses to 
aldonic acids, for example, D-glucose diethyl dithioacetal 251 is oxidised to D-xyio-
hexos-5-uiose diethyl dithioacetal 252 when treated with the bacterium in neutral 
aqueous solutions (scheme 1.30.). 56 
EtS. 	SEt 	 EtS 	SEt 
HO 
— OH A.suboxydans 	[—OH 	 0 
HO 
HO 	 HO- 
EtS 
HO 	
OH —OH 	 OH 	 EtS 
— OH 	 t 
251 252 
Oxidation of D-Glucose Diethyl Dithioacetal 251 with Acetobacter suboxydans. 
Scheme 1.30. 
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Enzymes that have recently been used for the mild and selective oxidation of 
carbohydrates include oxidase enzymes and oxidoreductases, for example, the 
metallo-oxidase galactose oxidase (Dactylium deudro ides) which contains copper 
(II) as a co-factor, oxidises D-galactose 144 at the C6 position in the presence of 
oxygen to give D-galactohexodialdose 253 (scheme 1.31.). 158 
CHO 	 CHO 
OH 	 OH 
HO-1 	 Galactose oxidase 	HO 
HO 	 HO — 
L OH 	02 	 H201 	 OH OH 	 CHO 
144 	 253 
Oxidation of D-Galactose 144 with Galactose Oxidase from Dactylium deudroides. 
Scheme 1.31. 
Enzymatic oxidoreductions are not common reactions in organic synthesis, 
although they are potentially very useful tools in many areas of chemistry including 
carbohydrate chemistry; a recent review published by Fang et a1 158 explores the 
potential applications of these enzymes in detail. 
Enzymes and whole cells could provide the mild and selective oxidation 
required to synthesise the elusive M6G 23 and succeed where chemical methods 
have so far failed. 
93 
Chemo -Enzymatic Approaches to M6G and Selected Analogues 
Section Two; Synthesis of M6G Analogues 
2.1. Synthesis of Morphine-6-Galactoside 
In a previous unpublished study by Hopkins and co-workers, 51 a silver (I) 
carbonate promoted coupling of the acetobromogalactose 46 and 3-0-acetylmorphine 
27 followed by a Zempldn deprotection afforded morphine-6-galactose 44 as an 
impure solid in low yield (9-28%). In order to synthesise morphine-6-galactose 44 in 
an improved yield and higher degree of purity, the silver (I) carbonate promoted 
couplings were re-examined using the glycosyl donors acetobromogalactose 46 and 
tetra-o-benzoyl-a-D -gal actopyranosyl bromide 256, with 3 -O-pivaloylmorphine 32 
as the glycosyl acceptor. 
2.1.1. Koenigs-Knorr Couplings 
Of the four structural types of 1-0-glycosides that exist, 1,2-trans-3-D-
linkages of glucosides and galactosides are among the most straight forward to 
synthesise with a Koenigs-Knorr coupling, where glycosyl bromides and chlorides 
are typically used as glycosyl donors. 56 
2.1.1.1. Synthesis of Tetra-o-benzoyl-cc-D-galactopyranosyl Bromide and Tetra-
o-acetyl-a-D-galactopyranosyl Bromide 
Glycosyl bromides and chlorides are synthesised by treating peracylated 
sugars with hydrogen halides in acetic acid. 56  The halide displaces the C  acyl group 
to give the J3-glycosyl halide (the kinetic product) which undergoes anomerisation to 
the a-glycosyl halide (the thermodynamic product) exclusively. 56 In this manner the 
glycosyl bromides 46 and 256 were prepared from the peracylated galactose 254 and 
perbenzoylated galactose 255, respectively, with hydrogen bromide-glacial acetic 
acid (scheme 2.1.). 
Peracetylated a-D-galactose 254 is commercially available but can be readily 
prepared with a base catalysed esterification of the free sugar with pyridine and 
acetic anhydride. The base catalysed esterification of free sugars with the appropriate 
anhydride or acyl chloride is a well known procedure for the synthesis of peracylated 
sugars. Varying the acylation conditions will determine the ratio of the a/13-anorners 
and pyranose/furanose ring sizes. 56  At low temperatures in pyridine the esterification 
reaction will proceed faster than anomerisation of the free sugar and so formation of 
the acylated a-anomer which retains a pyranose conformation is generally 
favoured.56 
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Bz H OBz 	255 i. AcOH, HBr, 255 Bz H Br 256 25% 
Synthesis of Glycosyl Donors 46 and 256. 
Scheme 2.1. 
As shown in scheme 2.1., the benzoylation of D-galactose 144 afforded the 
perbenzoylated a-D-galactopyranoside 255 exclusively in 25% yield after 
chromatography and crystallisation. The presence of compound 255 was confirmed 
by 'H NMR spectroscopy which showed the presence of 5 aromatic rings at a 
chemical shift of 8 7.25-8.40 ppm with the anomeric proton clearly visible as a 
doublet with a coupling constant of 4 Hz typical for a-glycosides at ö 6.95 ppm. An 
analogous reaction reported by Ness and co-workers 159 with D-glucose 49 under the 
same conditions gives the penta- O-benzoyl-a-D-glucopyranoside in a moderate yield 
of 50%. 
The peracetylated (X-D-galactose 254 and the perbenzoylated a-D-galactose 
255 were readily brominated with hydrogen bromide in glacial acetic acid to afford 
acetobromogalactose 46 in 77% yield and the tetra-o-benzoyl galactopyranosyl 
bromide 256 in a lower yield of 25% (scheme 2.1.). 'H NMR and mass spectroscopy 
readily confirmed the identity of the compounds 46 and 256 indicating that 4 acyl 
groups and a bromine group were present (for experimental see sections 1.5.1. and 
1.5.8. respectively). 
2.1.1.2. Synthesis of Morphine Tetraacety14-D-ga1actoside 
The initial silver (I) carbonate promoted coupling with the 
acetobromogalactose 46 and 3-0-pivaloylmorphine 32 afforded the acyl protected 
morphine-6-galactoside 257 in 16% yield (scheme 2.2.). 
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Synthesis of The Ac)'! Protected Morphine-6-galactoside 257 via a Koenigs-Knorr Coupling. 
Scheme 2.2. 
The presence of the acyl protected morphine-6-galactoside 257 was 
confirmed by the 'H and ' 3C NMR spectra (for 'H NMR spectra see appendix A.6.). 
The anomeric proton was observed as a doublet with a coupling constant of 8 Hz at a 
chemical shift of 6 4.80 ppm typical of a 3-glycosidic linkage and the pivaloyl and 
four acetyl protecting groups were observed at chemical shift of 8 1.35 and 1.97-2.14 
ppm, respectively. There was a slight overlap between the morphine and galactose 
protons, however, the morphine protons chemical shift changes very little after 
glycosidation and so by using the 'H NMR spectra of 3-0-pivaloylmorphine 32 (see 
appendix A.2.) the morphine protons were easily separated from the galactosyl 
protons. 
Although no side products such as the orthoester or transesterification 
products were observed, the yield of the acyl protected morphine-6-galactoside 257 
was lower than those previously reported. 51 This was probably the result of rapid 
decomposition of the glycosyl donor 46 under the reaction conditions. The coupling 
reaction with the tetra-o-benzoyl-(X-D-galactopyranosyl bromide 256 was not 
attempted as benzoylated glycosyl halides are often less reactive than the acetylated 
analogues, probably due to the bulky aromatic rings providing steric hindrance and 
conformational inertia, and the reaction yield would have probably been poorer. 56 
The thermal instability of glycosyl halides is a common problem with 
Koenigs-Knorr glycosidations, thus an alternative method was sought. The synthesis 
of 3 -O-pivaloylmorphine-6-(2' ,3' ,4' ,6' -tetra-O-valeryl)-3-D -glucoside 35 with a 
mixture of the glucose pentavalerate donors 225 and 34 and TMSOTf as the 
glycosidation promoter was successful, therefore these conditions were applied to the 
synthesis of morphine-6-galactose 44. 
2.1.2. TMSOTf Promoted Couplings 
The first coupling reaction attempted was between the f3-D-galactose 
pentaacetate 258 and 3-0-pivaloylmorphine 32 (scheme 2.3.). 
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Formation of the Morphine-/3-D-Galactoside 257 and the Side-Product Pivaloy1-6-0-acetvl-morphine 
259. 
Scheme 2.3. 
The reaction product was isolated and examined by 'H NMR spectroscopy 
which revealed the presence of two pivaloyl groups and five acetyl groups. On 
comparing the 'H NMR spectra of the isolated compound with that for the acetyl 
protected morphine-6-galactoside 257, the presence of compound 257 could be 
confirmed, however, the extra peaks present suggested a side product had been 
formed and this was identified as 3-0-pivaloyl-6-0-acetyl-morphine 259. 
Unfortunately the presence of the side product 259 showed that the reaction 
conditions were favourable for acyl migration. The acetyl group released from the 
anomeric carbon of the 3-D-galactose pentaacetate 258 migrated to the free hydroxyl 
group of the alcohol acceptor affording the side product 259. 
Acetyl protecting groups are generally the most labile of the ester protecting 
groups, although the presence of an electron-withdrawing group such as chlorine at 
the a position enhances lability (figure 2.1.). 160 
\/ 
+ 	0 	Ph 	< 	0 	
H 	<< 
Isobutyrate 	Benzoate 	 Acetate 	 ix-Chioroacetate 
The Relative Order of Susceptibility Towards Acyl Migration. 
Figure 2.1. 
Benzoates, pivaloates and isobutyrates are less susceptible to migration as 
they are large, bulky groups. Lability is reduced if the ester carbonyl group has a 
reduced electrophilic character; the delocalization of electrons over the benzene ring 
in benzoates reduces the electrophilic nature of the ester carbonyl group. 160  Interest 
therefore moved to the use of benzoates and isobutyrates as alternative acyl 
protecting groups for the galactosyl donor. 
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2.1.2.1. Synthesis of Pentaisobutyry1--D-Galactose and Pentabenzoyl-f3-D- 
Galactose 
As a result of the anomeric effect the acylated 3-glycosy1 donor is more 
reactive than the acylated a-anomer for TMSOTf promoted couplings. The synthesis 
of pentaisobutyryl-3-D-galactose 261 was examined first using a base catalysed 
acylation reaction. The initial reactions were performed under low temperature 
conditions, however, only pentaisobutyryl-a-D-galactose 260 was isolated in 92% 
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'PO2Cl, DMAP, Py, -10 C, 3 h 92% 
'PrCO2CI, DMAP, Py, 50'C, 2 h 84% 	1 
Base Catalysed Acylation of D-Galactose 144 with Isobutyryl Chloride. 
Scheme 2.4. 
When D-galactose 144 is dissolved in a solvent such as pyridine an 
equilibrium develops between the different anomers and ring sizes. Studies have 
shown that when sugars are dissolved in more polar solvents such as water a 
complex equilibrium develops between the a and 3-anomers of the furanose and 
pyranose rings via the acyclic sugar such as that shown for D-glucose 49 (scheme 
2.5.). 56 
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The Equilibrium of D-Glucose 49 in Water. 56 
Scheme 2.5. 
The proportions of the different anomers of D-glucose 49 and D-galactose 144 
in water are shown in table 2.1. with the equilibrium favouring the 3-pyranose for 
both D-glucose 49 and D-galactose 144. 56 
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Sugar 
The % composition at 31 °C in aqueous solution at equilibrium. 
% a-Pyranose % 3-Pyranose % a-Furanose % 3-Furanose 
Glucose 38 62 0 0.14 
Galactose 30 64 2.5 3.5 
Proportions of Anonzers and isomers Present at Equilibrium for D-Glucose 49 and D-Galactose 144 
in Water. 56 
Table 2.1. 
The equilibrium that develops when D-glucose 49 or D-galactose 144 is 
dissolved in water can be acid or base catalysed and favours cyclic forms over 
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Acid Catalysed Equilibration of D-Galactose 144 in Water. 
Scheme 2.6. 
In cold (0-4 °C) pyridine D-galactose 144 dissolves reluctantly and any 
equilibrium that does develop must heavily favour the a-D-galactopyranose. This 
would explain why isobutyrylation of D-galactose 144 in cold pyridine afforded the 
a-D-galactoside 260 exclusively. By increasing the temperature of the acylation 
reaction to 50 °C it was hoped to increase the rate of anomerisation between J3-D-
galactose and (X-D-galactose to a point where it exceeds the rate of acylation. As the 
13-anomer of D-galactose is more reactive than (X-D-galactose the formation of the 13-
acylated galactose, the kinetic product of acylation, will be favoured at higher 
temperatures. Unfortunately when the acylation reaction was repeated at 50 °C only 
pentaisobutyryl-(X-D-galactoside 260 was obtained in a crude yield of 84% (scheme 
2.6.). 
The temperature of the acylation reaction was still not high enough to 
encourage formation of the perisobutyryl-13-D-galactoside 261, thus the reaction was 
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repeated, this time heating a suspension of D-galactose 144 under reflux for 1 hour 
before the addition of the isobutyryl chloride (scheme 2.7.). 
HO OH 
Reflux, Py, 1 h 
HO wOH 
HO 
iPOCl/ 144 	\iPOC1 
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Prc 'PrCO, 	 iPrCO ..O,CPr 
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I 78% Total yield 
260 	 261 	263 
Base Catalysed Acylation of D-Galactose 144 with Isobutyryl Chloride Under Refluxing Conditions. 
Scheme 2.7. 
Examination of the 'H NMR spectrum of the crude product revealed three 
signals at ö 5.71 ppm (d), 6.12 ppm (s), and 6.32 ppm (d) in a ratio of 1:2:7. These 
signals corresponded respectively, to an inseparable mixture of pentaisobutyryl-a-D-
galactopyranose 260, pentaisobutyryl- -D-galactofuranose 263, and pentaisobutyryl-
13-D-galactopyranose 261 isolated in 78% yield after chromatography (scheme 2.7.). 
The acylated a and f3-pyranose isomers were readily distinguished in the 'H NMR 
spectrum by the coupling constants of the anomeric protons of 4 and 8 Hz 
respectively. However, as a result of the numerous signals in the 'H NMR spectrum, 
the presence of pentaisobutyryl-3-D-galactofuranose 261 could only be confirmed by 
examining the chemical shifts of the anomeric carbons in the ' 3C NMR spectrum. 
The anomeric carbons of the peracylated sugars typically have chemical shifts values 
of 90-100 ppm and so the signals observed at 8 91.88 ppm, 8 93.02 ppm, and 8 98.81 
ppm were identified as the anomeric carbons for pentaisobutyryl-3-D-
galactopyranose 261, pentaisobutyryl-a-D-galactopyranose 260, and pentaisobutyryl - 
3-D-galactofuranose 263, respectively. 
Unfortunately the furanose forms of D-galactose 144, for example, the J3-D-
galactofuranose 262 in scheme 2.7., are stable and the mixture of pyranose and 
furanose forms found in acylation reactions performed at high temperatures in 
pyridine is common. 161  There are other potential acylation procedures that could 
possibly give the pentaisobutyryl-3-D-ga1actopyranose 261 exclusively, for example, 
using a different base, such as sodium isobutyrate or using the anhydride. 56 
The use of benzoate groups as protecting groups for D-galactose 144 was also 
examined and synthesis of pentabenzoyl-3-D-ga1actopyranose 264 was attempted 
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using the base catalysed acylation procedure established for the synthesis of 
pentaisobutyry1-3-D-galactopyranose 261. A suspension of D-galactose 144 in 
pyridine was heated under reflux for 1 hour before the addition of benzoyl chloride. 
An inseparable mixture of 3-D-gaIactofuranose pentabenzoate 266 and F 
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Synthesis of the Pentabenzoyl-/3-D-Galactofuranose 266 and the Pen tabenzovl-/3-D - Galactopvranose 
264. 
Scheme 2.8. 
As observed with the isobutyrylation of D-galactose 144, conditions of 
refluxing pyridine were again required to increase the rate of anomerisation between 
13-D-galactose 267 and (X-D-galactose 268 sufficiently above the rate of acylation to 
ensure that 3-D-ga1actopyranose pentabenzoate 264 was the major product. 
The anomeric protons of pentabenzoyl-3-D-galactopyranose 264 and the 
pentabenzoy1-3-D-ga1actofuranose 266 were clearly visible in the 'H NMR spectrum 
as a doublet with a coupling constant of 8 Hz at 6 6.29 ppm and broad singlet at 6 
6.80 ppm respectively. The anomeric proton of galactofuranoses characteristically 
appears as a singlet in the 'H NMR spectra as the dihedral angle between the 
anomeric proton and the C2 proton is 900  which means the protons do not 
couple. 56 ' 162 
The chemical shift of the anomeric carbons in the ' 3C NMR spectrum could 
be found at 6 92.91 ppm for the pentabenzoyl--D-ga1actopyranose 264 and 699.75 
ppm for the pentabenzoyl-13-D-galactofuranose 266. These results were in agreement 
with the results of the ' 3 C NMR studies of benzoylated D-galactose 144 by 
D'Accorso and Thiel' 61 who reported the signal of the anomeric carbon of penta-o-
benzoyl-a-D-galactopyranose at 6 90.65 ppm, pentabenzoy1-3-D-galactopyranose 
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264 at ö 92.78 ppm, penta-O-benzoyl-a-D-galactofuranose at 8 94.25 ppm, and 
pentabenzoyl--D-galactofuranose 266 at 8 99.77 ppm. 
The benzoylated galactofuranose was the minor product of the benzoylation 
of D-galactose 144 as a result of the formation of a/-D-galactofuranose 265, but 
unlike the isobutyrylation of D-galactose 144, the acylated a-galactopyranose (the 
thermodynamic product of acylation for the galactopyranose) was not observed and 
this could reflect the relative rates of isobutyrylation and benzoylation for D-
galactose 144. At equilibrium in boiling pyridine the 13-anomer of D-galactose 267 
could be benzoylated rapidly enough to pull the equilibrium entirely in favour of the 
acylated -pyranose. If isobutyrylation of the -anomer of D-galactose 267 occurs at 
a significantly slower rate than a small amount of the thermodynamic product (the 
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Comparison of the Base catalysed Benzoylation and Isobuti'rylation of D-Galactose 144. 
Scheme 2.9. 
The acylation reactions produced inseparable mixtures of pentabenzoy1-3-D-
galactopyranose 264 and pentabenzoyl-3-D-ga1actofuranose 266, and 
pentaisobutyryl- 13 -D-galactopyranose 261, pentaisobutyryl- a-D -galactopyranose 260, 
and pentaisobutyry1-3-D-galactofuranose 263. These mixtures were used without 
further purification in TMSOTf promoted couplings with 3-0-pivaloylmorphine 32 
in an attempt to synthesise 3-0 -pivaloyl morphine tetraisobutyry1-3-D- 
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g alac topyranoside 	2 7 0 and 3-0-pivaloylmorphine tetrabenzoyl-13-D- 
galactopyranoside 272. 
2.1.2.2. Synthesis of 3-0-Pivaloylmorphine Tetraisobutyryl-13-D- 
galactopyranoside and 3-0-Pivaloylmorphine Tetrabenzoyl-f3-D-
galactopyranoside 
The synthesis of 3 -O-pivaloylmorphine tetraisobutyryl-3-D-galactopyranoside 
270 was attempted using the inseparable mixture of pentaisobutyryl-3-D-
galactopyranose 261, pentaisobutyryl-a-D-galactopyranose 260, and pentaisobutyryl-
3-D-ga1actofuranose 263 with 3-0-pivaloylmorphine 32 in a TMSOTf promoted 
coupling (scheme 2.10.). 
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Synthesis of 3-0-Pivaloylmorphine Tetraisobutyryl-/3-D-galactofuranoside 269 and 3-0- 
Pivaloylmorphine Tetraisobuzyo'1—/3-D-galactopyranoside 270. 
Scheme 2.10. 
Using an excess of the glycosyl donor mixture, the coupling reaction afforded 
a mixture of glycosides which, after examination by 'H NMR spectroscopy, were 
found to be 3-0-pivaloylmorphine tetraisobutyryl 3-D-galactofuranoside 269 and 3-
O-pivaloylmorphine tetraisobutyryl 3-D-galactopyranoside 270. Several attempts 
were made to separate this mixture by crystallisation but only a small quantity of one 
of the adducts was isolated in 7% yield. This was identified by the 1 H NMR spectrum 
as 3-0-pivaloylmorphine tetraisobutyryl 3-D-ga1actofuranoside 269 by the presence 
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of a singlet at ö 5.30 ppm corresponding to the anomeric proton (for NMR spectra 
see appendix A.7.) (scheme 2.10.). The replacement of the acetyl ester protecting 
group with the less labile isobutyryl protecting group ensured there was no acyl 
migration during the glycosidation reaction. However, the mixture of morphine 
glycosides afforded by the glycosidation reaction demonstrates the need for pure 
glycosyl donors. 
The synthesis of 3-0-pivaloylmorphine tetrabenzoyl- 13 -D-galactopyranoside 
272 was attempted using the mixture of f3-D-galactofuranose pentabenzoate 266 and 
13-D-galactopyranose pentabenzoate 264 with 3-0-pivaloylmorphine 32 in a TMSOTf 
promoted coupling (scheme 2.11.), which afforded a mixture of two products. These 
products were identified from the 1 H NMR spectrum as 3-0-pivaloylmorphine 
tetrabenzoyl-13-D-galactopyranoside 272 and 3 -O-pivaloylmorphine tetrabenzoyl-13 - 
D-galactofuranoside 271. However, repeated attempts to isolate the two morphine 
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Synthesis of 3-0-Pivaloylrnorphine Tetrabenzoyl-/3-D-galactopvranoside272 and 3-0- 
Pivaloylinorphine Tetrabenzoyl-13-D-galactofuranoside 271. 
Scheme 2.11. 
The formation of both 3-0-pivaloylmorphine tetrabenzoyl-13-D-
g alac topyrano side 272 and 3-0-pivaloylmorphine tetrabenzoyl-13-D-
galactofuranoside 271 indicates that perbenzoylated 13-D-galactofuranoses are highly 
reactive glycosyl donors. Unfortunately there was not enough time to investigate 
further acylation reactions which would possibly afford pentabenzoyl-13-D-
galactofuranose 266 and pentabenzoyl-13-D-galactopyranose 264 exclusively. 
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2.1.2.3. Synthesis of Morphine-6-galactofuranoside 
The potential biological activity of morphine- 6-galactofuranoside 273 was of 
interest and a Zemplén deprotection of 3-0-pivaloylmorphine tetraisobutyry1-3-D-
galactofuranoside 269 was attempted in order to obtain this novel morphine 
glycoside. 3- o-Pivaloylmorphine tetraisobutyry1-3-D-galactofuranoside 269 was 
treated with 10 equivalents of sodium methoxide in methanol for 22 hours affording 
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Synthesis of The Morphine Galactofuranoside 273. 
Scheme 2.12. 
Examination of the crude product by 'H NMR spectroscopy revealed the 
absence of the isobutyryl groups and pivaloyl group as expected. There was some 
overlapping of the morphine and galactosyl protons which were closer together on 
the spectra as a result of the high number of hydroxyl groups present. However, 
examination of the COSY spectra allowed all the signals to be assigned and the 
product identified as morphine-6-galactofuranoside 273. 
The large quantity of sodium methoxide required for the deprotection 
demonstrated the reduced lability of the isobutyryl groups compared to the acetyl 
protecting groups under Zemplén conditions. An attempt was made to purify the 
crude morphine galactofuranoside 273 by crystallisation from isopropanol-methanol, 
however, examination of the crystallised material revealed a small amount of 
impurity (for NMR spectra see appendix A.4.). Despite repeated attempts to 
recrystallise the material, elemental analysis did not indicate a high state of purity 
and as was the case with morphine-6-glucoside 31, contamination from by-products 
such as sodium isobutyrate and sodium pivaloate from the deprotection reaction had 
probably occurred. This was disappointing as the morphine galactofuranoside 273 
was not pure enough to undergo tests for biological activity and further attempts to 
recrystallise it resulted in a gradual decomposition. 
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2.2. Synthesis of Morphine-6-arabinopyranoside 
Among the morphine glycosides synthesised there have been no attempts to 
prepare morphine-6--D-arabinopyranoside 48.51  Synthesis of morphine-6- -D-
arabinopyranoside 48 would, with morphine-6--D-galactopyranoside, morphine-6- 
-D -gal actofuranoside 273 and morphine- 6--D-glucopyranoside 31, complete a 
series of morphine 3-glycosides which if biologically active could provide some 
novel analgesics. 
2.2.1. Attempted Synthesis of TetrabenzoyI-3-D-Arabinopyranose 
The synthesis of tetrabenzoyl-3-D-arabinopyranose was attempted with a base 
catalysed acylation reaction, in which a suspension of D-arabinose was heated under 
reflux in pyridine for 1 hour before the addition of benzoyl chloride (scheme 2.13.). 
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Synthesis of Tetrabenzoyl- a-D-A rabinopvranose 275. 
Scheme 2.13. 
The isolated material (in 29% yield) was examined by 'H NMR spectroscopy 
and the signal corresponding to the anomeric proton was identified as a doublet at 
6.25 ppm with a coupling constant of 5 Hz. The 'H NMR data was in agreement with 
the data reported by Durette and Horton 163 for the tetrabenzoyl-a-D-arabinopyranose 
275 and there was no evidence of the tetrabenzoyl--D-arabinose or the furanose 
isomers present. 
Sugar 
The % composition at 31 °C in aqueous solution at equilibrium. 
% a-Pyranose % 3-Pyranose % a-Furanose % 3-Furanose 
Arabinose 60 35.5 2.5 2 
Proportions of Anomers and Isomers Present at Equilibrium for D-Arabinose in Warer. 6 
Table 2.2. 
Arabinose is a sugar which readily adopts different conformations and in 
polar solvents such as water (table 2.2.)56  the a-pyranose isomer is favoured as a 
result of the presence of an axial C2 hydroxyl group which increases the anomeric 
effect. The furanose conformation of D-arabinose is unfavourable as a result of steric 
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interactions, these are destabilising interactions between the substituents on C  and 
C3 in the a-anomer and C  and C2 in the f-anomer. 56 
The isomers adopted by D-arabinose after acylation have been studied by 
Durette and Horton 163 who found that the peracylated sugar prefers to adopt the a-
pyranose isomer. It has been suggested by Durette and Horton 163  that the preference 
for the a-pyranose conformation is a result of an increase in the anomeric effect 
when an electronegative substituent, such as a benzoyl group, is placed on Cl, C2, 
C3, and C4. As a result of this effect, the peracylated arabinopyranose will adopt a 
chair conformation where the anomeric substituent is axial. Durette and Horton 163 
have also shown that the type of chair isomer peracylated D-arabinopyranose prefers 
depends on the substituent present. Durette and Horton 163 suggested that 
perbenzoylated arabinopyranose is found as the 'C 4 isomer possibly as a result of the 
attractive interactions between the syn-diaxial benzoxy groups at C2 and C4, 
however further investigation is required. 
These findings would suggest that in refluxing pyridine a complex 
equilibrium exists between the a and f3 -anomers of D-arabinopyranose with the 
pyranose ring equilibrating between the 'C 4 and 4C, conformers, for example, the 
equilibrium between the 'C 4 conformer 276 and the 4C, conformer 274 of a-D- 










The Equilibrium Between the 'C 4 and 4 C, Conformers of cx-D-Arabinopyranose. 
Scheme 2.14. 
Unfortunately the use of a benzoyl protecting group for the acylation of D-
arabinose encouraged the formation of the (X-D-arabinopyranose and not the desired 
f3-anomer, however, there was interest in observing whether the perbenzoylated a-D-
arabinopyranose 275 would participate as a glycosyl donor in a TMSOTf promoted 
coupling reaction with 3-0-pivaloylmorphine 32. 
2.2.2. Synthesis of 3-0-Pivaloylmorphine Tribenzoyl-a-D-arabinopyranoside 
A TMSOTf promoted glycosidation with tetrabenzoyl-a-D-arabinopyranose 
275 and 3-0-pivaloylmorphine 32 afforded 3-0-pivaloylmorphine tribenzoyl-a-D- 
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arabinopyranoside 277 in 44% yield after chromatography and crystallisation 
(scheme 2.15.). 
PivO, 
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Synthesis of 3-O-Pivaloylmorphine Tribenzoyl-cx-D-arabinopyranoside 277. 
Scheme 2.15. 
The formation of 3- O-pivaloylmorphine tribenzoyl-a-D-arabinopyranoside 
277 was confirmed by examination of the 'H NMR spectra. Three benzoyl groups 
were present at ö 7.23-8.13 ppm, however, the anomeric proton was less clearly 
defined as its signal appeared under the signal for the C5 morphine proton at 8 5.08 
ppm. The signal for the C2 proton was more clearly visible at 6 5.52 ppm as a 
doublet of doublets with a coupling constant of 5 Hz which is the same value as the 
signal for the C2 proton in the 'H NMR spectra of tetrabenzoyl-a-D-arabinopyranose 
275. As a result of the presence of the benzoyl protecting groups it is possible that 
the sugar moiety of 3-0-pivaloylmorphine tribe nzoyl-a-D-arabinopyranoside 277 
will retain the 'C 4 chair conformation observed in the perbenzoylated o-D-
arabinopyranose 275. 
The mechanism for the TMSOTf promoted glycosidation of 3-0-
pivaloylmorphine 32 with tetrabenzoyl-(X-D-arabinopyranose 275 is possibly similar 
to the TMSOTf promoted glycosidation reactions discussed earlier (scheme 2.16.). 
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Proposed Mechanism for TMSOTf Promoted Glycosidation of 3-0-Piva1o)'1norphine 32 with 
Tetrabenzoyl- a-D-arabinopyranose 275.70 
Scheme 2.16 
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Initial loss of the anomeric acyl group in scheme 2.16. gives the oxonium ion 
278, this is followed by neighbouring group participation from the C2 acyl group to 
afford intermediate 279 which will be attacked by the alcohol (ROH) from the (X-face 
only affording the a-glycoside 280. The 13-face of intermediate 279 is inaccessible to 
the incoming nucleophile (ROH) and so the a-glycosidic linkage is formed 
exclusively. 70 
The use of pure acylated a-pyranose anomer as the glycosyl donor in the 
glycosidation reaction avoided the mixture of products seen with the synthesis of the 
previous morphine galactosides. 3-0 -Pivaloylmorphine tribenzoyl-a-D-
arabinopyranoside 277 is a novel morphine glucoside and its potential biological 
activity was of interest. An attempt was made to obtain the pure morphine-6-cx-D- 
arabinopyranoside 278 using a Zemplén deprotection. 
2.2.3. Synthesis of Morphine-6-a-D-arabinopyranoside 
A Zemplén deprotection of 3-0-pivaloylmorphine tribenzoyl-a-D-
arabinopyranoside 277 afforded morphine- 6-a-D-arabinopyranoside 281 in 43% 














Synthesis of Morphine-6- a-D-arabinop)'ranoside 281. 
Scheme 2.17. 
Examination of the crude product by 'H NMR spectroscopy confirmed the 
formation of morphine-6-a-D-arabinopyranoside 281. The 'H NMR spectra revealed 
the loss of the benzoyl groups and pivaloyl group as expected while the signal at 4.48 
ppm corresponded to the anomeric proton which appeared as a doublet with a 
coupling constant of 7 Hz. This high coupling constant would suggest that an U.- 
glycosidic linkage is present, this is expected as the presence of an axial C2 on the 
sugar creates a strong anomeric effect which favours the a-anomer. It is also possible 
that the arabinose ring has retained the 'C 4 chair conformation and that this could be 
as a result of the attractive interactions between the syn-diaxial benzoxy groups at C2 
and C4 suggested by Durette and Horton. 163 Another possibility is that the 
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introduction of a large substituent at the anomeric position of D-arabinose could 
result in the 4C 1 isomer being a higher energy or less accessible conformation than 
the 'C4 chair conformation, thus, making this the preferred conformation for the 
sugar moiety of morphine-6-a-D-arabinopyranoside 278. 
The deprotection reaction went to completion much more rapidly than the 
Zemplén deprotection of 3 -o-pivaloylmorphine tetraisobutyryl-3-D-
galactofuranoside 269 demonstrating the increased lability of benzoyl groups 
compared to isobutyryl protecting groups under these conditions. Unfortunately, as 
was the case with morphine-6-galactofuranoside 273, attempts to crystallise the 
crude morphine-6-a-D-arabinopyranoside 281 from isopropanol-methanol failed to 
produce a compound which was pure enough to test for biological activity (for NMR 
spectra see appendix A.5.). 
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Section Three; Summary and Conclusions 
Attempts to synthesise M6G 23 using synthetic routes 1, 2 and 3 involved the 
use of a wide variety of chemical techniques and some interesting results were 
obtained. However, all three routes failed to produce the desired target compound 23 
(scheme 1.1.). 
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Summary of the Three Synthetic Routes Towards M6G 23. 
Scheme 1.1. 
The transglycosidation reactions examined in route 1 confirmed the 
versatility that f3-glucosidase from almonds has for a variety of alcohol acceptors. 
The model studies examining the glycosidations of alcohols containing an ct-allyl 
group were very encouraging, but disappointingly, the attempts to synthesise 
morphine-6-glucoside 31 using morphine derivatives 32 and 20 as acceptors were 
unsuccessful. 
The model studies for the glycosidation, selective deacylation, oxidation and 
deacylation steps of route two suggested this could provide a useful synthesis of 
M6G 23. However, there was a potential problem with contamination of the product 
with ruthenium as this was observed in the product of the ruthenium catalysed 
oxidation of 1-0-methyl 2,3 ,4-tri-o-valeryl-a-D-glucoside 229. 
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Unfortunately, the selective deacylation of 3-0-pivaloylmorphi ne 
tetravaleryl-f3-D-glucoside 35 was unsuccessful. Although the particular lipase used 
(Candida cylindracea lipase) did not cleave the valerate ester at C6' of 3-0-
pivaloy1morphine tetravaleryl-3-D-glucoside 35 there are currently many other 
sources of lipase commercially available, for example, Aspergillus niger lipase and 
porcine pancreatic lipase which might have accepted 3-0-pivaloylmorphine 
tetravaleryl-3-D-glucoside 35 as a substrate. The use of other ester groups such as 
acetates could also have been influential in increasing the acceptability of 3-0-
pivaloylmorphine tetravaleryl--D-glucoside 35 as a substrate for these enzymes. 
Route 3 resulted in the successful synthesis of morphine-6-glucoside 31 using 
a Koenigs-Knorr glycosidation promoted by silver (I) carbonate. Investigating the 
glycosidation reaction with some simple alcohols demonstrated the usefulness of the 
soluble Koenigs-Knorr promoter silver (I) triflate. This promoter could be useful for 
the synthesis of morphine-6-glucoside 31 if the reaction conditions are carefully 
controlled to avoid the formation of orthoester side-products. 
The model studies investigating the oxidation of simple sugars to uronic acids 
demonstrated the suitability of TEMPO and platinum catalysts for this reaction. Pt/C 
was found to be a mild and selective oxidant affording high yields of the uronic 
acids. However, the reactions were slow, taking several hours to complete and 
contamination with platinum could render the oxidation product unsuitable for use in 
biological analysis. TEMPO was, therefore, considered a more suitable oxidant. 
Attempts to oxidise morphine- 6-glucoside 31 using both Pt/C and TEMPO were 
unsuccessful and it would appear that milder reaction conditions will be required. 
Degradation of morphine-6-glucoside 31 could have been avoided by adjusting the 
oxidation reaction conditions. For example, during the TEMPO catalysed oxidation, 
lower temperatures, smaller quantities of sodium hypochlorite or even attempting the 
reaction in acidic or monophasic (aqueous) conditions might have proved effective, 
while attempting the platinum catalysed oxidations at lower temperatures could have 
been examined. 
After the successful synthesis of morphine-6-glucoside 31, attempts to 
synthesise analogues of this compound resulted in the production of two novel 
morphine glycosides, morphine-6- (X-D-arabinopyranoside 281 and morphine-6-
gal actofuranoside 273. The use of TMSOTf demonstrated that this is an efficient 
promoter for the glycosidation of morphine. The reaction conditions did not degrade 
the glycosyl donors unlike the conditions required for silver (I) carbonate promoted 
glycosidations. However, some problems were encountered. Firstly, suitable 
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protecting groups on the glycosyl donor were required to avoid migration of the acyl 
group onto the free hydroxyl group of the alcohol acceptor and secondly, the 
glycoside donor cannot be used as a mixture of 13-furanose and 3-pyranose isomers 
as the formation of an inseparable mixture of 3-0-pivaloylmorphine tetraisobutyrate-
13-D -g alactofuranoside 269, and 3-0-pivaloylmorphine tetraisobutyrate)-
galactopyranoside 270 demonstrated. 
The problems encountered with the use of acetate protecting groups for the 
glycosyl donor in TMSOTf promoted glycosidation reactions led to attempts to 
synthesise alternative ester derivatives of D-galactose 144 and D-arabinose. In 
general, the acid catalysed esterifications to afford the (X-anomer of acylated D-
glucose 49 and D-galactose 144 were very straight forward reactions. Preparing the 
anomerically less favourable acylated 3 -anomers required elevated temperatures 
which created some problems particularly with D-galactose 144 as the stability of the 
furanose isomer resulted in a mixture of isomers forming during base catalysed 
acylations. 
The base catalysed acylation of D-arabinose afforded the acylated a-pyranose 
isomer exclusively and unfortunately there was not time to attempt a synthesis of the 
acyl protected 3-arabinose. The conformation of this sugar is strongly influenced by 
the type of protecting group present and in order to obtain the 3-anorner the 
increased anomeric effect caused by an axial substituent on C2 would have to be 
overcome. It is possible that a less electron withdrawing group such as a benzyl 
group could influence the anomeric effect enough to obtain some of the 13-anomer 
although it is likely that to achieve the 13-anomer exclusively will be difficult. 
The investigations with the monosaccharides D-glucose 49, D-galactose 144, 
and D-arabinose demonstrated how differently these sugars can behave under the 
same reaction conditions and provided a fascinating insight into the vast field of 
carbohydrate chemistry. 
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Chapter Three; Experimental 
1.1. General Experimental 
All solvents and reagents used were of analytical grade, obtained from 
commercial suppliers and used as supplied unless stated. Diethyl ether and 
tetrahydrofuran were dried over sodium benzophenone ketyl and dichloromethane 
was dried over calcium hydride prior to use. Petroleum ether with a boiling point 
(b.p.) range of 40-60 °C is referred to as "light petroleum". High purity water (18.2 
Mcm) was obtained from a Milli-Q Ultra Pure Water System. 
Reagent quantities are reported in units of grams (g), milligrams (mg), 
millimoles (mmol) and millilitres (ml), units of time are reported as minutes (mins) 
and hours (h). Ambient or room temperature is referred to as "rt" and revolutions per 
minute as "rpm". 
Solution concentrations are expressed in the number of moles (M) per dm', or 
as weight/volume (w/v) or volume/volume (v/v) ratios. Saturated (sat) solutions were 
prepared by dissolving the maximum quantity of solid in the required volume of 
solvent, aqueous solutions are referred to as "aq". Solutions that have a concentration 
greater than 2 M dm 3 are referred to as concentrated (conc) and saturated aqueous 
solutions of sodium chloride are referred to as "brine". 
Analytical thin layer chromatography (tic) was conducted on Merck 
(Darmstadt, Germany) Kieselgel 60 F2540.25 nm pre-coated, glass backed plates and 
Merck HPTLC RP-18 F 254 S pre-coated glass backed plates, retention factor (R) 
values are reported. The plates were visualised using a low frequency ultraviolet 
(UV) lamp or the following dips 164  as stated; 
Naphthoresorcinol; an acidic solution for free or protected carbohydrates, 
preparation; add conc hydrochloric acid (4 ml) to a solution of naphthoresorcinol 
(1,3-dihydroxynaphthalene) (0.2 g) and diphenylamine (0.4 g) in 95% (v/v) ethanol 
(100 ml), store in an amber vessel, heating of the tic plate is required. 
Bromocresol green; a basic solution for carboxylic acids, preparation; dissolve 
bromocresol green (0.04 g) in 96% (v/v) ethanol (100 ml), add 0.1 M sodium 
hydroxide until a blue coloration appears, store in an amber vessel, heating of the tic 
plate is not required. 
Potassium permanganate; a basic solution and universal reagent, preparation; 
dissolve potassium permanganate (10.0 g), potassium carbonate (50.0 g) and sodium 
hydroxide (40 pellets) into water (1 L), heating of the tic plate is not required. 
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Jodoplatinate; a neutral solution for alkaloids and various nitrogen containing 
heterocyclic compounds, preparation; dissolve hydrogen hexachioroplatinate (IV) 
hydrate (chioric acid) (0.3 g) in water (100 ml), add a solution of potassium iodide 
(6.0 g) in water (100 ml), store in an amber vessel, heating of the tic plate is not 
required. 
Flash column-chromatography was conducted on Merck Kieselgel 60H silica 
gel, particle size 0.04-0.063 nm, 230-400 mesh ASTM under pressure and 
LiChroprep RP-18 was used for reverse-phase chromatography, particle size 40-63 
Jim under pressure. Size exclusion chromatography was conducted on Sigma 
Sephadex G-15 and a Pharmacia Biotech PD-10 column containing Sephadex G-25 
M under pressure. Eluent systems are given in volume/volume (v/v) ratios. 
Melting point (m.p.) and decomposition (decomp.) values, which are given in 
units of degrees centigrade (°C), were determined using a Gallenkamp melting point 
apparatus and are uncorrected. 
Elemental analysist was conducted in the Department of Chemistry, 
University of Edinburgh at the Elemental Analysis Laboratory using a Perkin Elmer 
2400 CHN Elemental Analyser. 
Infra-red (IR) measurements were made on a Perkin Elmer 881 Infra-red 
Grating Spectrometer, Bio-Rad FTS-7 Infra-red Spectrometer or a Perkin Elmer FT-
JR Paragon 1000 Spectrometer as solutions, nujol mulls, thin films on sodium 
chloride plates or as a potassium bromide (KBr) disc as stated. The frequencies are 
measured in wavenumbers (cm - ') and are reported as strong (s), medium (m) or weak 
(w), frequencies associated with aryl groups are referred to as "Ar". 
Optical rotations were performed on an Optical Activity Ltd., AA-1000 
polarimeter (serial number 84-16-08/A1000 DW) using a sodium D-line (589.5 nm) 
light source. Solvents were of spectroscopic grade, the cell path length was 0.5 or 1.0 
dm and optical rotation ([ail D ) values are given in units of 10 - ' deg cm2 g'. 
Proton ('H) and carbon (' 3C) nuclear magnetic resonance (NMR) spectra were 
recorded on either a Brüker AM 250 instrument at 250 megahertz (MHz) and 63 
MHz respectively, a Brüker AC 300 instrument at 300 and 75 MHz respectively, or a 
Variable Gemini 2000 instrument at 200 and 50 MHz respectively. Correlated 
spectroscopy (COSY) was recorded on a Brüker AM 250 instrument at 250 MHz. 
The chemical shifts (H)  of 'H NMR spectra are reported to the nearest 0.01 ppm 
relative to the following residual protic solvents; deuterated chloroform (CHC1 3 ) (oH 
7.25, singlet), deuterated methanol (CD2HOD) (OH  3.35, quintet), deuterated dimethyl 
Elemental analysis is reported, where possible, for novel compounds obtained as solids or syrups. 
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sulfoxide (DMSO) (6,., 2.50, quintet) and deuterated water (DHO) (6H 4.70, singlet). 
The spectral peaks are described using the following abbreviations; singlet (s), 
doublet (d), triplet (t), quartet (q), doublet of doublets (dd), triplet of doublets (td), 
quartet of doublets (qd), multiplet (m), and broad (b). Coupling constants (J) are 
quoted to the nearest 0.5 Hz and are further qualified as 3J, 2 which denotes the 
coupling of the protons at carbons Cl and C2 which are separated by 3 bonds, 
geminal (gem) coupling is reported as 2 Jge.. The protons are reported as 'CH and are 
further qualified as axial (ax), equatorial (eq) and where a mixture of isomers is 
present t as alpha pyranose ((R), beta pyranose (1W),  beta furanose (F), furanose (F), 
and pyranose (P). 
For ' 3C NMR spectra chemical shifts (6) are reported to the nearest 0.01 ppm 
relative to the following residual solvents; CDC1 1 (6 77.00, t), CD 1 0D (6 49.00, 
septet), and DMSO (6 39.70, septet) and the carbon-substituted patterns were 
assigned using Distortionless Enhancement by Polarisation Transfer (DEPT). The 
spectral peaks are described using the following abbreviations; quaternary carbon 
(Q), aryl (Ar), anomeric carbon (An) and where a mixture of isomers is present are 
further qualified as described for 'H NMR spectral peaks. 
Mass spectra (MS) were recorded at the Chemistry Department, University of 
Exeter using a Kratos Profile HV-3 high-resolution instrument, at the Chemistry 
Department, University of Edinburgh using a MS-50 high-resolution instrument or at 
the EPSRC Mass Spectrometry Centre, Swansea using a VG ZAB-E high-resolution 
instrument under Electron Impact (El.), Chemical lonisation (C.I.) or Fast Atom 
Bombardment (F.A.B.) conditions as stated. The mass to charge ratios (m/z) of the 
molecular ion (M) and daughter fragments are reported with the most abundant ion 
arbitrarily assigned a value of 100%. 
Enzymes were obtained from Sigma-Aldrich Company Ltd. and were used as 
supplied. J3-Glucosidase was used as a crude lyophilised powder from almonds (14 U 
per mg). Enzyme activity is defined in units where one unit hydrolyses 1.0 p.mol of 
glucose from salicin per min at pH 5.0 at 37 °C. Candida cylindracea lipase type VII 
was used as a crude lyophilised powder (700 - 1, 500 U per mg), enzyme activity is 
defined in units where one unit hydrolyses 1 tmol of fatty acid from a triglyceride 
per h at pH 7.2 at 37 °C. 
Analytical high pressure liquid chromatography (HPLC) was carried out 
using a WaterslM  600 pump fitted with a Rheodyne 7725i manual injector and a 
Mixtures of anomers are regarded as different isomers of the same compound, mixtures of furanose 
and pyranose forms of the same monosaccharide are considered as separate compounds. 
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WatersTM 486 detector set at 254 nm. A reverse phase analytical column (25 x 4.6 
mm internal diameter) packed with Spherisorb 5 jt octadecylsilyl (ODS) 2 was used. 
Solvents were of HPLC grade, filtered through Phenomenex (No. AFO-0504) nylon 
filter membranes, 0.45 pm thickness, 47 mm diameter prior to use and then purged at 
a rate of 40 ml per min with helium. Samples were dissolved in high purity water and 
injected onto the column through a 20 tl injection loop. The solvent system of 
acetonitrile and pH 6.5, 5 mM phosphate buffer (solutions of 5 mM dipotassium 
hydrogen phosphate and 5 mM potassium dihydrogen phosphate in high purity water 
were used in the appropriate proportions to give the desired pH) was applied as a 
gradient at a rate of 1 ml per mm (figure 1.1). 
Time (mins) Acetonitrile % Phosphate buffer % 
0-4.3 10 90 
4.3-4.6 20 80 
4.6-5.0 30 70 
5.0-6.0 40 60 
6.0-7.0 45 55 




For compounds obtained as an inseparable mixture or synthesised using a 
procedure previously reported in the literature, the recorded data is limited to the 
m.p. (if a solid), Rf, IR, 'H NMR, ' 3C NMR and nominal MS values. 
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1.2. Synthesis of Morphine-6-glucuronide; Synthetic Route One 
1.2.1. Cyclohex-6' -enyl 2,3,4,6-tetra-0-acetyl-f3 -D-glucopyranoside 203 
AcO H 
AcO 




A solution of 3-glucosidase from almonds (4 mg, 50 U) in pH 5.0, 70 mM 
phosphate buffer (1 ml) was added to a suspension of paranitropheny1-3-D-
glucopyranoside 33 (0.100 g, 0.33 mmol) in 2-cyclohexen-1-oi 204 (1.630 g, 16.60 
mmol). The reaction mixture was stirred at rt at 100 rpm for 16 h; tic at that time 
revealed that the reaction had gone to completion. The reaction was quenched by the 
addition of MeOH (5 ml) and the solvent removed by rotary evaporation to give a 
yellow solid (2.099 g) which was loaded onto silica (1 g). Flash column-
chromatography (9:2:1, Et0Ac-CH 2C12-Me0H) afforded a yellow oil (6 mg) which 
was suspended in dry Py (0.5 ml) and treated with Ac 7 0 (0.541 g, 5.30 mrnol) and 
DMAP (3 mg, 0.02 mmol). The reaction mixture was stirred under an atmosphere of 
N2 at rt for 1 h; tic at that time revealed that the reaction had gone to completion. The 
reaction was poured onto a mixture of ice (5 g) and 2 M aq HC1 (10 ml), extracted 
with EtOAc (3x 10 ml) and the combined organic extracts washed with 1 M aq HC1 
(2x 50 ml), sat aq NaHCO 3 (2x 50 ml), water (50 ml), brine (50 ml), dried over 
MgSO4 and the solvent removed by rotary evaporation to give a yellow oil (0.072 g). 
Flash column-chromatography (1:1, light petroleum-EtOAc) of the crude acetylated 
product followed by crystallisation (light petroleum-EtOAc) afforded the title 
compound in a 3:2 ratio of diastereoisomerst  as a white solid (2 mg, 1%); R f 0.56 
(1:1, light petroleum-EtOAc); the spectroscopic data was in agreement with that 
reported for cyclohex-6'-enyl 2,3,4,6-tetra-0-acetyl-3-D-glucopyranoside 196 
(section 1.4.5.). 
Diastereoisomer ratio is calculated from the relative peak heights of the anomeric protons in the 'H 
NMR spectrum. 
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A solution of 3-glucosidase from almonds (0.023 g, 322 U) in pH 5.0, 70 mM 
phosphate buffer (0.8 ml) was added to a suspension of paranitrophenyl-3-D-
glucopyranoside 33 (1.903 g, 6.32 mmoi) and phenethyl alcohol 198 (4.637 g, 37.96 
mmol) in pH 5.0, 70 mlvi phosphate buffer (30 ml). The reaction mixture was stirred 
at 100 rpm for 15 h at rt when further 13-glucosidase (0.023 g, 322 U) in pH 5.0, 70 
mM phosphate buffer (0.8 ml) was added. Tic revealed that the reaction had gone to 
completion after 24 h, the reaction was quenched by the addition of MeOH (50 ml) 
and the solvent removed by rotary evaporation to give a yellow solid (6.534 g) which 
was loaded onto silica (5 g). Flash column-chromatography (9:1, EtOAc-MeOH) 
afforded a yellow syrup (0.498 g) which was suspended in dry Py (5 ml) and treated 
with Ac 20 (1.08 g, 10.60 mmol) and DMAP (11 mg, 0.09 mmol) and stirred under 
an atmosphere of N 2 at rt. Tic revealed that the reaction had gone to completion after 
7 h and the reaction was poured onto a mixture of ice (20 g) and 2 M aq HC1 (25 ml), 
extracted with EtOAc (3x 10 ml) and the combined organic extracts washed with 2 
M aq HC1 (2x 100 ml), sat aq NaHCO 3 (2x 100 ml), water (100 ml), brine (100 ml), 
dried over MgSO4  and the solvent removed by rotary evaporation to give a yellow oil 
(0.659 g). Flash column-chromatography (1:1, light petroleum-EtOAc) of the crude 
acetylated product followed by crystallisation (light petroleum-ether) afforded the 
title compound as a white crystalline solid (0.358 g, 13%); R f 0.59 (6:4, light 
petroleum-EtOAc); m.p. 64-65 °C (from light petroleum-EtOAc); [a]' -20.94 (c 
1.02, CHC1 3); Vm  (CHCI 3)/cm' 3028s (CH), 2948s (CH), 2884s (CH), 1750s (CO,), 
1604m (Ar CH), 1432s (CH), 1374s (CH 3 ), 1051s (C-O-C); 8H  (250 MHz; CDCI) 
1.87 (3H, s, OAc), 1.97 (3H, s, OAc), 2.00 (3H, s, OAc), 2.06 (3H, s, OAc), 2.87 
(2H, t, 3J1 , 2 , 7, 2 'CH), 3.65 (2H, m, 2gem  10, ''CH, 'CH), 4.11 (2H, m, 2Jgfl1 10,''CH, 
6CH), 4.24 (1H, dd, 2gem  12, 6CH), 4.46 (1H, d, 3J12 8, 'CH), 4.97 (1H, dd, 3 j" . 1 8, 
'CH), 5.60 (1H, dd, 3J43  9, 4CH), 5.16 (1H, t, 3J34 9, 3 CH), 7.13-7.30 (5H, m, CA); 
(63 MHz; CDC1 3) 20.42 (CH 3 ), 20.47 (2x CH 3 ), 20.62 (CH 3 ), 35.75 (CH,), 61.77 
(CH 2 ), 68.23 (CH), 70.52 (CH 2 ), 70.94 (CH), 71.63 (CH), 72.62 (Ar CH), 100.61 
(An CH), 126.16 (Ar CH), 128.19 (2x Ar CH), 128.80 (2x Ar CH), 138.27 (Ar Q), 
169.14 (Q), 169.27  (Q), 170.16 (Q), 170.57  (Q); m/z 452 (M, 1%), 451 (M -H, 1%), 
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393 (M+-C 2H302,  3%),331 (M
+ -C8 H90,74%),169 (M -C 14H 19061  94%), 105 (M' - 
C 16H 27081  69%), 43 (M -C 20H250 91 100%); [Found MH 453.1733. C 72 H 280 10 
requires MH 453.1761] (F.A.B.). 




A solution of CeC1 3 .7H20 (8.454 g, 22.69 mmol) in MeOH (25 ml) was 
added dropwise at rt to a stirring solution of cyclopentenone (2.495 g, 22.56 mmol) 
in MeOH (25 ml). Finally NaBH4 (0.852 g, 22.53 mmol) was added over 15 mins, 
the temperature of the reaction mixture increased to 35 °C and when the 
effervescence had subsided, the reaction mixture was cooled to rt with an ice bath; 
the formation of a white precipitate was observed. Tlc at that time revealed that the 
reaction had gone to completion, the reaction mixture was poured onto ice, neutral 
pH was achieved with the addition of 1 M aq HC1 and the solution extracted with 
ether (4x 50 ml), dried over MgSO 4  and the solvent removed by rotary evaporation to 
give a yellow oil (13.521 g). Flash column-chromatography (ether) of the crude 
residue afforded the title compound as a colourless oil (2.060 g, 8 1%); R f 0.35 (1:1, 
light petroleum-EtOAc); V ç (nujol)/cm' 3336s (OH), 3022m (C=C-H), 2924s (CH), 
2851s (CH), 1652m (C=C); 5 H  (250 MHz; CDC1 3) 1.17-2.21 (8H, m, 4 CH, , 5 CR,, 
6 CH21  7CH2 ), 2.32 (1H, m, OH), 4.35 (1H, d, l,OH  7,'CH), 5.69 (2H, m, 
3j'. 3 2, 2CH, 
3CH); k (50 MHz; CDC1 1 ) 26.41 (CH 2 ), 26.56 (CH2 ), 28.29 (CH 7 ), 36.37 (CH ' ), 
71.78 (CH), 129.72 (C=CH), 137.71 (C=CH);in/z 113 (MH, 21%), 112 (M, 66%), 
111 (M -H, 41%), 97 (M -CH 3 , 68%), 95 (M -OH, 68%), 55 (M -C 3H 5 0, 100%) 
(E.I.). 
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1.2.4. Cyclohept-7' -enyl 2,3,4,6-tetra-0-acety1-3 -D-gtucopyranoside 219 
H 6 AcO 
3 CO,A I 7U 
219 
2 	3 
A solution of 3-g1ucosidase from almonds (1 mg, 140 U) in pH 5.0, 70 mM 
phosphate buffer (1 ml) was added to a suspension of paranitrophenyl-j3-D-
glucopyranoside 33(0.107 g, 0.36 mmoi) and 2-cyclohepten-l-ol 197 (0.251 g, 2.24 
mmol) in pH 5.0, 70 mM phosphate buffer (5 ml) and stirred at rt at 100 rpm. Tic 
revealed that the reaction had gone to completion after 2 h, the reaction was 
quenched by the addition of MeOH (25 ml), the solvent removed by rotary 
evaporation to give a yellow solid (0.199 g) which was loaded onto silica (1 g). Flash 
column-chromatography (9:1, EtOAc-MeOH) afforded a colourless syrup (2 mg) 
which was suspended in dry Py (1 ml) and treated with Ac,O (0.54 1 g, 5.30 mmol) 
and DMAP (1 mg, 0.008 mmol) with stirring at rt under an atmosphere of N,. Tic 
revealed that the reaction had gone to completion after 1 h and the reaction was 
poured onto a mixture of ice (5 g) and 1 M aq HC1 (10 ml), extracted with EtOAc (2x 
25 ml) and the combined organic extracts washed with 1 M aq HC1 (2x 50 ml), sat aq 
NaHCO3 (2x 50 ml), water (50 ml), brine (50 ml), dried over MgSO 4 and the solvent 
removed by rotary evaporation to give a colourless oil (0.011 g). Flash column-
chromatography (3:2, light petroleum-EtOAc) of the crude acetylated product 
afforded the title compound in a 3:2 ratio of diastereoisomers as a colourless syrup 
(5 mg, 1%); Rf 0.55 (1:1, light petroleum-EtOAc); [a] 2 -42.33 (c 0.11, CHC1,); Vniax  
(CHC1 3 )/cm' 2927m (CH), 2854m (CH), 1753s (CO2)1  1373m (CH 3), 1063m (C-0- 
Q, 1039s (C-O-C); 6  (250 MHz; CDC1 3 ) 1.20-1.67 (8H, m, 3CH21 4 CH,, "CH, 
6 CH2 ), 1.99 (3H, s, OAc), 2.01 (3H, s, OAc), 2.02 (1.2H, s, OAc), 2.03 (1.8H, s, 
OAc), 2.06 (1.2H, s, OAc), 2.07 (1.8H, s, OAc), 3.67 (1H, m, 'CH), 4.11 (IH, dt, 
2g,. 12, 6CH), 4.26 (1H, dd, 2g,.  12, 6CH), 4.34 (lH, bdd, 3J7 . 1 . 8, T CH), 4.57 (0.4H. 
d, 3J12 8, 'CH), 4.60 (0.6H, d, 3J12 8, 'CH), 4.97 (1H, d, 3J2 8, 2 CH), 5.07 (1 H, d, 3j4 
.3  
10, 'CH), 5.19 (1H, d, 3J 4 10, 3CH), 5.67-5.87 (2H, m, "CH, 2 CH); (63 MHz; 
CDC13 ) 20.49 (CH 1 ), 20.52 (CH 1 ), 20.59 (CH 1 ), 20.63 (CH,), 26.36 (0.6x CH,,), 26.41 
(0.4x CH 2), 26.84 (0.6x CH 2 ), 28.30 (0.4x CH 2 ), 28.46 (0.6x CH 2 ), 29.58 (0.4x CH,), 
Diastereoisomer ratio is calculated from the relative peak heights of the anomeric protons in the 'H 
NMR spectrum. 
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32.63 (0.4x CH 2 ), 33.50 (0.6x CH 2 ), 61.99 (CH2 ), 68.47 (CH), 71.38 (0.6x CH), 
71.44 (0.4x CH), 71.60 (1.4x CH), 72.85 (0.6x CH), 78.46 (0.6x CH), 80.09 (0.4x 
CH), 99.07 (0.6x An CH), 99.67 (0.4x An CH), 130.66 (0.4x CH), 132.56 (0.6x CH), 
134.12 (0.6x CH), 135.14 (0.4x CH), 169.09 (0.4x Q), 169.16 (0.6x Q), 169.29  (Q), 
170.23 (Q), 170.58  (Q); ,n/z 443 (MH, 1%), 331 (M -C 7 H, 1 0, 31%), 271 (M - 
C9 F1 15031  1%), 169 (M+-C 13H2106,  66%), 111 (M -C 14H 19091  6%); [Found MH 
443.1926. C21 H300 10 requires MH 443.1917] (F.A.B.). 
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1.3. Synthesis of Morphine-6-glucuronide; Synthetic Route Two 










5 	 9 We 
PrC 2',. 8 
3' iprco, V 	 222 
A solution of methyl (1,2,3 ,4-tetra-O-isobutyryl- 13-D-glucopyranosid)uronate 
221 (2.480 g, 5.18 mmol) in dry (CH 2 C1) 2  (5 ml) was added to 3-O-pivaloylmorphine 
32 (0.740 g, 2.00 mmol) and 4 A molecular sieves under an atmosphere of Ar. The 
reaction mixture was stirred at rt for 1 h and then at 4-5 °C for 30 mins, whereafter 
TMSOTf (2.013 g, 9.06 mmol) was added, the reaction mixture stirred for a further 4 
h at 4-5 °C when tic revealed that the reaction had gone to completion. The reaction 
mixture was poured onto a mixture of ice (10 g) and sat aq NaHCO 3 (30 ml), 
extracted with EtOAc (2x 25 ml) and the combined organic extracts washed with 5% 
(w/v) aq citric acid (3x 20 ml), sat aq NaHCO 3 (2x 20 ml), water (2x 20 ml), brine 
(2x 20 ml), dried over Na 2 SO4 and the solvent removed by rotary evaporation to give 
a white solid (3.110 g). Flash column-chromatography (1:9, MeOH-CH 2 C1 2) of the 
crude residue followed by crystallisation (PrOH-water) afforded the title compound 
as a white crystalline solid (0.740 g, 48%); R f 0.46 (1:9, MeOH-CH 3 C1); rn.p. 191-
192 °C (from PrOH-water); [Found: C, 63.83%; H, 7.08%; N, 1.58%. C41 H 55N0 13 
requires C, 63.95%; H, 7.21%; N, 1.82%]; [a] -110.38 (c 0.99, CHC13); Vniax  
(CHC13 )/cm' 2940s (CH), 2900s (CH), 2840m (COCH3 ), 2760m (NMe), 1720s 
(CO2 ), 1020s (C-O-C); 8H  (250 MHz; CDC1 3) (COSY) 1.11-1.35 (18H, m, 6x 
CHCH3 ), 1.38 (9H, s, C(CH3 ) 3 )
1 
 1.90-2.08 (3H, m, CHCH 31  15CHeq  15C1T1 ax ), 2.30 (1H, 
bdd, 2gem  19, ' °CHax ), 2.40 (3H, s, NMe), 2.42-2.58 (4H, m, 2x CHCH 31  16CH eC1 , 
' 6CHax ), 2.62 (1H, bt, 3J149 3, 14  CH), 3.04 (1H, d, 2gem  19, ' °CHeq ) 3.35 (lH, m, 
3jg. 
14 
3, 9CH), 3.70 (3H, s, OMe), 4.11 (1H, m, 3J67 10,6  CH), 4.28 (1H, m, 41 CH), 4.92 (IH, 
dd, 3J5 , 4 , 7, 5 'CH), 4.95 (1H, d, 'J]', 2' 81  "CH), 5.07 (1H, m, 3J7 , 1 . 8, 2 CH), 5.24-5.32 
(3H, m, 3J78 10 9  7CH, 5 CH, 3 'CH), 5.65 (1H, bd, 3J87 109 'CH), 6.52 (lH, d, 3J, 1 9, 
'CH), 6.60 (1H, d, 3J21 9, 2CH); 81 (63 MHz; CDC1 3 ) 18.57 (CH 3 ), 18.63 (CH 3 ). 
18.93 (CH 3 ) 9 20.66 (CH 2 ), 27.00 (6x CH 3 ), 33.62 (3x CH), 35.56 (CH,), 38.85 (Q), 
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40.91 (CH), 42.92 (NMe), 43.70 (Q), 46.07 (CH 7 ), 52.65 (OMe), 58.46 (CH), 68.95 
(CH), 70.67 (CH), 71.29 (CH), 72.61 (CH), 73.18 (CH), 89.64 (CH), 98.75 (An CH), 
118.77 (CH), 121.49 (CH), 128.52 (CH), 130.32 (CH), 131.13 (Q), 131.64  (Q), 
131.90 (Q), 150.11  (Q), 167.30  (Q), 175.10  (Q), 175.16  (Q), 175.73  (Q), 176.28  (Q); 
m/z 770 (MH, 6%), 769 (Mt, 31%), 685 (M -C4H4027  7%), 354 (M -C 19H,7010, 
19%); [Found MH 770.3784. C 41 H55N0 13 requires MH 770.3752] (F.A.B.). 
1.3.2. 3-D-Glucopyranose Pentavalerate 34 
ó<OVal 
ValO 	 2 
ValO OVa! 
3 	ValO I 
34 
A solution of valeryl chloride (5.486 g, 45.50 mmol) in dry (CH,C1) 2 (5 ml) 
was added dropwise to a suspension of D-(+)-glucose 49 (1.020 g, 5.66 mmol) in dry 
Py (10 ml) and dry (CH2C1) 2 (5 ml). The resulting mixture was stirred at 50 °C with 
the exclusion of water provided by a drying tube containing self indicating silica gel, 
tic revealed that the reaction had gone to completion after 1 h. The reaction mixture 
was allowed to cool to rt, extracted with CH 207 (6x 20 ml) and the combined 
organic extracts washed with 1 N aq HC1 (2x 50 ml), sat aq NaHCO 3 (2x 50 ml), 
water (2x 50 ml), brine (2x 50 ml), dried over MgSO 4 and the solvent removed by 
rotary evaporation to give a dark orange oil (4.570 g). Flash column-chromatography 
(100% hexane then a gradient to 100% EtOAc) of the crude residue afforded an 
inseparable mixture in a 3:1 ratio of the title compound and a-D-glucopyranose 
pentavalerate 225 as an orange syrup (4.410 g, quantitative yield; approximately 
2.205 g, 3.67 mmol of the title compound); R f O.6l (4:1, hexane-EtOAc); [a] 21 
+22.33 (c 1.17, CHC1 3); Vmax  (neat)/cm - '2962s (CH), 2936s (CH), 2875s (CH), 1755s 
(CO 2 ), 1381m (CH 3 ), 1078s (C-O-C); 8H  (300 MHz; CDCI 3 ) 0.85-0.98 (15H, m, 5x 
PP-CH 3 , 5x aP-CH 3 )
1 
 1.24-1.42 (10H, m, 5x 13P-CH 2 CH 3 , 5x aP-CH7 CH 3 )
1 
 1.42-1.69 
(10H, m, 5x 3P-OCH 2 CH2 , 5x PP-OCH2 CH2 ), 2.18-2.30 (10H, m, 5x PP-OCH 2 . 5x 
(xP-OCH2), 3.83 (0.75H, m, 3J54 10, 13P- 5 CH), 4.06-4.26 (2.25H, m, 2j g en] 12, P-
6 CH2 , cxP-'CH, (zP- 6 CH2 ), 5.06-5.20 (2H, m, 3J21 4, f3P- 2 CH, 13P- 4 CH, aP- 2 CH, cxP-
4CH), 5.29 (0.75H, t, 3J34 10, 3P- 3 CH), 5.51 (0.25H, t, 3J34 10, (XP- 3 CH), 5.73 (0.75H, 
d, 3 J 2 8,PP-'CH), 6.35 (0.25H, d, 3J, 4, (xP-'CH); ö (75 MHz; CDC1 3 ) 13.55 
(2.25x P-CH3 , 0.75x aP-CH3 )
1 
 13.62 (1.5x 13P-CH 3 , 0.5x (tP-CH 3), 22.16 (3.75x 13P-
CH2 , 1.25x aP-CH 2), 26.53 (1.5x 13P-CH 2 , 0.5x aP-CH2), 26.74 (1.5x PP-CH, 0.5x 
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ctP-CH 2), 26.85 (0.75x P-CH21  0.25x aP-CH2), 33.66 (1.5x P-CH,, 0.5x (xP-CH,), 
33.80 (1.5x P-CH21  0.5x (R-CH2), 34.49 (0.75x 3P-CH71  0.25x (XP-CH,), 61.38 
(0.75x fP-CH21  0.25x aP-CH2), 67.67 (0.75x 13P-CH, 0.25x (xP-CH), 70.02 (0.75x 
PP-CH, 0.25x(R-CH), 72.41 (0.75xPP-CH, 0.25x (R-CH), 73.23 (0.75x PP-CH, 
0.25x (R-CH), 91.65 (0.75x An 3P-CH, 0.25x An aP-CH), 172.04 (3.75x 13P-Q, 
1.25x (xP-Q); m/z 600 (M, 6%), 584 (M -CH49  33%), 553 (M -CH 3 0,, 10%), 500 
(M -05 H802 , 29%),499 (M+ -05 H902 ,100%),498 (M+-0 5 H 100,, 16%); [Found M 
600.3535. C31 H520 11 requires M 600.3510] (E.I.). 
1.3.3. 3-0-Pivaloylmorphine-6-(2',3' ,4',6'-tetra-o-valeryl)-
3-D-glucopyranoside 35 














I H I 
	
ValO 0 6 	 35 
3' 	ValO I 
To a stirred solution of 3-0-pivaloylmorphine 32 (0.670 g, 1.82 mmol) in dry 
(CH2 C1) 2 (2.5 ml) in the presence of 4 A molecular sieves under an atmosphere of Ar 
was added a mixture of a-D-glucopyranose pentavalerate 225 and 13-D-glucopyranose 
pentavalerate 34 (2.000 g; approximately 1.02 1 g, 1.70 mmol of 13-D-glucopyranose 
pentavalerate 34) in dry (CH 2 C1) 2  (2.5 ml). The reaction mixture was stirred for a 
further 1 h, whereafter, the temperature was lowered to 0 °C and TMSOTf (90.805 g, 
3.62 mmol) was added dropwise while maintaining the temperature below 5 °C. The 
reaction mixture was stirred for a further 4 h at 0 °C until tic revealed that the 
reaction had gone to completion. The reaction mixture was poured onto a mixture of 
ice (20 g) and sat aq NaHCO 3 (20 ml), the aqueous layer was isolated and extracted 
with EtOAc (2x 25 ml). The combined organic extracts were washed with 5% aq 
citric acid (5x 25 ml), sat aq NaHCO 3 (2x 25 ml), water (2x 25 ml), brine (2x 25 ml), 
dried over MgSO 4 and the solvent removed by rotary evaporation to give a dark 
yellow oil (1.700 g). Flash column-chromatography (1:9, MeOH-CH 2 C1,) of the 
crude residue followed by crystallisation ('PrOH-water) afforded the title compound 
as a white crystalline solid (0.016 g, approximately 14%); R f 0.43 (1:9, MeOH-
CH202); m.p. 82-84 °C (from 'PrOH-water); [a] -53.75 (c 2.00, CHCI 3 ); [Found: 
C, 66.29%; H, 7.94%; N, 1.69%. C 48H69N0 13 requires C, 66.40%; H, 8.02%; N, 
1.61%]; v,,, , , (CHC1 3)/cm' 2920s (CH), 2880s (CH), 2820s (CH), 1720s (CO,), 
125 
Chemo-Enzymatic Approaches to M6G and Selected Analogues 
101Om (CO-C); oH  (250 MHz; CDC1 3 ) (COSY) 0.78-0.92 (12H, m, 4x CH 7 CH), 
1.22-1.47 (8H, m, 4x CH2 CH 3 ), 1.35 (9H, s, C(CH3 ) 1 )
1 
 1.49-1.64 (8H, m, 4x 
OCH2CH2 ), 1.93 (111, bs, ' 5CHeq) 1.98 (1H, bs, 15CHax) 2.18-2.34 (8H, m, 4x OCH 2 ). 
2.43-2.52 (2H, m, 10CH, 16CHax ), 2.56 (3H, s, NMe), 2.77 (1H, bd, 16CH eq ) 2.94 
(1H, bs, 14  CH), 3.06 (1H, d, 2"gem  19, ' °CHeq), 3.54 (1H, bs, 9CH), 3.74 (IH, m, 3J5 . 4 . 
10, 5 CH), 4.16 (2H, d, 3J65 ' 4, CH), 4.26 (1H, m, 3J65 3, 6  CH), 4.83-5.00 (2H, rn, 
3J2 ., 1 8, 2'  CH, 'CH), 5.04 (1H, d, 3J12 . 8, "CH), 5.05-5.20 (2H, m, 3J4 .
5 
 10, 4 CH, 
3' CH), 5.24 (1H, dt, 3J78 10, 7  CH), 5.73 (1H, bd, 3J87 10, 8 CH), 6.55 (1 H, d, 3J, 8, 
'CH), 6.70 (1H, d, 3j2'  1 8, 2 CH); O (63 MHz; CDC1 3 ) 13.50 (2x CH 1 ), 13.57 (2x 
CH 3 ), 21.14 (CH 2 ), 21.98 (CH 7 ), 22.05 (2x CH,), 26.63 (CH,), 26.66 (2x CH,), 26.90 
(CH2 ), 27.03 (3x CH 3 ), 29.57 (Q), 33.56 (OCR,), 33.61 (2x OCH 7 ), 33.75 (OCR,). 
34.58 (CH2 ), 38.90 (Q), 39.74 (CH), 42.41 (NMe), 43.11 (Q), 46.38 (CH,), 59.08 
(CH), 61.69 (CH2 ), 68.02 (CH), 71.00 (CH), 72.11 (CH), 72.22 (CH), 73.15 (CH), 
77.10 (CH), 89.72 (CH), 99.36 (An CH), 118.90 (CH), 122.07 (CH), 127.00 (CH), 
130.49 (Q), 131.45 (CH), 132.09 (Q), 150.31  (Q), 171.90  (Q), 172.00  (Q), 172.72 
(Q), 173.28  (Q), 176.25  (Q); m/z 868 (MH, 81%), 867 (M, 32%), 784 (M -0 5H 7 0. 
34%), 499 (M -C 22H 26N04, 15%), 370 (M -C 26H41099 39%), 368 (M -C, 6H430 9 , 
47%); [Found MH 868.4847. C 48H69N0 13 requires MH 868.4717] (F.A.B.). 










Valeric anhydride (4.710 g, 25.29 mmol) was stirred at 0 °C and 70% (w/v) 
aq perchioric acid (0.832 g;  0.350 g, 3.48 mmol HC104) added dropwise while 
maintaining the temperature below 10 °C. D-(+)-Glucose 49 (1.000 g, 5.56 mmol) 
was added over 30 mins and stirring was continued for a further 30 mins at 0 °C and 
then at rt for 90 mins. The reaction mixture was poured onto ice (22 g), partitioned 
with CH 202 (20 ml) and the organic extract washed with water (5x 10 ml), sat aq 
NaHCO 3 (4x 10 ml), water (8x 10 ml) until the aqueous washings reached neutral 
pH, washed with brine (10 ml), dried over MgSO 4 and the solvent removed by rotary 
evaporation to give an orange oil (2.680 g). Flash column-chromatography (13: 1, 
hexane-PrOH) of the crude residue afforded the title compound as a yellow syrup 
(2.549 g, 76%); R f 0.50 (light petroleum); [a] +63.10 (c 1.04, CHC1,); V 11,, 
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(neat)/cm - ' 2963s (CH), 2936s (CH), 2875s (CH), 1752s (CO,), 1467s (CH), 138 is 
(CH 3 ) 1  1107s (C-0-C), 1037s (C-0-C); 6H  (250 MHz, CDC1 1 ) 0.80-0.96 (15H, rn, 5x 
CH3 ), 1.08-1.42 (10H, m, 5x CH2 CH 1 ) 1  1.43-1.70 (10H, m, 5x OCH,CH,), 2.28 
(10H, m, 5x OCH2), 4.06 (1H, dd, 2gem  12, 6CH), 4.10 (1H, m, 3J56 5, 'CH), 4.17 (1H, 
dd, 2gem  12, 6CH), 5.06 (1H, dd, 3J2 4,
2  CH), 5.12 (1H, t, 3J43 10, 4CH), 5.46 (1H, t, 
3J34 10, 3  CH), 6.31 (1H, d, 3J12 4, 'CH); E, (63 MHz, CDC1 3 ) 13.47 (3x CH 3 ), 13.51 
(2x CH 1 ), 22.04 (2x CH 2 ), 22.12 (3x CH 2 ), 26.68 (CH,), 26.71 (CH,), 26.77 (CH"), 
26.83 (2x CH 2 ), 33.47 (CH 2 ), 33.63 (CH 2 ), 33.75 (CH), 33.79 (2x CH 2 ), 61.41 
(CH2 ), 67.73 (CH), 69.26 (CH), 69.57 (CH), 70.05 (CH), 88.86 (An CH), 171.38 (Q), 
171.97 (Q), 172.21  (Q), 172.68  (Q), 173.22  (Q); m/z 601 (MH, 2%),600 (M, 35%), 
585 (M -CH3 , 100%), 499 (M -05 H9027  46%), 368 (M+-C 11 H,005 , 27%), 284 (M - 
C 16H2806 , 50%); [Found M 600.3536. C 31 H520 11 requires M 600.35011 (E.I.). 






Valeric anhydride (4.710 g, 25.29 mmol) was stirred at 0 °C and 70% (w/v) 
aq perchioric acid (0.832 g;  0.350 g, 3.48 mmol HC104) added dropwise while 
maintaining the temperature below 10 °C. Methyl -D-glucopyranoside 230 (1.006 
g, 5.18 mmol) was added over 5 mins and stifling continued for a further 45 mins at 
0 °C. The reaction mixture was then allowed to warm to rt and poured onto ice (22 
g), partitioned with CH 202 (20 ml) and the organic extract washed with water (5x 10 
ml), sat aq NaHCO 3 (3x 20 ml), water (2x 20 ml) until the aqueous washings reached 
neutral pH, washed with brine (20 ml), dried over Na 2 SO4 and the solvent removed 
by rotary evaporation to give a yellow oil (2.749 g). Flash column-chromatography 
(9: 1, light petroleum-EtOAc) of the crude residue afforded the title compound as a 
yellow syrup (1.401 g, 51%); Rf O.S7 (8:2, light petroleum-EtOAc); [a] 7 +83.09 (c 
0.47, CHC13); Vmax (neat)/cm' 2962s (CH), 2960s (CH), 2874s (CH), 1754s (CO,), 
1462s (CH), 1418m (CH), 1339m (CH3), 1170s (C-0-C), 1107s (C-0-C), 1047s (C-
0-C); oH  (250 MHz, CDC1 3 ) 0.79-0.97 (12H, m, 4x CH 1 ), 1.18-1.41 (8H, m, 4x 
CH2 CH 3 ) 1  1.45-1.68 (8H, m, 4x OCH 2 CH2 ), 2.16-2.39 (8H, m, 4x OCR,), 3.25 (3H, 
s, OMe), 3.95 (1H, m, 3J56 5, 5 CH), 4.14 (2H, qd, 2gem  12, 6CH 2 ), 4.87 (1H, dd, V, 4, 
2CH), 4.92 (1H, d' 3j 1 ,2  4, 'CH), 5.07 (1H, t, 3J43 10, CH), 5.47 (1H, t, 3J34 10, 3CH); 
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(63 MHz, CDC1 3 ) 13.56 (2x CH 3 ), 13.63 (2x CH 3 ), 22.89 (2x CH,), 22.16 (2x 
CH2 ), 26.74 (CH 2 ), 26.82 (CH2 ), 26.89 (2x CH 2 ), 33.69 (CH,), 33.73 (CH,), 33.83 
(2x CH 2 ), 55.38 (OMe), 61.82 (CH2), 67.36 (CH), 68.30 (CH), 69.68 (CH), 70.78 
(CH), 96.83 (An CH), 172.23 (Q), 172.61  (Q), 172.94  (Q), 173.38 (Q); in/z 531 
(MH, 1%), 530 (M, 1%), 499 (M -CH 3 0, 3 1%), 428 (M+ -C 5 H 1002 , 11%), 369 (M 
-C8 H 17031  82%), 271 (M -C 13H23051  100%); [Found M 530.3069. C27H460 10 requires 
M 530.3091] (E.I.). 
1.3.6. 1,2,3,4-Tetra-0-valeryl-cx-D-glucopyranose 228 
6 OH 
ValO 
Valo 	 1 
3 	VaIO I 
OVal 
228 
A suspension of a-D-glucopyranose pentavalerate 225 (0.212 g, 0.35 mmol) 
in 10% (v/v) pH 7.0, 0.05 M phosphate buffer-DMF (20 ml) was treated with 
Candida cylindraceae lipase (0.305 g, 213,500-457,500 U) and the reaction mixture 
stirred at rt at 100 rpm. The neutral pH was maintained by the addition of 1 M aq 
NaOH for 6 days; tic at that time revealed that the reaction had gone to completion. 
The reaction mixture was extracted with EtOAc (4x 20 ml), the combined organic 
extracts dried over Na 2SO4  and the solvent removed by rotary evaporation to give a 
yellow oil (0.850 g). Flash column-chromatography (24:1, hexane-PrOH) of the 
crude residue afforded the title compound as a colourless syrup (0.083 g, 45%); R 
0.20 (9:1, hexane-PrOH); [a]7 +8 1.42 (c 0.60, CHC13); Vmax  (neat)/cm' 2962s (CH). 
2936s CH), 2874s (CH), 1759s (CO 2), 1463m (CH), 1418m (CH), 1380m (CH 3 ), 
1165s (C-O(H)), 1105s (C-U-C), 1048s (C-U-C); 8 H  (300 MHz; CDC1 3) 0.84-0.97 
(12H, m, 4x CH0 1  1.16-1.39 (8H, m, 4x CH2 CH1 ) 1  1.41-1.58 (8H, m, 4x OCH,CHI ), 
2.18-2.34 (8H, m, 4x OCH 2), 3.64 (2H, bdd, 2"gem  12, 6CH2 ), 3.90 (1H, m, 3J 6 4, 
5 CH), 5.03-5.15 (2H, m, 3J43 10,4  CH, 2CH), 5.56 (1H, t, 3J34 10, 3 CH), 6.37 (1H, d, 
3J1 , 2 4, 'CH); ö (75 MHz; CDC1 3 ) 13.57 (2x CH 3 ), 13.59 (2x CH 3 ), 22.09 (2x CH,), 
22.15 (CH 2 ), 22.18 (CH2 ), 26.70 (CH 2 ), 26.83 (CH2 ), 26.91 (2x CH 2 ), 33.50 (CH-1), 
33.73 (CH2), 33.82 (CH 2 ), 33.84 (CH,), 60.92 (CH 2 ), 68.10 (CH), 69.21 (CH), 69.37 
(CH), 72.18 (CH), 88.92 (An CH), 171.66 (Q), 172.33  (Q), 172.75  (Q), 173.06  (Q); 
m/z 415 (M -C 5H902 , 6%), 284 (M -C 1 1 H2005 , 11%), 279 (M* -C 13H]704, 20%), 149 
(M -C 19H27079 36%), 85 (M+_C 21H35099 100%); [Found M -0 5 H902 415.2328. 
C26H010  requires M-05 H902 415.2332] (E.I.). 
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3 	VaIO I 
OMe 
229 
A suspension of 1-0-methyl 2,3 ,4,6-tetra-o-valeryl-a-D-glucopyranoside 195 
(0.061 g, 0.12 mmol) in 10% (v/v) pH 7.0, 0.05 M phosphate buffer-DMF (20 ml) 
was treated with Candida cylindraceae lipase (0.091 g, 63,700-136,500 U) and the 
reaction mixture stirred at rt at 100 rpm. The neutral pH was maintained by the 
addition of 1 M aq NaOH for 6 days; tic at that time revealed that the reaction had 
gone to completion. The reaction mixture was extracted with EtOAc (5x 20 ml), the 
combined organic extracts dried over Na 2 SO4 and the solvent removed by rotary 
evaporation to give a yellow oil (0.592 g). Flash column-chromatography (24: 1, 
hexane-PrOH) of the crude residue afforded the title compound as a colourless syrup 
(0.029 g, 56%); Rf 0.65 (9:1, CH2C12-MeOH); [a]21  1.50 (c 0.41, CHCI 3 ), (Lit) 22 
[a] 22  +98.2 (c 0.55, CHC1 3 ); Vmax  (CHC1 3)/cm' 2920s (CH), 1740s (CO,,), 1140s (C- D 
O(H)), 1070s (C-0-C), 1030s (C-0-C); 8 H  (300 MHz; CDC1 3 ) 0.80-1.03 (9H, m, 3x 
CH3 ), 1.21-1.43 (6H, m, 3x CH2 CH 3 ), 1.49-1.67 (6H, m, 3x OCH7CH2 ). 2.18-2.39 
(6H, m, 3x OCH 2), 3.43 (3H, s, OMe), 3.60 (1H, dd, 2j gem 12, 6CH), 3.78 (1H, rn. 
'CH), 3.80 (1H, dd, 2'gem  12, 6CH), 4.88 (1H, dd, 3J71 4, 2CH), 4.98 (1H, d, 3 2  4, 
'CH), 5.03 (1H, t, 3J43 10, 4  CH), 5.60 (1H, t, 3J34 10, 3 CH); & (75 MHz; CDCI 1 ) 
13.63 (3x CH3 ), 22.20 (OMe), 26.88 (2x CH 2 ), 27.00 (CH 2 ), 33.76 (CH-,), 33.80 
(CH2 ), 33.90 (CH,), 55.42 (3x CH 7 ), 61.04 (CH2 ), 68.73 (CH), 69.26 (CH), 69.38 
(CH), 70.96 (CH), 96.86 (An CH), 172.62 (Q), 173.01  (Q), 173.51 (Q); mn/z 446 (M, 
1%), 415 (M -CH 3 0, 100%), 344 (M -0 5H 10023  2%),103 (M -C 7H,707 , 13%),85 
(M -C 17H29081  100%); [Found W 446.2518. C 27H3809 requires M446.2516] (E.I.). 
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1.3.8. 1-0-Methyl 2,3,4-tri-o-valeryl-(X-D-glucopyranosiduronic acid 231 
4 6CO 3 H 
Vali 
VaIO 
3 	ValO I 
OMe 
231 
To a solution of Na104 (0.047 g, 0.22 mmol) in water (3 ml) was added a 
solution of 1-0-methyl 2,3,4-tri-O-valeryl-a-D-glucopyranoside 229 (0.021 g, 0.05 
nimol) in CH1CN (2 in]) and Cd 4 (2 ml) and a solution of RuCl 3 .3H2 O (5 mg, 0.02 
mmol) in CH 1 CN (1 ml). The reaction mixture was stirred vigorously at rt for 40 h; 
tic at that time revealed that the reaction had gone to completion. The aqueous layer 
was isolated, extracted with CH 202 (4x 10 ml) and the combined organic extracts 
were dried over MgS0 41  filtered through a pad of Celite and the solvent removed by 
rotary evaporation to give the title compound as a red solid (0.029 g, quantitative 
yield); Rf 0.76 (45: 15:10:30, n-BuOH-acetone-acetic acid-1.6% (v/v) aq NH 3 ); v,11 
(neat)/cm' 2963m, (CH), 2933m (CH), 2872m (CH), 1743s (CO,), 1375w (CH 3 )
1 
 
1166s (C-O(H)), 1105s (C-U-C), 1048s (C-O-C); 8 H  (300 MHz; CHC1 3) 0.76-0.96 
(9H, m, 3x CH0 1  1.13-1.39 (6H, m, 3x CH2CH 1 ) 1  1.40-1.62 (6H, m, 3x OCHI CHI ), 
2.13-2.40 (6H, m, 3x OCH 2 ), 3.41 (3H, s, OMe), 4.16 (1H, bd, 3J 10, 5 CH), 4.89 
(1H, dd, 3J21 4, 3J23 10,2  CH), 5.05-5.28 (2H, m, 3J43 10,4  CH, 'CH), 5.53 (IH, t, 3J34 
10, 3 CH); E (75 MHz; CHC1 3 ) 13.57 (3x CH 3 ), 22.07 (CH 3 ), 22.13 (2x CH,), 26.64 
(CR 2 ), 26.81 (CH,), 26.90 (CH 2), 29.64 (OMe), 33.70 (CH 2), 33.75 (CH,), 33.82 
(CH2 ), 69.33 (CH), 69.57 (CH), 70.53 (2x CH), 96.90 (An CH), 171.61 (Q), 172.45 
(2x Q), 173.03  (Q); m/z 460 (M, 1%), 429 (M -CH 3 0, 1%), 301 (M -C 7 H 11 04 , 7%), 
241 (M+-C 10H 1905 , 17%), 85 (M -C 17H2709, 97%); [Found M 460.2313. C 72H 360 10  
requires M 460.23091 (E.I.). 
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1.4. Synthesis of Morphine-6-glucuronide; Synthetic Route Three 




3 	AcO I 
OAc 
227 
Acetic anhydride (270.5 g, 2.65 mol) was stirred at 0 °C and 70% (w/v) aq 
perchioric acid (3.9 g; 1.6 g, 0.02 mol, HC10 4) added dropwise while maintaining the 
temperature below 10 °C. D-(+)-Glucose 49 (50.0 g, 0.28 mol) was added over 30 
mins and stirring continued for a further 30 mins at 0 °C, then allowed to warm to rt 
overnight. The reaction mixture was poured onto ice (500 g), partitioned with CH,C1, 
(4x 250 ml) and the combined organic extracts washed with water (lOx 250 ml), sat 
aq NaHCO 3 (8x 250 ml), water (2x 250 ml) until the aqueous washings reached 
neutral pH, washed with brine (250 ml), dried over MgSO 4 and the solvent removed 
by rotary evaporation to give a white solid (136.5 g). Crystallisation (EtOH-water) of 
the crude residue afforded the title compound as a white crystalline solid (93.6 g, 
86%); Rf 0.53 (1:1, light petroleum-EtOAc); m.p. 98-99 °C (from EtOH-water), 
(Lit. 165 109-111 °C); [a] 3 +93.95 (c 1.00, CHC1 3), (Lit. [a] +102.00 (c 1.00, 
CHC1 3 ); Vmax  (KBr)/cm 1 1754s (CO2), 1430w (CH), 1371m (CH 3 ) 1  1043s (C-O-C); 8H 
(250 MHz, CDC1 3 ) 1.97 (3H, s, OAc), 1.99 (3H, s, OAc), 2.00 (311, s, OAc), 2.05 
(3H, s, OAc), 2.14 (3H, s, OAc), 3.97-4.13 (2H, m, ' gem 12, 6CH, 5 CH), 4.23 (1 H, dd, 
2'g,. 12, 6CH), 5.05 (111, dd, 
3j2 '  1 4, 'CH), 5.08 (1H, t, 3J43 10, CH), 5.43 (1 H, t, 3 J3.4 
10, 3 CH), 6.29 (1H, d, 3J12 4, 'CH); ö (75 MHz, CDC1 3 ) 20.35 (CH 3 ), 20.48 (CH 1 ), 
20.57 (CH 3 ), 20.60 (CH 3 ), 20.78 (CH 3 ), 61.45 (CH 2 ), 67.91 (CH), 69.18 (CH), 69.81 
(2x CH), 89.04 (An CH), 168.65 (Q), 169.31  (Q), 169.56  (Q), 170.12  (Q), 170.51 
(Q); mlz 390 (M, 1%), 347 (M -C 2H 3 0, 6%), 332 (M -C 2 H2 01 , 16%), 331 (M - 
CH 3 0, 100%); [Found M*  390.1153. C 16H220 11 requires M 390.11621 (E.I.). 
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A solution of 33% (w/v) HBr in glacial acetic acid (36.0 g; 11.9 g, 0. 15 mol 
HBr) was stirred at rt while a-D-glucopyranose pentaacetate 227 (20.0 g, 0.05 mol) 
was added over 5 mins. Stirring was continued for 2 h after which time tic revealed 
that the reaction had gone to completion. The reaction mixture was poured onto ice 
(500 g), extracted with CHC1 3 (250 ml) and the organic extract washed with ice cold 
water (2x 250 ml), sat aq NaHCO 3 (250 ml), water (2x 250 ml), brine (250 ml), dried 
over MgSO4 and the solvent removed by rotary evaporation to give a white solid 
(21.0 g). Crystallisation (light petroleum-ether) of the crude residue afforded the title 
compound as a white crystalline solid (18.5 g, 88%); Rf 0.67 (1:1, light petroleum-
21EtOAc); m.p. 87-89 °C (from light petroleum-ether), (Lit. 165 88-89 °C); [a] 
+195.80 (c 1.00, CHC1 3 )
1 
 (Lit.165 [a]28D  +196.00 (c 2.00, CHC1 3 ); Vniax  (KBr)/cm 1 
2962w (CH), 2925w (CH), 2854w (CH), 1745s (CO 2), 1433m (CH), 1370s (CR3, 
1042s (C-O-C); 8 H (300 MHz, CDC1 3) 1.99 (3H, s, OAc), 2.01 (3H, s, OAc), 2.05 
 11 , (311, s, OAc), 2.06 (3H, s, OAc), 4.09 (1H, dt, 2g"" 	6 CH), 4.25-4.37 (2H, m, 
11, 6CH, 'CH), 4.80 (1H, dd, 3J 4, 2  CH), 5.12 (1H, t, 3J43 10, CH), 5.52 (1 H, t, 3J 4 
10, 3 CH), 6.58 (1H, d, 3J12  4, 'CH); 5c (75 MHz, CDC1 3 ) 20.46 (CH 3 ), 20.53 (CH3. 
20.55 (CR3, 20.57 (CR3, 60.93 (CH 2 ), 67.17 (CH), 70.15 (CH), 70.56 (CH), 72.14 
(CH), 86.58 (An CH), 169.36 (Q), 169.67  (Q), 169.72  (Q), 170.37 (Q); ,n/z 411 
(MH, 3%), 331 (M -Br, 54%), 289 (M -C 7 H2 OBr, 22%), 70 (M -C I 1 H 17O 7 Br, 
100%); [Found MH 411.0270. C 14H 19O9Br requires MH 411.0291] (E.I.). 




AcO I 	1' 	3' 
232 
A suspension of AgOTf (0.311 g, 1.21 mmol) and n-butanol (0.810 g, 10.93 
mmol) in dry CH 2 C12 (5 ml) was stirred at -30 °C, in the presence of 4A molecular 
sieves, under an atmosphere of N 2 and in the absence of light. A solution of tetra-O-
acetyl-a-D-glucopyranosyl bromide 37 (0.518 g, 1.26 mmol) in dry CH,C1, (10 ml) 
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was added over 10 mins while maintaining the temperature below -20 °C. The 
reaction mixture was stirred at this temperature for a further 30 mins; tic at that time 
revealed that the reaction had gone to completion. The reaction mixture was allowed 
to warm to rt, filtered through a pad of Celite and the filtrate washed with water (25 
ml), sat aq NaHCO 3 (25 ml), dried over Na 2SO4 and the solvent removed by rotary 
evaporation to give a clear colourless oil (0.736 g). Flash column-chromatography 
(8:2, light petroleum-EtOAc) of the crude residue followed by crystallisation (ether-
light petroleum) afforded the title compound as a white crystalline solid (0.204 g, 
40%); Rf 0.81 (1:1, light petroleum-EtOAc); m.p. 58-59 °C (from ether-light 
13 
petroleum), (Lit. 166  61-62 °C); [a]D  -12.55 (c 1.00, CHC1 3) 1  (Lit. 166  [c] D  -20.6 (c 2, 
CHC1 3 ); [Found: C, 52.88%; H, 6.98%; N, 0%. C 18H 280 10 requires C, 53.44%; H, 
6.56%; N, 0%1; Vmax  (KBr)Icrn' 2963m (CH), 2874m (CH), 1758s (CO,), 1432rn 
(CH), 1376s (CH 3 )
1 
 1041s (C-O-C); 8H  (250 MHz; CDC1 3 ) 0.88 (3H, t, 3J43 . 7, 4 CH 3 ), 
1.32 (2H, m, 3J3 ' 4 7, 'CH2 ), 1.52 (2H, m, 3J2 , 3 . 7, 'CH,), 1.98 (3H, s, OAc), 1.99 
(3H, s, OAc), 2.01 (3H, s, OAc), 2.06 (3H, s, OAc), 3.46 (1H, td, 2j geni 10, 'CH), 
3.66 (1H, m, 3J54 10,5  CH), 3.83 (1H, td, 2gem  10, "CH), 4.07 (1H, dd, 2Jg1 , 12, 6CH). 
4.21 (1H, dd, 2g""  12, 6CH), 4.47 (1H, d, 3J12 8, 'CH), 4.95 (1H, dd, 3J, 8, 2 CH), 
5.05 (1H, t, 3J43 10, 4 CH), 5.18 (1H, t, 3J34 10, 3 CH); ö, (75 MHz; CDCI 3) 13.66 
(CH 3 ), 18.93 (CH 2 ), 20.55 (CH 3 ), 20.58 (2x CH 3 ), 20.68 (CH 3 ), 31.38 (CH,), 62.04 
(CH 2 ), 68.56 (CH), 69.86 (OCH 2 ), 71.39 (CH), 71.76 (CH), 72.90 (CH), 100.85 (An 
CH), 169.24 (Q), 169.36  (Q), 170.27  (Q), 170.63 (Q); ,n/z 405 (MH, 2%),404 (M, 
2%), 331 (M+-C 4H90, 100%), 243 (M -C 6H9059  15%), 103 (M+-C 13H, 708 , 25%), 73 
(M -C 14H 1909 , 22%); [Found MH 405.1737. C 18H 280 10 requires MH 405.1761] 
(F.A.B.). 
1.4.4. n-Octyl 2,3,4,6-tetra-0-acety14-D-g1ucopyranoside 233 
8' AcO 	
AcO 	I' 	3' 	5' 	7' 
233 
A suspension of AgOTf (0.311 g, 1.21 mmol) and n-octanol (1.675 g, 12.86 
mmol) in dry CH 2 C12 (2 ml) was stirred at -30 °C, in the presence of 4A molecular 
sieves, under an atmosphere of N 2 and in the absence of light. A solution of tetra-O-
acetyl-a-D-glucopyranosyl bromide 37 (0.497 g, 1.21 mmol) in dry CH,Cl, (2 ml) 
was added over 15 mins while maintaining the temperature below -20 °C. The 
reaction mixture was stirred at this temperature for a further 30 mins, whereafter, tic 
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revealed that the reaction had gone to completion. The reaction mixture was allowed 
to warm to rt, filtered through a pad of Celite and the filtrate washed with water (2x 
25 ml), 1% (w/v) aq NaHCO 3 (2x 25 ml), dried over Na 2 SO4 and the solvent 
removed by rotary evaporation to give a yellow oil (1.863 g). Flash column-
chromatography (1:1, light petroleum-EtOAc) of the crude residue followed by a 
Kugelrohr distillation (to remove excess n-octanol) and finally crystallisation 
(EtOAc-EtOH) afforded the title compound as a white crystalline solid (0.352 g, 
63%); Rf 0.62 (1:1, light petroleum-ethyl acetate); m.p. 57-58 °C (from EtOAc-
EtOH), (Lit. 167 54 °C); [a]
24 
 (c 1.00, CHC1 3), (Lit. []D  -23.8); [Found: 
C, 57.49%; H, 8.07%; N, 0%. C 22H360 10 requires C, 57.36%; H, 7.88%; N, 0%]; V,,77 
(KBr)/cm 1 2930m (CH), 2862w (CH), 1750s (CO2)1  1373m (CH 3 ) 1  1044s (C-U-C); 
6H  (300 MHz; CDC1 3 ) 0.88 (3H, t, 3J8 , 7 , 7, 8 'CH 3 ), 1.32 (12H, bs, T CH, , 6 CH 2 , 5 CH 7 , 
4 'CH21  3 'CH29  2 'CH2 ), 2.00 (3H, s, OAc), 2.02 (3H, s, OAc), 2.03 (3H, s, OAc), 2.08 
(3H, s, OAc), 3.45 (1H, td' 3j 1 ' , 2'  10, "CH), 3.68 (1H, m, 'CH), 3.86 (1H, td, 3J17 . 10, 
"CH), 4.13 (1H, dd, 2j 9'rn 12, 6 CH), 4.26 (1H, dd, 2gem 12, 6CH), 4.49 (1H, d, 3J 2  8 1  
'CH), 4.95 (1H, dd, 3J21 8, 2 CH), 5.08 (1H, t, 3J43 9, 4  CH), 5.20 (1H, t, 3J34 9, 3 CH); 
E (75 MHz; CDC1 3) 14.03 (CH 3 ), 20.56 (2x CH 3 ), 20.59 (CH 3 ), 20.69 (CH 3 ), 22.61 
(CH2 ), 25.78 (CH,), 29.21 (CH 2 ), 29.34 (CH 2 ), 29.38 (CH 2 ), 31.77 (CH ' ), 62.04 
(CH), 68.56 (CH), 70.21 (OCH,), 71.40 (CH), 71.76 (CH), 72.91 (CH), 100.84 (An 
CH), 169.22 (Q), 169.36  (Q), 170.28  (Q), 170.64  (Q); rn/z 460 (M, 1%), 459 (M - 
H, 4%),401 (M -C 2H3029 21%), 387 (M -C,H 5021  100%), 331 (M+-C 8H170'  10%), 
157 (M+-C 13H 1908 , 94%); [Found M 460.2325. C 22H 360 10 requires M 460.23091 
(E.I.). 




203 	 2 
A suspension of AgOTf (0.312 g, 1.21 mmol) and 2-cyclohexen-l-ol 204 
(1.189 g, 12.21 mmol) in dry CH2 C12  (2 ml) was stirred at -30 °C, in the presence of 
4A molecular sieves, under an atmosphere of N, and in the absence of light. A 
solution of tetra-o-acetyl-a-D-glucopyranosyl bromide 37 (0.509 g, 1.24 mmol) in 
dry CH202 (2 ml) was added over 10 mins while maintaining the temperature below 
-20 °C. The reaction mixture was stirred at this temperature for a further 30 mins, 
whereafter, tic revealed that the reaction had gone to completion. The reaction 
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mixture was allowed to warm to rt, filtered through a pad of Celite and the filtrate 
washed with water (2x 25 ml), 1% (w/v) aq NaHC0 1 (2x 25 ml), dried over Na,SO 4 
and the solvent removed by rotary evaporation to give a yellow oil (1.001 g). Flash 
column-chromatography (1:1, light petroleum-EtOAc) of the crude residue followed 
by crystallisation (EtOAc-light petroleum) afforded the title compound in a 1: 1 ratio 
of diastereoisomerst  as a colourless crystalline solid (0.150 g, 28%); R f 0.64 (1:1, 
light petroleum-ethyl acetate); m.p. 156-158 °C (from EtOAc-light petroleum); [a] 24 
-22.90 (c 1.00, CHC1 3); Vmax  (KBr)/cm' 2938w (CH), 1754s (CO 2 ), 1633w (CH), 
1039s (C-U-C); oH  (250 MHz; CDC1 1 ) 1.24 (2H, t, 3J4 , 5 7, CH2 ), 1.44-1.90 (4H, rn, 
3 'CH2 , 5 'CH 2), 2.00 (3H, s, OAc), 2.01 (3H, s, OAc), 2.02 (1.5H, s, OAc), 2.03 (1.5H, 
s, OAc), 2.08 (3H, s, OAc), 3.68 (1H, m, 'CH), 4.05-4.29 (3H, m, 6CH21 6 CH), 4.60 
(0.5H, d, 3J1 , 8, 'CH), 4.64 (0.5H, d, 3J12 8, 'CH), 4.95 (1H, dd, 3J21 8, 2 CH), 5.07 
(1H, dt, 3J43 9,4  CH), 5.19 (1H, t, 3J34 9, 3  CH), 5.70 (1H, m, 3J1 . 2 . 11, 'CH), 5.86 (1 H, 
M, 2 'CH); & (75 MHz; CDC1 3 ) 18.68 (0.5x CH2 ) 1  18.89 (0.5x CH,), 20.57 (2x CH 1 ), 
20.60 (CH 3 ), 20.70 (CH 3 ), 24.92 (0.5x CH,), 25.03 (0.5x CH2 ), 28.52 (0.5x CH"), 
29.72 (0.5x CH 2), 62.18 (0.5x CH 2 ), 68.64 (CH), 68.68 (CH), 71.57 (0.5x CH), 71.73 
(0.5x CH), 71.76 (0.5x CH), 72.92 (0.5x CH), 72.98 (0.5x CH), 73.40 (0.5x CH), 
73.52 (0.5x CH), 99.47 (0.5x An CH), 99.56 (0.5x An CH), 126.12 (0.5x CH), 
127.49 (0.5x CH), 131.64 (0.5x CH), 132.33 (0.5x CH), 169.14 (Q), 169.23 (0.5x Q), 
169.36 (Q), 170.32  (Q), 170.63 (0.5x Q); m/z 429 (MH, 10%), 428 (M, 3%), 331 
(M -C6H90, 35%), 271 (M+-C 8H13039  14%),97 (M -C 14H 19U9 , 59%); [Found MH 
429.1913. C20H280 10 requires MH 429.1761] (E.I.). 
1.4.6. 3-o-Pivaloylmorphine-6-(2',3' ,4',6'-tetra-o-acety1)-3 -D-glucopyranoside 
38 
Pivo 	2 





	AcO 	 38 
To a solution of 3-0-pivaloylmorphine 32 (1.238 g, 3.35 mmol) and A9 2 CO 3 
(4.472 g, 16.22 mmol) in dry benzene (20 ml) stirring at rt was added a solution of 
tetra-O-acetyl-a-D-glucopyranosyl bromide 37 (6.873 g, 16.71 mmol) in dry benzene 
Diastereoisomer ratio is calculated from the relative peak heights of the anomeric protons in the 'H 
NMR spectrum. 
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(20 ml). The reaction mixture was heated under reflux using Dean-Stark apparatus, at 
18 h tic showed that some starting material remained, thus, further A9 7CO 1 (2.035 g, 
7.38 mmol) and dry benzene (10 ml) were added. Six hours later, tic revealed that the 
reaction had gone to completion. The reaction mixture was allowed to cool to rt, 
filtered through a pad of Celite and the filtrate concentrated by rotary evaporation to 
give a dark red oil (6.193 g). The crude residue was dissolved in CH, C1,(150 ml) and 
the solution washed with 5% (w/v) aq citric acid (2x 250 ml), sat aq NaHCO, (2x 
250 ml), water (250 ml), brine (250 ml), dried over MgSO 4 and the solvent removed 
by rotary evaporation to give a brown foam (5.9 19 g). Flash column-chromatography 
(1:4, MeOH-CHC1 3 ) of the crude residue followed by crystallisation (EtOH-water) 
afforded the title compound as a white crystalline solid (0.852 g, 36%); R, 0.22 (1:9, 
MeOH-CHC13); m.p. 195 °C (from EtOH-water); [a] -105.88 (c 1.01, CHCI 3 ); 
[Found: C, 62.08%; H, 6.59%; N, 2.00%. C 36H45N0 11 requires C, 61.78%; H, 6.49%; 
N, 2.00%]; Vmax  (KBr)/cm' 2969m (CH), 1756s (CO2 ), 1640m (Ar CH), 1449m (Ar 
CH), 1117s (C-O-C); 6H  (250 MHz; CDC1 3 ) (COSY) 1.34 (9H, s, C(CH0 3 ) 1  1.91 
(1H, m, 3j 15eq,16ax , ' 5 CHeq) 1.94 (1H, m, 15CHax ), 1.99 (3H, s, OAc), 2.01 (3H, s, 
OAc), 2.03 (3H, s, OAc), 2.05 (3H, s, OAc), 2.29 (1H, dd, 2em  19, ' °CHax ), 2.37 
(1H, d, 3l6ax,15eq  5, 16C1T1ax), 2.41 (3H, s, NMe), 2.51 (1H, d, 
3j 
16eq,15ax 3, 16CHeq ) 2.61 
(1H, m, 3J149 3, 14  CH), 3.04 (1H, d, 21gem  19, ' °CHeq), 3.34 (1H, q, 3J9 3, 9CH), 3.7414 
(1H, m, 3J5 , 6 , 2, 5 'CH), 4.18 (2H, dd, 3J6,5, 2 ,  6 'CH2 ), 4.20 (1H, m, 'CH), 4.84 (2H, d, 
3J2 ', 1 8, 2 'CH, 5 CH), 4.97-5.21 (3H, m, "CH, 3 'CH , 4 CH), 5.28 (1H, dt, 3J78 10, 7CH), 
5.70 (1H, bd, 3J87 10, 8CH), 6.52 (1H, d, 3j j  8, 'CH), 6.67 (IH, d, 3 J, 8, 2CH); E,, 
(63 MHz; CDC1 1 ) 20.48 (CH 2 ), 20.61 (3x CH 3 ), 27.02 (4x CH 3 ), 35.63 (CH,), 38.85 
(Q), 40.97 (CH), 42.94 (NMe), 43.59 (Q), 46.08 (CH,), 58.46 (CH), 61.80 (CH,), 
68.26 (CH), 71.23 (CH), 71.79 (CH), 72.61 (CH), 73.53 (CH), 89.87 (CH), 99.18 
(An CH), 118.82 (CH), 121.51 (CH), 128.44 (CH), 130.53 (CH), 131.12 (Q), 131.63 
(Q), 131.95  (Q), 150.16  (Q), 169.16  (Q), 169.28  (Q), 170.09  (Q), 170.46  (Q), 176.25 
(Q); m/z 700 (MH, 56%), 699 (M, 11%), 656 (M -C 2H 3 0, 3%), 462 (M -C 8 H 1303 , 
3%), 368 (M+-C 16H 29N06 , 3 1%); [Found MH 700.2969. C 16H45N0 13 requires MH 
700.2969] (F.A.B.). 
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1.4.7. n-Butyl -D-g1ucopyranoside 238 
6 OH 
HO> 4 HO 	 ' 
3 	HO I 	1. 	' 
238 
To a solution of n-butyl 2,3,4,6-tetra-0-acety1-3-D-g1ucopyranoside 232 
(0.071 g, 0.18 mmol) in dry MeOH (1 ml) under an atmosphere of N, was added a 
solution of NaOMe (0.013 g, 0.24 mmol) in dry MeOH (1 ml). The reaction was 
stirred for 1 h; tic at that time revealed that the reaction had gone to completion. The 
solvent was removed by rotary evaporation to give a yellow oil (0.082 g), flash 
column-chromatography (9:1, CH 2 C17-MeOH) of the crude residue afforded the title 
compound as a yellow syrup (0.043 g, quantitative yield); R f 0.63 (9:4:2, EtOAc-
PrOH-water); Lit. 168  m.p. 68-69 °C; [a] 3 -23.08 (c 1.06, MeOH), (Lit. []a  - 
36.9); Vmax (neat)/cm' 2961s (CH), 2935s (CH), 2876s (CH), 1377m (CH 3 ), 1268m 
(C-O(H)), 1078s (C-O-C), 1032s (C-O-C); oH  (300 MHz; CD 3 0D) 0.95 (3H, t, 3J4 
'CH 3 )
1 
 1.42 (2H, m, 3J3 , 4 , 7, 3 'CH), 1.63 (2H, m, 3J2 . 3 . 7, 2 'CH 2 ), 3.16 (1 H, dd, 3J2 , 
2CH), 3.21-3.28 (3H, m, 3J1 , 2 . 7, "CH, 6CH, 3 CH), 3.55 (1H, td, 2geni  13, 6 CH). 3.68 
(1H, dd, 3J45 5, 4  CH), 3.79-3.99 (2H, m, 5 CH, "CH), 4.26 (1H, d, 3J 2 8, 'CH); E, (75 
MHz; CD 3 0D) 14.12 (CH 3 ), 20.09 (CH2 ), 32.79 (CH 2 ), 62.70 (CH 2 ), 70.49 (OCR,), 
71.60 (CH), 75.03 (CH), 77.78 (CH), 78.04 (CH), 104.26 (An CH); in/Z 237 (MH, 
1%), 163 (M _C 4H9 0, 3%), 116 (M+ -C6 H 1202 , 7%), 103 (M + -05 H 11 04 , 21%), 57 
(M -C 6H 11 06 , 100%); [Found MH 237.1333. C 10H2006 requires MH 237.1416] 
(E.I.). 
1.4.8. n-Octyl 3-D-g1ucopyranoside 239 
6 OH 
HO 	
8 HO ' 
3 	HO I 	I' 	3' 	5' 	7' 
239 
To a solution of n-octyl 2,3,4,6-tetra-o- acetyl -f3-D-glucopyranoside 233 
(0.10 1 g, 0.22 mmol) in dry MeOH (1 ml) under an atmosphere of N, was added a 
solution of NaOMe (0.017 g, 0.32 mmol) in dry MeOH (1.5 ml). The reaction was 
stirred for 10 mins; tic at that time revealed that the reaction had gone to completion. 
The solvent was removed by rotary evaporation to give a yellow oil (0.104 g), flash 
column-chromatography (9: 1, CH 2 C12-MeOH) of the crude residue afforded the title 
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compound as a yellow syrup (0.067 g, quantitative yield); R f 0.78 (9:4:2, EtOAc-
PrOH-water); Lit. 169 m.p. 110 °C; [a] -20.50 (c 1.34, MeOH), (Lit. 17° [a] - 
28.3); Vmax  (neat)/cm' 2961s (CH), 1376m (CH 3), 1030s (C-O-C); 8H  (250 MHz; 
CD 3 0D) 0.89 (3H, t, 3J8 , 7 , 7, 8 'CH), 1.30 (12H, bs, 7'CH2, 6' CH21 5 CH 2 , 4 CH,, "CH, 
2 'CH 2 ), 3.17 (1H, dd, 3j2,  1 8, 2CH), 3.22-3.41 (3H, m, 6CH 21  3CH), 3.53 (1H, td, 3J1 .,. 
10, "CH), 3.67 (1H, dd, 3J45 5, 4  CH), 3.83 (1H, m, 5 CH), 3.90 (1H, td, 3J 1 . 2 . 10 1  'CH), 
4.25 (1H, d, 3J12 8, 'CH); 8c (75 MHz; CD 3 0D) 14.40 (CH 3 ), 23.66 (CH,), 27.07 
(CH 2 ), 30.35 (CH 2 ), 30.54 (CH 2 ), 30.79 (CH 2 ), 32.96 (CH,), 82.64 (CH,), 70.98 
(OCH2), 71.74 (CH), 75.14 (CH), 77.85 (CH), 78.14 (CH), 104.36 (An CH); in/z 293 
(MH, 100%), 292 (M, 1%), 261 (M -CH 3 0, 82%), 163 (M -C 8 H 170, 21%), 144 
(M -C 5H805, 26%), 133 (M -C 9 H 190 29  2%); [Found MH 293.1955. C 14 H, 80 6 
requires MH 293.1964] (E.I.). 
1.4.9. Cyclohex-6'-enyl f-D-g1ucopyranoside 202 
6 OH 
HO 	 H 
HO 
3 	HO 1 
I , )3 , 
	
202 	2 
To a solution of cyclohex-6' -enyl 2,3 ,4,6-tetra-o-acetyl- 13  -D-glucopyranoside 
203 (0.071 g, 0.18 mmol) in dry MeOH (1 ml) under an atmosphere of N, was added 
a solution of NaOMe (0.022 g, 0.41 mmol) in dry MeOH (1.5 ml). The reaction was 
stirred for 30 mins; tic at that time revealed that the reaction had gone to completion. 
The solvent was removed by rotary evaporation to give a yellow oil (0.148 g), flash 
column-chromatography (9:1, CH 2 Cl 2-MeOH) of the crude residue afforded the title 
compound in a 1:1 ratio of diastereoisomerst  as a colourless oil (0.097 g, quantitative 
yield); R f 0.66 (9:4:2, EtOAc-PrOH-water); [a] -22.03 (c 0.45, MeOH); v,,, 
(neat)/cm- '2980m (CH), 2935s (CH), 1682m (C=C-H), 1169s (C-O(H)), 1047s (C-
O-C); H  (300 MHz; CD 3 0D) 1.47-2.16 (6H, m, 3 CH 2 , 4 CR,, 5 CH,), 3.16 (1 H, dd, 
3J2 , 1 8, 2 CH), 3.21-3.42 (3H, m, 6'CH, 3CH, 4CH), 3.68 (1H, dd, 2gefli  12, 6CH), 3.87 
(1H, bd, 2gem  12, 6CH), 4.29 (1H, m, 5 CH), 4.39 (0.5H, d, 3J12 8, 'CH), 4.42 (0.5H, d, 
3J1,2 8, 'CH), 5.47-5.95 (2H, m, "CH, 2'  CH); ö (75 MHz; CD 3 0D) 20.03 (0.5x CH,), 
20.36 (0.5x CH 2 ), 25.94 (0.5x CH 2 ), 25.99 (0.5x CH 2 ), 29.27 (0.5x CH,), 31.15 (0.5x 
CH 2 ), 62.69 (CH 2 ), 71.59 (CH), 73.60 (0.5x CH), 74.51 (0.5x CH), 74.97 (0.5x CH), 
75.09 (0.5x CH), 77.75 (0.5x CH), 77.78 (0.5x CH), 78.00 (CH), 102.53 (0.5x An 
Diastereoisomer ratio is calculated from the relative peak heights of the anomeric protons in the 'H 
NMR spectrum. 
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CH), 103.23 (0.5x An CH), 128.51 (0.5x CH), 129.79 (0.5x CH), 131.41 (0.5x CH). 
131.70 (0.5x CH); m/z 261 (MH, 2%),260 (M, 1%), 163 (M -C 6H90, 19%).143 
(M -C 4H5049 25%), 97 (M -C 6H 11 051  20%), 81 (M -C 6H 11 06 , 100%), 73 (M - 
C9H 1504 , 34%); [Found M 260.1274. C 12H2006 requires M 260.1260] (E.I.). 
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A suspension of 3-o-pivaloy1morphine-6-(2,3,4,6-tetra-o-acety1)-3-D-
glucopyranoside 38 (0.252 g, 0.36 mmol) in dry MeOH (10 ml) was stirred at rt 
under an atmosphere of N 2 . A 0.23 M solution of NaOMe (0.012 g, 0.23 mmol) in 
dry MeOH (1 ml) was added with the addition of further NaOMe (0.012 g, 0.23 
mmol) in dry MeOH (1 ml) at 17 h, 21 h and 24 h. Tic revealed that the reaction had 
gone to completion after 48 h, the pH of the reaction mixture was neutralised using 2 
M aq HCl and the solvent removed by rotary evaporation to give an off white solid 
(0.380 g). Crystallisation (MeOH-ether) of the crude residue afforded the title 
compound as an off white solid (0.151 g, 94%); R f 0.30 (1:1:1, butanol-acetone-
water); m.p./decomp. 234-235 °C (from MeOH-ether); [a] -140.22 (c 0.37, water), 
(Lit. 52 [a] -132 (c 1, water); [Found: C, 53.84%; H, 6.43%; N, 1.79%. C7 IH,9NOS 
requires C, 61.72%; H, 6.55%; N, 3.10%1; v.,,, (KBr)/cm' 1655m (CH), 1616m 
(CH), 1459s (CH), 1040s (C-O-C); oH  (250 MHz; D,O) (COSY) 2.06 (1H, bd, 2 J,, 
12, 15CHeq) 2.27 (1H, bt, 2g,.  12, "CH.), 2.83-3.14 (2H, m, 
14  CH, '°CHax)  2.94 (3H, 
s, NMe), 3.21 (3H, bs, 16CHaX ), 3.27-3.55 (6H, m, 2gem  19, ' °CHeq 2 'CH , 3 'CH , 4 CH, 
5 'CH, ' 6CHeq) 3.68 (1H, dd, 2 lgem 12, 6' 6'  3.86 (1H, dd, 2gem  12, 6 CH), 4.18 (IH. 
M, 9CH), 4.55 (1H, m, 6CH), 4.70 (1H, d, 3J1 8, "CH), 5.21 (1H, d, J5.6  8, 5 CH), 
5.38 (1H, bd, 3J78 11, 'CH), 5.82 (1H, bd, 3J87  11, 8 CH), 6.62 (1H, d, 3J 2 8, 'CH), 
6.73 (1H, d, 3j2 ,  1 8, 2CH); O (63 MHz; D 2 0) 20.93 (Cl-I2 ), 34.47 (CH 2 ), 38.55 (CH), 
40.94 (NMe), 41.59 (Q), 47.20 (CH2 ), 60.61 (CH 31  CH2 ), 69.51 (CH), 72.78 (CH), 
73.24 (CH), 75.66 (CH), 76.06 (CH), 88.14 (CH), 101.52 (An CH), 117.73 (CH), 
120.45 (CH), 123.28 (Q), 126.04 (CH), 129.05 (Q), 131.40 (CH), 137.97 (Q), 145.58 
(Q); m/z 448 (MH, 17%), 269 (M+-C6H 11 06 , 7%), 237 (M+-C 7H 16N06 , 31%), 214 
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(M -C 16H9029  28%); [Found MH 448.1961. C 21H 29N08 requires MT-I 448.19711 
(F.A.B.). 
1.4.11. Methyl (n-Butyl f3-D-glucopyranosid)uronate 240 
6CO 3Me 
HO 	 0 	 4. 
3 HO I 
240 
TEMPO Oxidation; A solution of n-butyl 3-D-g1ucopyranoside 238 (0.054 g, 
0.23 mmol) and TEMPO (1 mg, 0.01 mmol) in CH 2 C12  (1 ml) stirring at rt was 
treated with a solution of KBr (0.028 g, 0.23 mmol) and Bu 4NC1 (3 g, 0.23 mmol) in 
sat aq NaHC0 1 (1 ml), whereafter, the temperature was lowered to 0 °C and a 
solution of 0.6 M NaOClt  (0.0828 g, 0.05 mmol) in sat aq NaHCO 3 (0.5 ml) and 
brine (1 ml) was added over 45 mins. Further 0.6 M NaOC1 (0.120 g, 0.072 mmol) 
was added at 3 h. Tlc revealed that the reaction had gone to completion after 17 h, 
the organic layer was isolated, washed with water (3x 5 ml) and the pH of the 
combined aqueous washings was adjusted to pH 3 with 2 M HCl, extracted with 
EtOAc (5x 25 ml) and the volume of the combined organic extracts reduced by 
rotary evaporation to give a white solid (0.018 g). Flash column-chromatography 
(9:1, CH 2 C12-MeOH) of the crude residue afforded a yellow syrup (0.030 g) which 
was dissolved in MeOH (4 ml) and stirred at rt with Dowex 50W x8 H (0.114 g), for 
21 h. The reaction mixture was filtered and the volume of the filtrate reduced by 
rotary evaporation to give a yellow syrup (0.011 g). Flash column-chromatography 
(9:1, CH 2 C12-MeOH) of the crude residue afforded the title compound as a yellow 
syrup (1 mg, 20%); R f 0.72 (9:1, CH 2C12-MeOH); [a] -27.22 (c 0.19, MeOH); v 11  
(nujol)/cm' 1744s (CO 2)
1 
 1068s (C-O-C), 1026s (C-O(H)); 6H  (300 MHz; CD 3 0D) 
0.95 (3H, t, 3J43 , 7, 'CH 3 ), 1.41 (2H, sextet, 3J34, 7, 3 'CH), 1.61 (2H, quintet, 3J2 . 3 . 7, 
2 'CH 2 ), 3.21 (1H, dd, 3J, 3 8, 2 CH), 3.39 (1H, t, 3J34 9,3  CH), 3.47-3.61 (2H, m, 3J1 . 2 . 7. 
"CH, 4CH), 3.76 (3H, s, CO 2 CH1 ), 3.79-3.87 (2H, m, 2gem  13, 'CH, 'CH), 4.29 (IH, 
d, 3J12 8, 'CH); 6 (63 MHz; CD 1 0D) 14.12 (CH 1 ), 20.10 (CH2), 32.62 (CH,), 57.79 
(CO 2 CH1 ), 70.93 (OCH 2), 73.15 (CH), 74.80 (CH), 76.63 (CH), 77.41 (CH), 104.80 
(An CH), 171.30 (Q); m/z 282 (MNH41  86%), 265 (MH, 7%), 208 (M+-C4H5, 
100%), 191 (M -C 4H9 0, 30%); [Found MNH4 282.1552. C 11 H2007 requires MNH4 
282.15531 (C.I.). 
Each batch of sodium hypochiorite solution obtained from the commercial supplier contained 
varying quantities of sodium hypochlorite. Initial titration against potassium iodide and standardised 
sodium thiosulfate gave a molarity of 0.6 M for the sodium hypochlorite solution. 
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Platinum Oxidation; A solution of P102 (Adams Catalyst) (0.031 g, 0.11 
mmol) in high purity water (2 ml) was stirred for 5 h at rt under an atmosphere of H,. 
A solution of n-butyl -D-glucopyranoside 238 (0.031 g, 0.13 mmol) in n-heptane (2 
ml) was added and the reaction mixture heated to 60 °C with a continuous stream of 
02 supplied by a sintered bleed. After 42 h at this temperature, tic revealed that the 
reaction had gone to completion. The reaction mixture was allowed to cool to rt, 
filtered through a pad of Celite and the volume of the filtrate concentrated by rotary 
evaporation to give a yellow syrup (0.012 g). The crude residue was dissolved in 
MeOH (2 ml) and the temperature of the solution lowered to 0 °C, a solution of 
diazomethane (0.424 g, 10.08 mmol) in ether (10 ml) was added dropwise. After 1 h 
at this temperature, tic revealed the reaction had gone to completion, the reaction 
mixture was allowed to warm to rt and the solvent removed by rotary evaporation to 
give a yellow syrup (9 mg). Flash column-chromatography (9:1, CH,Cl,-MeOH) of 
the crude residue afforded the title compound as a white solid (3 mg, 10%). 






A solution of methyl (X-D-glucopyranoside 230 (0.307 g, 1.6 mmol) in high 
purity water (50 ml) was stirred for 15 mins at rt while a continuous stream of 0, 
supplied by a sintered bleed was applied at a vigorous rate. The rate of 0-, delivery 
was reduced to a gentle stream and 5% Pt/C (0.500 g) was added. The reaction 
mixture heated to 55 °C and the pH maintained between pH 6-7 by the addition of 
0.1 M aq NaHCO 3 , after 48 h tic revealed that the reaction had gone to completion. 
The reaction mixture was allowed to cool to rt, filtered through a pad of Celite and 
the solvent removed by rotary evaporation to give an off white solid (1.870 g). A 
suspension of the crude residue was stirred at rt in MeOH (60 ml) with Amberlyte 
Resin 1R 120(H) (15 g), tic revealed that the reaction had gone to completion after 3 
days. The reaction mixture was filtered and the solvent removed by rotary 
evaporation to give a glassy solid (1.369 g), flash column-chromatography (9:1, 
EtOAc-MeOH) of the crude residue afforded the methyl (methyl 
glucopyranosid)uronate as a colourless glass (0.824 g). The methyl (methyl 
glucopyranosid)uronate was stirred in dry Py (5 ml) under an atmosphere of N, at rt 
and treated with with Ac 2 0 (4.328 g, 42.39 mmol) and DMAP (4 g, 0.03 mmol). 
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After 1 h tic revealed that the reaction had gone to completion, the reaction mixture 
was poured onto a mixture of ice (40 g) and 2 M aq HC1 (25 ml), extracted with 
EtOAc (4x 50 ml) and the combined organic extracts washed with 2 M aq HCl (2x 
100 ml), sat aq NaHCO 3 (2x 100 ml), water (100 ml), brine (100 ml) and dried over 
MgSO4 and the solvent removed by rotary evaporation to give a yellow syrup (1.172 
g). Flash column-chromatography (3:2, light petroleum-EtOAc) of the crude 
acetylated product afforded the title compound as a clear, glassy solid (1.088 g, 
40%); Rf O.6l (1:1, light petroleum-EtOAc), Lit. 171  m.p. 150-151 °C; [a]22  1.77 
(c 0.98, CHC1 3 )
1 
 (Lit. 172  [a] +106 (c 0.65, CHC13 ); [Found: C, 48.13%; H, 6.07%; 
N, 0%. C 14H200 10 requires C, 48.26%; H, 5.79%; N, 0%]; Vmax  (nujol)/crn' 1755s 
(CO2), 1133s (C-0-C), 1051s (C-0-C); 6H  (250 MHz; CDC1 3 ) 1.98 (3H, s, OAc), 
1.99 (3H, s, OAc), 2.04 (3H, s, OAc), 3.42 (3H, s, OMe), 3.74 (3H, s, CO3 CH3 ), 4.26 
(1H, d, 3J54 10, 5 CH), 4.86 (1H, dd, 3J214 , 2 CH), 4.99 (1H, d, 3J, 4, 'CH), 5.13 (1 H, 
t, 3J43 10,4  CH), 5.48 (1H, t, 3J34 10, 3 CH); E (63 MHz; CDC1 3) 20.33 (CH 3 ), 20.49 
(2x CH 3 ), 52.71 (OMe), 55.83 (CO 2 CH 3 ), 67.95 (CH), 69.09 (CH), 69.44 (CH), 
70.30 (CH), 96.92 (An CH), 167.92 (Q), 169.36  (Q), 169.72  (Q), 169.84 (Q); in/z 
349 (MW, 2%),348 (M, 1%), 257 (M+-C 3H7039  5%), 197 (M+-C 3 H 11 05 , 19%), 155 
(M -C7H 1306 , 62%), 43 (M+-C 12H 1709 , 100%); [Found MH 349.1136. C 14H 200 1() 
requires MH 349.1135] (F.A.B.). 
1.4.13. Methyl (methyl 2,3,4-tri-o-acetyl-f3-D-galactopyranosid)uronate 250 
ACO 





A solution of 1-0-methyl 3-D-galactopyranoside 249 (1.535 g, 7.90 mmol) in 
high purity water (50 ml) was stirred for 5 mins at rt while a continuous stream of 0, 
supplied by a sintered bleed was applied at a vigorous rate. The rate of O delivery 
was reduced to a gentle stream and 5% Pt/C (0.494 g) was added. The reaction 
mixture heated to 55 °C and the pH was maintained between pH 6-7 by the addition 
of 0.1 M aq NaHCO 3 , after 48 h tic revealed that the reaction had gone to 
completion. The reaction mixture was allowed to cool to rt, filtered through a pad of 
Celite and the solvent removed by rotary evaporation to give an off white solid 
(1.873 g). A suspension of the crude residue was stirred at rt in MeOH (60 ml) with 
Amberlyte Resin 1R 120(H) (5 g), tic revealed that the reaction had gone to 
completion after 5 days, the reaction mixture was filtered and the solvent removed by 
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rotary evaporation to give an off white syrup (1.412 g), flash column-
chromatography (17:3, EtOAc-MeOH) of the crude residue afforded the methyl 
(methyl galctopyranosid)uronate as a white solid (0.665 g). A suspension of the 
methyl (methyl galctopyranosid)uronate was stirred in dry Py (5 ml) and treated with 
Ac2 0 (3.246 g, 31.80 mmol) and DMAP (5 g, 0.04 mmol). After 4 h tic revealed that 
the reaction had gone to completion. The reaction mixture was poured onto a mixture 
of ice (20 g) and 1 M aq HC1 (50 ml), extracted with EtOAc (4x 50 ml) and the 
combined organic extracts washed with 1 M aq HC1 (2x 100 ml), sat aq NaHCO 3 (2x 
100 ml), water (100 ml), brine (100 ml), dried over MgSO 4 and the solvent removed 
by rotary evaporation to give a white foam (0.875 g). Flash column-chromatography 
(1:1, light petroleum-EtOAc) of the crude acetylated product followed by 
crystallisation (ether-EtOAc-light petroleum) afforded the title compound as a white 
crystalline solid (0.571 g, 21%); R f O.34 (1:1, light petroleum-EtOAc); m.p. 106-107 
°C (from ether-EtOAc-light petroleum), (Lit. 173  95-96 °C); [a] 24  + 15.52 (c 1.07, 
CHC1 3 )
1 
 (Lit.173 [(X]22D  +160 (CHC1 1 ); [Found: C, 48.33%; H, 5.85%; N, 0%. 
C 14H200 10 requires C, 48.26%; H, 5.79%; N, 0%]; Vniax  (KBr)/cm' 3014w (CH), 
2968w (CH), 1754s (CO 2 )
1 
 1455m (CH 1 ), 1374s (COCH 3), 1146s (C-O-C), 1081s 
(C-O-C), 1054s (C-O-C); 6H  (250 MHz; CDC11 ) 1.96 (3H, s, OAc), 2.04 (3H, s, 
OAc), 2.10 (3H, s, OAc), 3.55 (3H, s, OMe), 3.74 (3H, s, CO 2 CH1 ), 4.30 (1 H, d, 3J54 
2, 5 CH), 4.41 (1H, d, 3J12 8, 'CH), 5.05 (1H, dd, 3J32 10, 3 CH), 5.23 (1H, dd, 3J, 8, 
2 CH), 5.68 (1H, dd,.3J45 2, 4CH); ö (63 MHz; CDC1 1 ) 20.43 (CH 3 ), 20.45 (CH 3 ). 
20.64 (CH 3 ), 52.67 (OMe), 57.22 (CO 2 CH 1 ), 68.20 (CH), 68.26 (CH), 70.42 (CH), 
72.21 (CH), 101.82 (An CH), 166.37 (Q), 169.26  (Q), 169.75  (Q), 169.96 (Q); mn/z 
349 (MH, 7%), 348 (M, 1%), 317 (M -CH 1 0, 100%), 197 (M -CH 11 0 51  3t%), 
155 (M -C7 H 1306 , 62%),43 (M -C 12H 17099  76%); [Found MH 349.1148. C 14H 200 10  
requires MH 349.1135] (F.A.B.). 
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1.5. Synthesis of Morphine-6-3-D-glucoside Analogues 





A solution of 45% (w/v) HBr in glacial acetic acid (1 ml; 0.450 g, 5.60 mmol 
HBr) was stirred at rt while a-D-galactopyranose pentaacetate (0.715 g, 1.80 mmoi) 
was added over 5 mins, whereafter stirring was continued for 30 mins; tic revealed at 
that time that the reaction had gone to completion. The reaction mixture was poured 
onto ice (20 g), partitioned with CHC1 3 (15 ml) and the organic extract was washed 
with ice cold water (4x 15 ml), sat aq NaHCO 3 (2x 15 ml), water (15 ml), brine (15 
ml) and dried over MgSO 4 . The solvent was removed by rotary evaporation to give a 
clear colourless oil (0.764 g), crystallisation (from ether-light petroleum) of the crude 
residue afforded the title compound as a white crystalline solid (0.579 g, 77%); R 
0.67 (1:1, light petroleum-EtOAc); m.p. 79-80 °C (from ether-light petroleum), 
(Lit. 174 83-85 °C); [a] 14  (c 1.01, CHC1 1), (Lit. 174 [u]D +215 (CHC1 3 ); 
[Found: C, 40.47%; H, 4.71%; N, 0%. C 14H 1909Brrequires C, 40.97%; H, 4.67%; N, 
0%]; V max  (CHC11 )/cm' 3000s (CH1 ), 1750s (CO 2 ), 1078m (C-U-C); 6H  (250 MHz; 
CDC13 ) 2.00 (3H, s, OAc), 2.05 (3H, s, OAc), 2.10 (3H, s, OAc), 2.14 (3H, s, OAc), 
4.14 (2H, qd, 3J65 7, 'CH), 4.48 (1H, t, 3J56 7, 5CH), 5.04 (1H, dd, 3J2 4, 2 CH), 5.40 
(1H, dd, 3J34 3, 3 CH), 5.50 (1H, d, 3J43 3, 4CH), 6.68 (1H, d, 3J12 4, CH); ö (63 
MHz; CDC1 3 ) 20.39 (CH 3 ), 20.42 (CH 3 ), 20.47 (CH3, 20.58 (CH 3 ), 60.66 (CH,), 
66.80 (CH), 67.59 (CH), 67.81 (CH), 70.88 (CH), 87.94 (An CH), 169.59 (Q), 
169.73 (Q), 169.90  (Q), 170.16  (Q); m/z 411 (MW, 1%), 331 (M -Br, 55%), 353 
(M -C 2H2029 28%), 351 (M+_C A0 2 , 28%) 9 169 (M*  -C6 H 10UBr, 100%); [Found 
M 410.0343. C 14H 19O9Br requires M410.0212] (F.A.B.). 
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A solution of 3-0-pivaloylmorphine 32 (0.105 g, 0.29 mmol) and A9 7CO 3 
(0.480 g, 1.74 mmol) in dry benzene (10 ml) was stirred at rt, a solution of tetra-O-
acetyl-cx-D-galactopyranosyl bromide 46 (0.195 g, 0.48 mmol) in dry benzene (10 
ml) added and the reaction mixture heated under reflux using Dean-Stark apparatus. 
After 24 h tic revealed that the reaction had gone to completion. The reaction mixture 
was allowed to cool to rt, filtered through a pad of Celite and the filtrate concentrated 
by rotary evaporation to give a dark red oil (0.362 g). Flash column-chromatography 
(13:1, CH 2 C12-MeOH) of the crude residue afforded the title compound as a white 
solid (0.032 g, 16%); R f 0.62 (9:1, CHC1 5-MeOH); oH  (250 MHz; CDC1 3 ) 1.35 (9H, 
s, C(CH3 ) 3 ) 1  1.90 (1H, m, ' 5CHeq) 1.97 (3H, s, OAc), 2.01 (1H, m, 
15  CH,, , )2.03 (3H, 
s, OAc), 2.06 (3H, s, OAc), 2.14 (3H, s, OAc), 2.38 (lB. dd, 2g,.  19, 10C4), 2.42 
(3H, s, NMe), 2.44 (1H, m, ' 6CHax ), 2.56 (1H, bd, 3J1615 5, 
1 6  CH,
q
), 2.64 (1H, rn, 
14 CH), 3.05 (1H, d, 2 Jgem 19, ' °CHeq) 3.36 (1H, q, 3j9' 1 4, 9CH), 3.94 (1H, t, 3J5 . 6 7, 
5 'CH), 4.02-4.20 (2H, m, 3J6 . 5 , 7, 6 'CH2 , 6CH), 4.80 (1H, d, 3J12 8, 'CH), 4.88 (1H, dd, 
3J5 ,6 6, 5 CH), 5.00 (iH, dd, 3J3 , 4 4, 3 'CH), 5.25 (1H, dd, 3J21 8, 2 'CH), 5.30 (1H, m, 
7 CH), 5.38 (1H, dd, 3J4 , 3 , 4, 4 'CH), 5.72 (1H, bd, 3J87 10, 'CH), 6.53 (111, d, 3J. 8, 
'CH), 6.67 (1H, d,  3j2 ' 1 8, 2CH); O, (63 MHz; CDC1 3 ) 20.50 (CH 7 ), 20.56 (2x CH 3 ), 
20.74 (CH 3 ), 27.05 (3x CH 3 ), 29.55 (CH 2 ), 35.61 (CH,), 38.87 (Q), 40.95 (CH), 
42.92 (NMe), 43.59 (Q), 46.11 (CH 2 ), 58.51 (CH), 61.22 (CH,), 66.97 (CH), 68.68 
(CH), 70.70 (CH), 70.80 (CH), 73.94 (CH), 90.00 (CH), 100.11 (An CH), 118.81 
(CH), 121.60 (CH), 128.30 (CH), 130.71 (CH), 131.11 (Q), 131.65  (Q), 131.82  (Q), 
150.25 (Q), 169.29  (Q), 170.05  (Q), 170.17  (Q), 170.24  (Q), 176.29  (Q); a full 
characterisation was not possible as result of the limited quantity of material 
available. 
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Base catalysed synthesis at low temperature; A suspension of D-(+)-galactose 
144 (0.107 g, 0.59 mmol) and DMAP (5 g, 0.04 mmol) was stirred in dry Py (5 ml) 
at -10 °C with the exclusion of water provided by a drying tube containing CaCl 2 . 
Isobutyryl chloride (0.712 g, 6.68 mmol) was added dropwise over 45 mins while 
maintaining the temperature below -5 °C. The reaction mixture was stirred for a 
further 2 h at this temperature and then allowed to warm to rt overnight. The reaction 
mixture was poured onto ice (20 g), extracted with CH 2 C1 2 (4x 20 ml) and the 
combined organic extracts were washed with 2 M aq HCl (2x 100 ml), sat aq 
NaHCO 3 (2x 100 ml), water (100 ml), brine (100 ml), dried over MgSO 4 and the 
solvent removed by rotary evaporation to give a yellow oil (0.289 g). Flash column-
chromatography (8:2, light petroleum-EtOAc) afforded the title compound as a 
colourless syrup (0.534 g, 87%); R f O.SO (8:2, light petroleum-EtOAc); [a] 22  +84.62 
(c 1.06, CHC1 3 ); [Found: C, 59.07%; H, 7.89%; N, 0%. C 26H420 11 requires C, 
58.84%; H, 8.98%; N, 0%]; Vmax  (neat)/cm - '2974s (CH), 2936s (CH), 2877s (CH), 
1754s (CO2 ), 1099s (C-U-C), 1037s (C-U-C); 8 H (250 MHz; CDC1 3 ) 1.04-1.26 (30H, 
m, 1 O CHCH3 ), 2.31-2.74 (5H, m, 5x CHCH 3 ), 4.02 (2H, d, 3J65 7, 6 CH 2 ), 4.35 (1H, 
t, 3J5 , 6 7, 'CH), 5.36 (2H, dd, 3J21 2, 2CH, 4CH), 5.52 (1H, t, 3J34 2, 3 CH), 6.35 (IH, d, 
3J1 , 2 2, 'CH); ö (63 MHz; CDC1 3) 18.36 (CH 3 ), 18.49 (CH 3 )
1 
 18.61 (4x CH 3 ), 18.69 
(Cl3 )
1 
 18.77 (CH3 )
1 
 18.81 (CH 3 )
1 
 18.95 (CH3 ), 33.61 (CH), 33.67 (CH), 33.75 (CH), 
33.83 (CH), 33.89 (CH), 60.96 (CH,), 66.30 (CH), 66.93 (CH), 67.35 (CH), 68.81 
(CH), 89.29 (An CH), 174.75 (Q), 175.55  (Q), 175.71  (Q), 175.79  (Q), 176.29  (Q); 
m/z 531 (MH, 2%), 530 (M 1 , 3%), 445 (M -C 4H5023 100%), 375 (M -C 8 H 30 31  
52%), 375 (M -C 8 H 1304 , 17%); [Found 530.2734. C 26H 420 11 requires 530.27271 
(F.A.B.). 
Base catalysed synthesis at an elevated temperature; A suspension of D-(+)-
galactose 144 (0.105 g, 0.58 mmol) and DMAP (0.022 g, 0.18 mmol) was stirred in 
dry Py (5 ml) with the exclusion of water provided by a drying tube containing 
CaC1 2 . Isobutyryl chloride (0.712 g, 6.68 mmol) was added dropwise and the reaction 
mixture heated to 50 °C, and stirring was continued at this temperature for 2 h; tic 
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revealed that the reaction had gone to completion. The reaction mixture was poured 
onto ice (20 g) and extracted with CH 2 C12 (4x 20 ml). The combined organic extracts 
were washed with 2 M aq HC1 (2x 100 ml), sat aq NaHC0 1 (2x 100 ml), water (100 
ml), brine (100 ml), dried over MgSO 4 and the solvent removed by rotary 
evaporation to give a yellow oil (0.261 g, 84% crude yield); the spectroscopic data 
was in agreement with that reported for the title compound of the previous synthesis. 




PrCO, -----•':---•-- O,CPr 3 	'PrCO,  I 
261 
A suspension of D-(+)-galactose 144 (5.070 g, 28.14 mmol) in dry Py (48.900 
g, 618.20 mmol) was heated under reflux with the exclusion of water provided by a 
drying tube containing CaC1 21  for 1 h, thereafter isobutyryl chloride (30.510 g, 
286.34 mmol) was added dropwise and the reaction mixture heated under reflux for a 
further 1 h, then allowed to cool to rt. The reaction mixture was poured onto a 
mixture of ice (100 g) and 2 M aq HC1 (100 ml), extracted with EtOAc (3x 100 ml) 
and the combined organic extracts washed with sat aq NaHC0 1 (4x 250 ml), water 
(2x 250 ml), brine (2x 250 ml), dried over MgSO 4 and the solvent removed by rotary 
evaporation to give a brown oil (16.698 g). Flash column-chromatography (1:99, 
EtOAc-light petroleum) of the crude residue afforded an inseparable mixture in a 
ratio 7:1:2 of 3-D-galactopyranose pentaisobutyrate 261, a-D-galactopyranose 
pentaisobutyrate 260 and f3-D-galactofuranose pentaisobutyrate 263 respectively, as a 
yellow syrup (11.711 g, 78%; approximately 9.452 g, 2.17 mmol of the title 
compound); Rf O.S6 (8:2, light petroleum-EtOAc); Vmax  (neat)/cm' 2981s (CH), 2940s 
(CH), 2876s (CH), 1749s (CO 2), 1386s (CH 3 )
1 
 11 12s (C-U-C); 8H  (250 MHz; CDCI 3 ) 
1.00-1.24 (60H, m, lOx 13F-CHCH3 , lOx P-CHCH 3 ), 2.39-2.70 (10H, m, 5x 13F-
CHCH3 , 5x P-CHCH3 ), 4.00-4.40 (5H, m, F- 5 CH, 13F- 6 CH,, 13P- 5 CH, 13P- 6 CH 7 , CLP-
5 CH, (XP- 6CH2 ), 5.05-5.15 (2.6H, m, 13P- 4CH, P- 3CH, 13F- 2 CH), 5.19-5.55 (4.4H, m. 
3J2 , 1 8, 3P- 2CH, cxP- 3 CH, fF- 2 CH, aP- 4CH, 3F- 3 CH, 13F- 4 CH, xP- 2 CH), 5.71 (0.8H, ci, 
3J1 , 2 8, 3P-'CH), 6.12 (1H, s, 13F-'CH), 6.32 (0.2H, d, 3J 2  4, (xP-'CH); 3 (63 MHz. 
CDC13 ) 18.17-19.00 [18.17, 18.27, 18.32, 18.40, 18.52, 18.54, 18.59, 18.65, 18.69, 
18.78, 19.00] (lOx F-CH3 , lOx P-CH3 ), 33.56-33.87 [33.56, 33.59, 33.66, 33.70, 
33.76, 33.82, 33.87] (5x 13F-CH, 5x P-CH), 60.51 (0.8x 3P-CH 7), 61.70 (0.2x aP-
CH2), 62.26 (F-CH 2), 66.30 (0.8x 13P-CH), 67.51 (0.8x 13P-CH), 68.79 (13 F- CH), 
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70.09 (0.2x (R-CH), 70.64 (0.8xPP-CH), 71.68 (0.8x 13P-CH), 73.11 (0.2x ctP-CH), 
75.16 (0.2x (R-CH), 75.70 (13F-CH),  78.90 (0.2x aP-CH), 80.22 (3F-CH), 82.27 
(OF-CH), 91.88 (0.8x AnPP-CH), 93.02 (0.2x An (R-CH), 98.81 (An J3F-CH), 
174.77-176.21 [174.77, 174.89, 175.16, 175.51, 175.55, 175.78, 175.85, 176.21] (5x 
13F-Q, 5x P-Q); mlz 529 (MH, 2%), 457 (M+ -C4H9 0, 6%), 443 (M -C 4 1-1 7 0,, 88%), 
442 (M-C4H8 O 2 , 42%),197 (M-C 15H25O8 , 100%) (F.A.B.). 







- 	14 9NMe 
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iprCO, 	 269 
iPr 	 2' 
6' 	 0,CPr 
A solution of the inseperable 3-D-ga1actopyranose 261, (X-D-galactopyranose 
260 and 3-D-galactofuranose pentaisobutyrate 263 (7.988 g, approximately 1.598 g, 
3.01 mmoi of 3-D-ga1actofuranose pentaisobutyrate 263) in dry CH,Cl, (20 ml) was 
added to a solution of 3-0-pivaloyimorphine 32 (0.829 g, 2.24 mmol) in dry CH 2 C! 7 
(11 ml) under an atmosphere of N 2 . The resulting solution was stirred at rt for 10 
mins, whereafter the temperature was lowered to 0 °C and TMSOTf (2.415 g, 10.87 
mmol) was added dropwise while maintaining the temperature below 5 °C. Tic at 3 h 
showed the reaction was incomplete, thus, further 3-0-pivaloylmorphine 32 (0.687 g, 
1.84 mmoi) in dry CH2C12 (9 ml) and TMSOTf (1.150 g, 5.17 mmol) was added and 
more TMSOTf (1.150 g, 5.17 mmoi) added again at 5 h. Tic revealed the reaction 
had gone to completion after 7 h; the reaction mixture was poured onto a mixture of 
ice (100 g) and sat aq NaHCO 3 (100 ml), extracted with CH 2 C1 2 (4x 100 ml) and the 
combined organic extracts washed with 5% (w/v) aq citric acid (3x 250 ml), sat aq 
NaHCO3 (2x 250 ml), water (2x 250 ml), brine (250 ml), dried over MgSO 4 and the 
solvent removed by rotary evaporation to give a yellow oil (8.147 g). Flash column-
chromatography (1:29, MeOH-CHC1 3 ) of the crude residue followed by 
crystallisation (EtOH-water) afforded an inseparable mixture of the title compound 
and 3-O-pivaloylmorphine-6-(2' ,3' ,4' ,6' -tetra-O-isobutyryl)-3-D-galactopyranoside 
270 as a white foam (0.778 g) and the title compound as a white solid (0.238 g, 7%); 
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Rf 0.54 (9:4:2, EtOAc-?rOH-water); m.p. 124-125 °C (from EtOH-water); [Found: 
C, 65.18%; H, 7.73%; N, 1.52%. CH 61 NO 11 requires C, 65.07%; H, 7.58%; N, 
1.73%]; 
[a] 13 
 (c 1.00, CHC13); Vmax  (KBr)/cm' 2976m (CH), 2932m (CH), 
2871m (CH), 2792w (NMe), 1741s (CO 2 ), 1388m (CH 7 ), 1153s (C-O-C); 8H  (250 
MHz; CDC1 3) (COSY) 1.10-1.19 (24H, m, 8x CHCH1 ), 1.30 (9H, s, C(CH3 ) 3 ) 1  1.95- 
1.97 (2H, m, ' 5CHeq ' 5CHax), 2.34 (1H, dd, 2gem  19, ' °CHax ), 2.42 (3H, s, NMe), 2.44-
2.64 (7H, m, 4x CHCH1 ), 16CHeq , 16CHax 14  CH), 3.05 (1H, d'2j gem  19, ' °CHeq ) 335 
(1H, q, 3j9' 1 4 3, 9CH), 4.12-4.22 (3H, m, 6 CH, 6 'CH 2 ), 4.36 (1H, dd, 3J
5 
-. 6- 12, 5 CH), 
4.99 (2H, m, 3 'CH, 5 CH), 5.08 (1H, d, 2 'CH), 5.28-5.40 (3H, m, 3J78 10, 7 CH, 'CH. 
4' CH), 5.63 (1H, bd, 3J87 10, 'CH), 6.53 (1H, d, 3j2 '  1 8, 'CH), 6.70 (1H, d, 3j,  8, 
2 CH); E,, (63 MHz; CDC1 3) 18.59 (CH 7 ), 18.63 (CH3 ), 18.66 (2x CH 1 ), 18.73 (2x 
CH1 ), 18.78 (CH 7 ), 18.83 (CH 3 ), 20.75 (CH,), 27.01 (3x CH 1 ), 33.53 (CH), 33.57 
(CH), 33.74 (CH), 33.89 (CH), 35.56 (CH,), 38.87 (Q), 40.97 (CH), 42.99 (We), 
43.48 (Q), 46.22 (CH2), 58.65 (CH), 62.19 (CH 2), 68.93 (CH), 69.82 (CH), 76.26 
(CH), 80.48 (CH), 81.08 (CH), 88.73 (CH), 102.90 (An CH), 118.86 (CH), 121.50 
(CH), 128.82 (CH), 130.29 (CH), 131.38 (Q), 131.97  (Q), 131.99  (Q), 150.26  (Q), 
175.00 (Q), 175.69  (Q), 175.82  (Q), 176.04  (Q), 176.27  (Q); m/z 812 (MH, 2%), 
811 (M, 14%), 724 (M -C 4H7029 5%), 638 (M -C8 H 13041  5%), 443 (M - 
C22H26N04, 14%), 268 (M -C 27H430119 15%); [Found MH 812.4216. C44 H 61 NO 1 
requires MH 812.4221] (F.A.B.). 
1.5.6. Morphine-6-3-D-ga1actofuranoside 273 
2 






6 	 OH 
A suspension of 3-O-pivaloylmorphine-6-(2' ,3' ,4' ,6' -tetra-O-isobutyryl)- 13-D-
galactofuranoside 269 (0.094 g, 0.12 mmol) in dry MeOH (5 ml) was stirred at rt for 
1 h under an atmosphere of N 2 . A 0.52 M solution of NaOMe (0.056 g, 1.04 mmol) 
in dry MeOH (2 ml) was added and stirring was continued for 2 h. Tic indicated that 
the reaction was proceding slowly, thus a further addition of NaOMe (0.056 g, 1.04 
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mmol) in dry MeOH (2 ml) was carried out. Tic revealed that the reaction had gone 
to completion after 22 h, the reaction mixture was neutralised with 2 M aq HC1 and 
the solvent removed by rotary evaporation to give an off white solid (0.181 g). The 
crude residue was dissolved in warm MeOH and filtered through a sintered funnel. 
Rotary evaporation of the filtrate gave a white solid (0.15 1 g) which on 
crystallisation (MeOH- PrOH) afforded the title compound as a white solid (0.061 g, 
quantitative yield); Rf 0.36 (9:4:2, EtOAc-'PrOH-water); m.p./decomp. 158 °C (from 
MeOH-EtOAc); [a]' -89.35 (c 0.47, MeOH); [Found: C, 29.60%; H, 3.42%; N. 
1.35%. C 21H 29N07 requires C, 61.72%; H, 6.54%; N, 3.13%]; Vmax  (KBr)/cm' 292 Is 
(CH), 2852m (CH), 1612m (Ar CH), 1558m (Ar CH), 1499m (Ar CH), 1387m 
(CH 1 )
1 
 1 121s (C-O(H)), 1097s (C-O-C), 1028s (C-O-C); 8H  (250 MHz; CD 1 0D) 1.96 
(1H, bd, 2j gem 
1 1 , 15CHeq ), 2.23 (1H, td, 2gem ' 5CHax ), 2.57 (1H, dd, 2Jg 19, 
' °CHax), 2.60 (1H, m, 16 CH), 2.61 (3H, s, NMe), 2.77 (111, bd, 2 1gem 11, '6CHeq),  2.82 
(1H, m, 14  CH), 3.16 (1H, d, 2gem  19, ' °CHeq), 3.58 (1H, m, 'CH), 3.71 (III, d, 3J,. 6, 
2' CH), 3.83 (1H, m, 3'  CH), 3.99-4.20 (4H, m, 5 CH, 4CH, 6'  CH,), 4.42 (III, m, 6CH), 
5.12 (1H, dd, 3J56 6, 5 CH), 5.33 (lH, d, 3 l OH 2, "CH), 5.46 (iH, dt, 3J78 11, 7 CH), 
5.81 (1H,bd, 3J87 11, 8CH), 6.54 (1H, d, 3J17 8, 'CH), 6.64 (1 H, d, 3J"1 8 , 2 CH); & (63 
MHz; CD 1 0D) 19.92 (CH 2 ), 34.09 (CH 2 ), 39.28 (CH), 40.97 (NMe), 42.34 (Q), 
45.78 (CH 2 ), 58.65 (CH), 62.54 (CH 2), 70.18 (CH), 70.48 (CH), 76.80 (CH), 81.48 
(CH), 82.84 (CH), 88.08 (CH), 105.93 (An CH), 115.83 (CH), 118.49 (CH), 124.52 
(CH), 127.08 (CH), 129.60 (Q), 130.54 (CH), 138.07 (Q), 145.48 (Q); ,n/z 448 
(MH, 1%), 385 (M -C 2H60 2 , 19%), 357 (M -C 3 H60 1 , 25%), 338 (M -C 6H 6 0 2 , 
1%), 268 (M+-C 6H,,06 , 6%), 43 (M -C 21 H26N077  100%); [Found MH 448.1958. 
C23H29N08 requires MH 448.1971] (F.A.B.). 
1.5.7. a-D-Galactopyranose Pentabenzoate 255 
BzO 
I 	OBz 




A cooled (0 °C) and stirred solution of D-(+)-galactose 144 (1.018 g, 5.65 
mmol) in Py (9.780 g, 123.64 mmol) was treated with benzoyl chloride (7.872 g, 
56.00 mmol), added dropwise, while the temperature was maintained below 4 °C. 
After 3 h a white precipitate had formed which dissolved on addition of CHC1 1 (20 
ml). The reaction mixture was poured onto ice (20 g), the aqueous layer isolated and 
extracted with CHC1 1 (3x 30 ml). The combined organic extracts were washed with 1 
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M aq HC1 (2x 100 ml), water (100 ml), sat aq NaHCO 3 (2x 100 ml), water (100 ml), 
brine (100 ml), dried over MgSO 4 and the solvent removed by rotary evaporation to 
give a yellow oil (5.588 g). Flash column-chromatography (8:2, light petroleum-
EtOAc) of the crude residue followed by crystallisation (ether-light petroleum) 
afforded the title compound as a white powder (1.002 g, 25%); Rf O.59 (7:3, light 
petroleum-EtOAc); m.p. 149-150 °C (from ether-light petroleum); [a] +182.18 (c 
1.00, CHC1 3 )
1 
 (Lit.175 [(XID  +187.1); [Found: C, 69.86%; H, 4.50%; N, 0%. C4, H320 1,
requires C, 70.27%; H, 4.61%; N, 0%]; Vmax  (KBr)/cm 2975w (CH), 1730s (CO,), 
1602m (Ar CH), 1454m (Ar CH), 1108s (C-O-C), 1026s (C-O-C); 5 H  (250 MHz; 
CDC13 ) 4.42 (1H, dd, 3J65 7, 6CH), 4.64 (1H, dd, 3J65 7, 6CH), 4.84 (1H, t, 3J 6 7, 
5 CH), 6.03 (1H, dd, 3J23 7, CH), 6.13 (1H, dd, 3J32 4, 3 CH), 6.19 (1H, dd, 3J43 4, 
4CH), 6.95 (1H, d, 3J12 4, 'CH), 7.25-8.40 (25H, m, 5x CA); 3, (63 MHz; CDCI 3 ) 
61.69 (CH2 ), 67.54 (CH), 68.31 (CH), 68.39 (CH), 69.29 (CH), 90.53 (An CH), 
128.23 (2x Ar CH), 128.28 (5x Ar CH), 128.55 (Ar Q), 128.61 (Ar Q), 128.66 (3x Ar 
CH), 128.80 (Ar Q), 128.83 (Ar Q), 129.13 (Ar Q), 129.63 (7x Ar CH), 129.82 (3x 
Ar CH), 133.12 (Ar CH), 133.28 (Ar CH), 133.36 (Ar CH), 133.61 (Ar CH), 133.79 
(Ar CH), 164.41 (Q), 165.35  (Q), 165.43  (Q), 165.57  (Q), 165.79  (Q); m/z 699 (M - 
H, 1%), 580 (M -C 7H402 , 30%), 579 (M -C 7H5029 80%), 459 (M -C 14H904 , 1%), 
335 (M -C 21 H 1706 , 4%); [Found 699.1885. C41 H 320 11 requires 699.1866] (F.A.B.). 





A solution of 45% (w/v) HBr in glacial acetic acid (15 ml; 6.750 g, 83.33 
mmol HBr) was stirred at rt while a-D-galactopyranose pentabenzoate 255 (3.151 g, 
4.50 mmol) was added over 5 mins. Stiring was continued for 4 h; tic at that time 
revealed that the reaction had gone to completion. The reaction mixture was poured 
onto ice (20 g), extracted with CH 202 (4x 30 in]) and the combined organic extracts 
washed with water (2x 100 ml), sat aq NaHCO 3 (2x 100 ml), water (100 ml), brine 
(100 ml), dried over MgSO4 and the solvent removed by rotary evaporation to give a 
white foam (2.591 g). Flash column-chromatography (8:2, light petroleum-EtOAc) 
of the crude residue followed by crystallisation (light petroleum) afforded the title 
compound as a fine white powder (0.750 g, 25%); R f 0.54 (7:3, light petroleum-
EtOAc); m.p. 61-62 °C (from light petroleum); [a] 23  (c 1.04, CHC1 3 ). 
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(Lit.176 [OC]IO 	(c 1, CHC1 3); [Found: C, 62.13%; H, 4.20%; N, 0%. 
C34H2709Br requires C, 61.81%; H, 4.06%; N, 0%); Vmax  (KBr)/cm 1 3071s (CH), 
2968s (CH), 1730s (CO 2), 1602m (Ar CH), 1451m (Ar CH), 1095s (C-U-C); 8H  (250 
MHz; CDC1 3) 4.47 (1H, dd, 3J65 7, 6 CH), 4.65 (1H, dd, 3J65 7, 6CH), 4.93 (1H, t, 3J 6 
7, 5 CH), 5.68 (1H, dd, 3J21 4, 2CH), 6.07 (1H, dd, 3J34 4, 3  CH), 6.13 (1H, dd, 3J43 4, 
4CH), 6.99 (1H, d, 3J12 4, 'CH), 7.20-8.10 (20H, m, 4x CA); 8c (63 MHz; CDC1) 
61.52 (CH2 ), 67.91 (CH), 68.43 (CH), 68.73 (CH), 71.67 (CH), 88.13 (An CH), 
128.20 (2x Ar CH), 128.32 (2x Ar CH), 128.36 (Ar Q), 128.42 (2x Ar CH), 128.60 
(2x Ar CH), 129.07 (Ar Q), 129.60 (Ar Q), 129.66 (3x Ar CH), 129.80 (2x Ar CH), 
129.87 (3x Ar CH), 133.20 (Ar Q), 133.25 (2x Ar CH), 133.66 (2x Ar CH), 165.17 
(Q), 165.21  (Q), 165.41  (Q), 165.77  (Q); m/z 661 (MH, 1%), 660 (Mt, 2%),579 (M 
-Br, 43%), 539 (M -C7 H5 02 , 7%), 459 (M'-C7H502Br, 4%); [Found M 660.0831. 
C34H2709Br requires M660.0818] (F.A.B.). 





3 	BzO I 
264 
A suspension of D-(+)-galactose 144 (0.500 g, 2.77 mmol) in Py (10 ml) was 
heated under reflux for 1 h with the exclusion of water provided by a drying tube 
containing CaCl 2 . Benzoyl chloride (3.633 g, 25.85 mmol) was added dropwise and 
the reaction mixture was heated under reflux for a further 1 h, then allowed to cool to 
rt. The reaction mixture was poured onto a mixture of ice (20 g) and sat aq NaHCO 3 
(20 ml), extracted with CH 202 (3x 20 ml) and the combined organic extracts washed 
with 1 M aq HC1 (4x 100 ml), sat aq NaHCO 3 (2x 100 ml), water (100 ml), brine 
(100 ml), dried over MgSO 4 and the solvent removed by rotary evaporation to give a 
brown oil (3.840 g). Flash column-chromatography (8:2, light petroleum-EtOAc) of 
the crude residue followed by crystallisation (light petroleum-ether) afforded an 
inseparable mixture in a 6:1 ratio of the title compound and 3-D-galactofuranose 
pentabenzoate 266 respectively, as an off white foam (0.991 g, 51%; approximately 
0.849 g, 1.21 mmol of the title compound); R f 0.46 (7:3, light petroleum-EtOAc); 
Lit. 175 m.p. 169-170 °C; Lit. 175 [a]° +53.5 (c 0.8, CHC1 3 ); Vmax  (KBr)/cm 1 3067m 
(CH), 2974 (CH), 2361m (Ar CH), 2341m (Ar CH), 1731s (CU,), 1107s (C-U-C), 
1068s (C-O-C), 1026s (C-U-C); 8 H  (250 MHz; CDC1 3 ) 4.45 (1H, dd, J6.5  6, PP-'CH), 
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4.59 (1H, t, 346 6, PP-'CH), 4.68 (1H, dd, 2 1gem 10, 13P- 6CH), 4.78 (2H, m, 3J6 5, J3F-
6CH2), 4.87 (1H, t, 3J56 5, 3F- 5 CH), 5.78 (2H, m, 3F- 3 CH, 13F- 4CH), 5.79 (1H, dd, 3J3•4 
9, 13P- 3 CH). 6.06-6.16 (3H, m, 3j2 , 1 8, 3P- 2CH, f3P- 4CH, F- 2 CH), 6.29 (1H, d, 3J1 , 8 1 
3P-'CH), 6.80 (1H, bs, 13F-'CH), 7.20-8.15 (50H, m, 5x f3P-C 6H5 , 5x F-C 6H5 ); 6 
(63 MHz; CDC1 3 ) 61.63 (13P-CH2),  63.50 (F-CH2), 67.79 (13P-CH),  68.58  (13P-CH), 
70.25 (F-CH), 71.41 (PP-CH), 72.28 (13P-CH),  76.90 (3F-CH), 81.00 (F-CH), 
84.40 (3F-CH), 92.91 (An 13P-CH), 99.75 (An 3F-CH), 128.20 (2x Ar 3P-CH, 2x 
OF-CH), 128.30 (4x Ar 13P-CH, 4x PF-CH), 128.40 (2x Ar PP-CH, 2x PF-CH), 
128.51 (ArPP-Q), 128.55 (2x Ar 3P-CH, 2x PF-CH), 128.64 (Ar 3P-Q, 2x Ar 3F-
Q), 128.80 (Ar 13P-Q), 129.09 (Ar PF-Q), 129.15 (Ar PP-Q), 129.32 (Ar f3F-Q), 
129.57 (Ar 3P-Q, Ar OF-Q), 129.62 (2x Ar 3P-CH, 2x 13F-CH), 129.67 (Ar PP-CH, 
Ar 3F-CH), 129.71 (ArPP-CH, Ar 13F-CH), 129.80 (Ar 13P-CH, Ar f3F-CH), 129.91 
(2x ArPP-CH, 2x PF-CH), 130.05 (ArPP-CH, Ar 13F-CH), 130.12 (2x Ar PP-CH, 
2x 3F-CH), 132.89 (Ar 3F-CH), 133.14 (Ar 13P-CH), 133.26 (ArPP-CH, Ar 3F-CH), 
133.32 (Ar 13P-CH), 133.41 (Ar 13F-CH), 133.56 (Ar 13P-CH), 133.59 (Ar 13P-CH), 
133.73 (2x Ar f3F-CH), 164.50 (f3F-Q), 164.56 (P-Q, PF-Q), 165.17 (13P-Q,  13F-Q), 
165.34 (2x PP-Q, 13F-Q), 165.80 (F Q), 165.86  (13P-Q); m/z 700 (M, 1%), 699 (M 
-H, 1%), 579 (M-C 7 H5 027  82%), 459 (M-C 14H9 O2 , 1%), 105 (M- -C34H,7010,  100%) 
(F.A.B.). 




A suspension of D-(-)-arabinose (5.024 g, 33.47 mmol) in dry Py (48.900 g, 
618.20 mmol) was heated under reflux for 1 h with the exclusion of water provided 
by a drying tube containing CaCl 2 . Benzoyl chloride (48.440 g, 344.60 mmol) was 
added dropwise and the reaction mixture heated under reflux for a further 1 h, then 
allowed to cool to rt. The reaction mixture was poured onto a mixture of ice (100 g) 
and 2 M aq HC1 (100 ml), extracted with EtOAc (3x 100 ml) and the combined 
organic extracts washed with sat aq NaHCO 3 (4x 250 ml), water (4x 250 ml), brine 
(2x 250 ml), dried over MgSO 4 and the solvent removed by rotary evaporation to 
give a brown oil (33.480 g). Flash column-chromatography (1:9, EtOAc-light 
petroleum) of the crude residue followed by crystallisation (EtOAc-light petroleum) 
afforded the title compound as a white crystalline solid (0.821 g, 29%); R f 0.53 (8:2, 
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light petroleum-EtOAc); m.p. 148-149 °C (from EtOAc-light petroleum), (Lit. 177 
21 
162-163 °C); [a] -112.61 (c 1.09, CHC1 3), (Lit. 177 [aJ-112 (c 0.55, CHC1 3 ); 
[Found: C, 69.74%; H, 4.66%; N, 0%. C 33H2609 requires C, 69.95%; H, 4.63%; N, 
0%]; Vmax  (KBr)/cm' 1729s (CO 2 ), 1636m (Ar CH), 1602m (Ar CH), 1492m (Ar 
CH), 1087s (C-O-C); 6 (250 MHz; CDC1 3 ) 4.14 (1H, dd, 2"g,.  12, 5 CH), 4.43 (1H, 
dd, 2 g,. 12, 5 CH), 5.79 (2H, m, 3 CH, 4CH), 5.94 (1H, dd, 3J21 5,
2  CH), 6.25 (1H, d, 
3J12 5, 'CH), 7.28-7.62 (12H, m, Ar CH), 7.93-8.00 (8H, m, Ar CH); 3, (63 MHz; 
CDC13 ) 62.61 (CH2 ), 67.43 (CH), 68.78 (CH), 69.78 (CH), 92.30 (An CH), 128.37 
(4x Ar CH), 128.41 (4x Ar CH), 128.67 (Ar Q), 128.73 (Ar Q), 128.97 (Ar Q), 
129.16 (Ar Q), 129.79 (3x Ar CH), 130.03 (5x Ar CH), 133.38 (2x Ar CH), 133.48 
(Ar CH), 133.59 (Ar CH), 164.62 (Q), 165.00  (Q), 165.35  (Q), 165.44 (Q); in/z 567 
(MH, 1%), 566 (M, 1%), 461 (M- -C7 H5 0, 1%), 446 (M-C 7 H4 O 7 , 10%), 445 (M-
C7H5 02 , 50%), 443 (M+-C 7H7021  29%), 105 (M*C27H,1O8,  59%); [Found MH 
565.1489. C 33H2609 requires MH 565.1499] (F.A.B.). 
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A solution of a-D-arabinopyranose tetrabenzoate 275 (2.033 g, 3.59 rnmol) in 
dry CH2 Cl2 (15 ml) was added to a solution of 3-0-pivaloylmorphine 32 (0.277 g, 
0.75 mmol) in dry CH 2 C12 (2.8 ml) under an atmosphere of N 2 . The resulting mixture 
was stirred at rt for 10 mins, whereafter, the temperature was lowered to 0 °C and 
TMSOTf (0.805 g, 3.62 mmol) was added dropwise while maintaining the 
temperature below 5 °C. The reaction was stirred at this temperature for a further 2 h; 
tic at that time showed that the reaction was not complete so further 3-0-
pivaloylmorphine 32 (0.297 g, 0.80 mmol) in dry CH 202 (3 ml) and TMSOTf (0.805 
g, 3.62 mmol) was added. TMSOTf (0.345 g, 1.55 mmol) was added again at 4 h, 
and after 5 h tic revealed that the reaction had gone to completion. The reaction 
mixture was poured onto a mixture of ice (50 g) and sat aq NaHC0 1 (50 ml), 
extracted with CH 202 (4x 100 in]) and the combined organic extracts washed with 
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5% (w/v) aq citric acid (3x 100 ml), sat aq NaHCO 3 (2x 100 ml), water (2x 100 ml), 
brine (100 ml), dried over MgSO 4 and the solvent removed by rotary evaporation to 
give an off white foam (0.724 g). Flash column-chromatography (1:19, MeOH-
CHC13 ) of the crude residue followed by crystallisation (EtOH-water) afforded the 
title compound as a white solid (0.724 g, 44%); R f 0.55 (1:9, MeOH-CH 3C1); m.p. 
138-140 °C (from EtOH-water); [Found: C, 70.41%; H, 5.91%; N, 1.54%. 
C48H47N0 11 requires C, 70.82%; H, 5.82%; N, 1.72%]; 
[a] 13 
 (c 1.06, CHC1 3 ); 
Vmax  (KBr)/cm' 2971m (CH), 2924m (CH), 2857m (CH), 2780m (NMe), 1731s 
(CO2 )
1 
 1121s (C-O-C); 6H  (250 MHz; CDC1 3) (COSY) 1.00 (9H, s, C(CH 3 ) 1 ) 1  1.95 
(1H, bd, 2j gem 12, 15CHeq) 2.06 (1H, td, 2"gem  12, 15 CHax ), 2.33 (1H, dd, 2
j 
gem 19, 
10CHax), 2.42 (3H, s, NMe), 2.46 (1H, d, 3 j 16ax,15eq 4, 16CHax ) 2.55 (111, d, 3
j 
16eq.15ax 3' 
16CHeq), 2.62 (1H, m, 3J149 3, 14  CH), 3.08 (1H, d, 2gem  19, 10CHeq)  3.37 (1H, q, 3J914 3, 
9CH), 4.00 (1H, dd, 3J5 , 4 , 4, 5 CH), 4.14(111, m, 3J65 3, 6 CH), 4.74 (1H, dd, 2 Jgem. 11 
"CH), 5.08 (2H, m, 3J56 3, 5 CH, "CH), 5.29 (111, dt, 3J78 10,7  CH), 5.52 (1H, dd, 3J,.. 
5, 2 'CH), 5.60 (1H, d, 3J87 10, CH), 5.71 (2H, m, 3J3 , 2 , 3, 3 'CH, 4 CH), 6.57 (111, d, 
3J1 ,2 8, 'CH), 6.74 (1H, d, 3j2, 1 8, 2CH), 7.23-7.67 (9H, m, Ar), 7.81-8.13 (6H, m, Ar); 
6 (63 MHz; CDC1 3 ) 20.88 (CH 2 ), 26.85 (3x CH 3 ), 35.72 (CH 2 ), 38.55 (Q), 41.48 
(CH), 43.02 (NMe), 44.08 (Q), 46.04 (CH 2 ), 58.42 (CH), 58.88 (CH 2), 67.02 (CH), 
68.51 (CH), 69.98 (2x CH), 92.54 (CH), 99.75 (An CH), 118.82 (CH), 121.66 (CH), 
128.21 (3x CH), 128.33 (2x CH), 128.42 (2x CH), 129.07 (Q), 129.34  (Q), 129.38 
(Q), 129.63 (CH), 129.83 (4x CH), 130.14 (2x CH), 131.57 (Q), 131.82  (Q), 132.20 
(Q), 133.07 (CH), 133.20 (CH), 133.41 (CH), 150.71 (Q), 165.00  (Q), 165.47  (Q), 
165.60 (Q), 176.16  (Q); m/z 814 (MU', 40%), 813 (M, 46%), 712 (M -0 5 H9 0 2 , 
1%), 693 (M -C 7H402 , 2%), 445 (M -C 22H26N04, 65%); [Found MH 814.3218. 
C481147N0 11 requires MH 814.3227] (F.A.B.). 
1.5.12. Morphine-6-a-D-arabinopyranoside 281 
15 1,o 
5 (9NMe 
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A suspension of 3-O-pivaioylmorphine-6-(2' ,3' ,4' -tri-O-benzoy!)-a-D-
arabinopyranoside 277 (0.270 g, 0.25 mmol) in dry MeOH (10 ml) was stirred at rt 
for 1 h under an atmosphere of N 2 . A 0.52 M solution of NaOMe (0.140 g, 2.60 
mmol) in dry MeOH (5 ml) was added and stirring was continued for 2 h. Tic 
indicated that the reaction was proceding slowly, thus a further addition of NaOMe 
(0.084 g, 1.56 mmol) in dry MeOH (3 ml) was carried out. Tic revealed that the 
reaction had gone to completion after 5 h, the reaction mixture was neutralised with 2 
M aq HCl and the solvent removed by rotary evaporation to give an off white solid 
(0.351 g). The crude residue was dissolved in MeOH and filtered through a sintered 
funnel. Rotary evaporation of the filtrate gave a white solid (0.250 g) which on 
crystallisation (MeOH-EtOAc) afforded the title compound as a white solid (0.043 g, 
43%); R f 0.29 (9:4:2, EtOAc-PrOH-water); m.p./decomp. 159 °C (from MeOH-
EtOAc); [a]-129.78 (c 0.39, MeOH); [Found: C, 51.74%; H, 5.95%; N, 2.56%. 
C22H27N07 requires C, 63.28%; H, 6.52%; N, 3.36%]; Vmax  (KBr)/cm' 2921m (CH), 
2852w (CH), 1386m (CH 3)
1 
 1087s (C-O(H)), 1067s (C-O-C); oH  (250 MHz; CD 3 0D) 
(COSY) 1.94 (1H, dd, 2'gem  13, 15CHeq) 2.25 (1H, td, 2gefl  13, 
15  CH,,,), 2.59 (IH, dd, 
2 J8em 19, "CH.), 2.63 (3H, s, NMe), 2.69 (1H, dd, 2gem  13, 16CHax ), 2.82 (2H, m. 
14 ' 6CHeq) 3.17 (1H, d, 21gem  19, ' °CHeq ) 3.61-3.72 (3H, m, 9CH, 2 'CH. 3 CH, 	 CH), 3.77 
(1H, dd, 2gem  12, 
5 '  CH), 3.94 (1H, m, 4'  CH), 4.05 (1H, dd, 2g,.  12, 5 CH), 4.42 (IH, 
M, 6CH), 4.48 (1H, d, 3J 1 , 2 ,7, "CH), 5.05 (1H, dd, 3J56 6, 5 CH), 5.46 (1H, dt, 3J7 10, 
7 CH), 5.90 (1H, dq, 3J87 10, 'CH), 6.55 (1H, d, 3J17 8, 'CH), 6.63 (1H, d, 3J, 1 8, 2 CH); 
O (63 MHz; CD 1 0D) 20.05 (CH,), 33.96 (CH 2 ), 39.40 (CH), 40.91 (NMe), 42.70 
(Q), 45.65 (CH2), 58.61 (CH), 65.07 (CH 2 ), 67.60 (CH), 70.36 (CH), 72.21 (CH), 
73.84 (CH), 90.84 (CH), 103.12 (CH), 115.87 (CH), 118.61 (CH), 124.33 (Q), 
127.91 (CH), 129.38 (CH), 129.56 (Q), 138.15  (Q), 145.50  (Q); m/z 418 (MH, 
55%), 268 (M -0 5 H905 , 16%), 239 (M -C 6H 12N05 , 100%), 237 (M -C 6 H 4NO. 
51%), 131 (M -C 17H20N01 , 96%); [Found MH 418.1864. C 22H 27N07 requires MH 
418.18661 (F.A.B.). 
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Appendix 
A.1. Synthesis of 3-0-Pivaloylmorphine and 3-0-Acetylmorphine 
The synthesis of 3-0-pivaloylmorphine 32 is achieved in 74% yield by 
treating morphine sulphate 20 with pivaloyl chloride and potassium hydroxide 




















KOH, CH 2C12,  
32 
Synthesis of 3-0-Pivaloylinorphine 32 and 3-0-Acetylmorphine 27. 
Scheme A.1. 
The synthesis of 3-0-acyl morphine derivatives under basic conditions has 
been established for many years and a classic example is the synthesis of 3-0-
acetylmorphine 27 which was reported by Welsh 179 in the 1950's. This acylation 
reaction is still commonly used and involves treating morphine with acetic anhydride 
and sodium bicarbonate to afford 3-0-acetylmorphine 27 in good yields (scheme 
A.1.). 39 
A.2. 'H and COSY NMR Spectra of 3-0-Pivaloyl Morphine 
Assigning the peaks in the 'H NMR spectra of the synthesised morphine 
glycosides was made more straight forward when the peaks corresponding to the 
morphine protons could be identified. The 'H NMR (figure A.2.) and COSY (figure 
A.3.) spectra of 3-0-pivaloylmorphine 32 were therefore recorded and proved to be 
of great value in understanding the 'H NMR spectra of the morphine glycosides 
synthesised. 
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3-0-Pivaloylmorphine 32 contains 5 chiral centres at C5, C6, C9, C13 and 
C14 with the protons at C9 and C14 lying trans to each other. There are three CH, 
groups at CIO, C15 and C16, two benzylic protons on Cl and C2 and two allylic 




N- XT HO 
7 
Structure of 3-0-Pivaloylinorphine 32. 
Figure A. 1. 
By examining the three dimensional structure of 3-0-pivaloylmorphine 32 
(figure A.4.) and applying the Karplus equation the splitting patterns observed in the 
'H NMR spectrum (figure A.2.) can be explained; 
The signals of the C15 and C16 protons are split as a result of two types of 
coupling, geminal and vicinal, however, the spatial orientation of the vicinal protons 
greatly affects the splitting patterns observed. The equatorial C15 proton is initially 
coupled to the axial C15 proton with an observed geminal coupling constant of 13 
Hz. The signal for the equatorial C 1 proton is then split as a result of coupling to the 
C16 protons, both of which are at a dihedral angle of 50-60° to the equatorial C15 
proton which according to the Karplus equation should give a coupling constant of 
approximately 4 Hz. However, multiple splitting of the peaks and extensive 
overlapping results in the signal for the equatorial C15 proton appearing as a broad 
doublet at 6 1.91 ppm in the 'H NMR spectrum. Coupling of the axial C15 proton to 
the C16 protons, which are at a dihedral angle of approximately 50° and 180°, gives 
observed coupling constants of 5 and 12 Hz respectively, and signal appears as a 
triplet of doublets at 6 2.1 ppm. 
A similar splitting pattern is observed for the two C16 protons, the signal for 
the axial C16 proton lies under the peaks of the axial CIO proton at 6 2.38 ppm and 
only one coupling constant of 4 Hz can be measured, which corresponds to the 
coupling of the equatorial C15 proton. The signal of the equatorial C16 proton 
appears at 6 2.65 ppm, the equatorial C 1 proton is initially coupled to the axial C16 
proton with an observed coupling constant of 13 Hz. The signal is then split again by 
the two C15 protons which both lie at a dihedral angle of 50-60° to the equatorial 
158 
Chemo-Enzymatic Approaches to M6G and Selected Analogues 
C16 proton and the spectral lines extensively overlap to give the broad doublet of 
doublets observed in the 'H NMR spectrum. 
The geminal coupling for the protons at ClO has an unusually large coupling 
constant of 19 Hz as a result of the close proximity of the aromatic ring. The axial 
and equatorial protons at CIO have different signal splitting patterns in the 'H NMR 
spectrum, the equatorial CIO proton at ö 3.04 ppm appears as a doublet while the 
axial C 10 proton appears at ö 2.32 ppm as a doublet of doublets. The equatorial C 10 
proton lies at a dihedral angle of about 90° to the C9 proton and so according to the 
Karplus equation, no coupling exists between these two protons and this is what is 
observed in the 'H NMR spectrum. However, the axial C 1 proton lies at a dihedral 
angle of approximately 30° to the C9 proton and there is an observed coupling 
constant of 6 Hz between these two protons. 
The peak corresponding to the C6 hydroxyl proton lies between ö 3.4-3.7 
ppm, its close proximity to the C6 proton distorts its signal so that it is not possible to 
measure any coupling constants. However, the value of the coupling constant for the 
C6 proton can be obtained from the C5 proton signal which is observed to be 7 Hz 
corresponding to a vicinal coupling between the C5 and C6 protons which have cis 
stereochemistry. 
The coupling constant of the C9 and C14 protons is observed to be 3 Hz and 
so the dihedral angle of these vicinal protons would be approximately 60°. The 
coupling constant of the C7 and C8 protons is observed to be 10 Hz and this 
confirms that the protons are in a cis conformation. The C8 proton is observed to 
have a higher chemical shift than C7 as a result of the electron withdrawing effect of 
the C6 hydroxyl group through the double bond (figure A.2.). 
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4. 	 r. 
'H NMR Spectrum of 3-0-Pii'alovlmorp/iine 32. 
Figure A.2. 
(250 MHz; CDC1.) 1.33 (9H, s, (CH) 3 ), 1.91 (1H, bd, 2J 	13, CH 1 ). 2.10 (1 H, 
td, 2"gern  13 , 15CH ax ), 2.32 (1 H, dd, 2'gern  19 , ' °CH 1 ), 2.38 (1 H, rn, 	4, 
2.45 (3H, s, NCH,), 2.65 (1H. bdd, 2gem  13, 16CHeq)  2.74 (1 H. t, 3 J149 3, 
14  CH), 3.04 
(1H, d, 2gem  19, ' °CHeq ) 3.38 (1H. q, J91 3, 9CH), 4.13 (1H, m, 6CH). 4.91 (1H. dd. 
31 7, 'CH), 5.25 (1H, bd, 3J7 10, 7 CH), 5.75 (1H, bd, 3J 10, CH). 6.59 (11-1. d, 





















- 	 . 
5.5 	 5.0 	 4.5 	 4.0 	 3.5 	 9.0 	 9.5 	 9.0 
pp 
'H-'H Correlated (COSY) NMR Spectrum of 3-0-Pivalov1norp/iiiie 32. 
Figure A.3. 
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The Three Dimensional Structure of 3-0-Pivalovlmorphine 32. 
Figure A.4. 
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A.3. 1 H and COSY NMR Spectra of Morphine-6-3-D-gIucoside 31 
'H NMR Spectrum of Morphine-6-f3-D-glucoside 31. 
Figure A.5. 
H (250 MHz; D 2 0) (COSY) 2.06 (1H, bd, 2gem  12, '5CHeq)  2.27 (1H. bt . J. 1 12. 
' 5CH), 2.83-3.14 (2H, m, 14  CH, 0CH j .ç ) 2.94 (3H, s, We), 3.21 (3H. bs . boCH) .  
3.27-3.55 (6H, m, 2gem  19, ' °CHeq CH, 3 CH, 4 CH, 5 CH, 16CH.q ) 3.68 (1 H, dd. gern 
12, 6 CH), 3.86 (1H, dd, 2gefli  12, 6 CH), 4.18 (1H. m. 9 CH), 4.55 (1H, m. CH). 4.7() 
(1H, d, 3J1 . 2 . 8, "CH), 5.21 (1H, d, 34 8, 'CH), 5.38 (1H, bd. 3J7 11, 'CH), 5.82 (1 H. 
bd, 3J8 11, 8 CH), 6.62 (1H, d, 3J1 2 8, 'CH), 6.73 (IH, d. 8. 2 CH). 
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5 	 6.0 	 55 	 5.0 	 4.5 	 4.0 	 3.5 	 3.0 
PPM 
'H-'H Correlated (COSY) NMR Spectrum of Morphine-6--D-g/ucoside 31. 
Figure A.6. 
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A.4. 'H NMR Spectrum of Morphine-6-J3-D-galactofuranoside 273 
_ 
10.0 	 9.0 	 3.0  
'H NMR Spectrum of Morphine-6-0-D-galactofuranoside 273. 
Figure A.7. 
614 (250 MHz; CD 3 0D) 1.96 (1H, bd, 
2g,., 
	15CHeq ) 2.23 (1H, td. 2en  11, 'CH). 
2.57 (1H, dd, 2em  19, ' °CHax ), 2.60 (1H, m, 
16  CH,,,,), 2.61 (3H. s. We), 2.77 (1 H, bd. 
21 11, 16 m, -  2.82 (1H,  14  CH), 3.16 (1H, d, 2 1 gern 19, '°CHeq)  3.58 (1 H. ni. 
9 CH), 3.71 (1H, d, 3J2 . 1 6, "CH), 3.83 (1H, m, 3 CH). 3.99-4.20 (4H, m. CH. 4'  CH. 
6' CH,,), 4.42 (1H, m, 6CH), 5.12 (1H, dd, 3J 6 6, 5 CH), 5.33 (1H, d, I.OH 2. 'CH). 
5.46 (1H, dt, 3J78 11, 7  CH), 5.81 (1H, bd, 3j8 . 7 11, 'CH), 6.54 (1H, d, 3J12 8, 'CH). 6.64 
(1H, d, 3 J21 8, 2 CH). 
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A.5. 'H and COSY NMR Spectra of Morphine-6-CC—D-arabinopyranoside 278 
_5 	.o 	 u.c 	:. 
'H NMR Spectrum of Morp/iine-6- a-D -arabinopvranoside 278. 
Figure A.8. 
oH (250 MHz; CD,OD) (COSY) 1.94 (1H, dd, 2j gem 13, 
15CIIeq ), 2.25 (I H. td, 2J 11 13. 
15CH ax ), 2.59 (1H, dd, 2j gem 19, '°CHax), 2.63 (3H, s, We), 2.69 (1H. dd, 2J 111 13. 
' 6CH ax ) 2.82 (2H, m, ' 4CH, 16Cftq ) 3.17 (IH, d, gefli 3.61-3.72 (3H. m. 
9CH, 2 CH, 3 CH), 3.77 (1H, dd, 2gem  12, 5 CH), 3.94 (1H, m, 4 CH), 4.05 (1 H, dd, 2J.. 
12, "CH), 4.42 (1 H, m, 6 CH), 4.48 (1H, d, 3J1 . 2 .7, 'CH), 5.05 (1H, dd, 3J6. 'C EL).5,6 
5.46 (1H, dt, 3J78 10. 7 CH), 5.90 (1H, dq, 3J87 10, 'CH), 6.55 (1H. d. 3 1 1 8. 'CH). 6.63 



























4.0 	3.5 	3.0 	 2.5 	 2.0 
PPM 
'H-'H Correlated (COS Y) NMR Spectrum of Morphine-6- a-D-arabinopviwiosidc 278. 
Figure A.9. 
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A.6. 'H NMR Spectrum of 3-o-Pivaloylmorphine-6-(2',3',4',6'-tetra-O-acetyl )-[3-
D-gaiactopyranoside 257 
'H Proton NMR Spectrum of 3-O-Pivalovlmorphine-6-(2 '.3 '.4 '.6 '-ret ra-O-acetvl)-,13-D- 
galacropvranoside 257. 
Figure A.10. 
H (250 MHz; CDCI 1 ) 1.35 (9H, s, C(CH.4 ) 1 ), 1.90 (1 H, m. '5CHC(I),  1.97 (3H. s. OAc). 
2.01 (1H, m, 15CHax ) 2.03 (3H, s, OAc), 2.06 (3H, s, OAc), 2.14 (3H, s. OAc). 2.38 
(1H, dd, 2 1 em 19, ' °CHax ), 2.42 (3H, s, NMe), 2.44 (1H, m. 16  CH,,,), 2.56 (1 H. bd. 
3J 615 5, 16 CH,q ) 2.64 (1H, m, 14  CH), 3.05 (1H, d, 2J,,, 19. ' °CH q ) 3.36 (1 H. q. .L )  
4, CI{), 3.94(1H, t. 3 J" . 6 - 7, 5 'CH), 4.02-4.20(2H. m, 3J6 . 7, 6 CH. CH). 4.80 (1 H. 
d, 3J2 8, 'CH), 4.88 (1H. dd, 3j  6, 'CH), 5.00 (1H. dd, 4. CH). 5.25 (1 H, dd. 
3
1 2 ., 1 . 8, 3J,. 10, 2'CH), 5.30 (1 H, m, 'CH), 5.38 (11-1. dd, 3J3.4 ,  4 CH), 5.72 (IH. bd. 
3J87 10, 'CH), 6.53 (1 H, d, 1J 2  8, 'CH), 6.67 (1H, d, J,, 8, 'CH). 
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A.7. 'H NMR Spectrum of 3-o-Pivaloylmorphine-6-(2',3',4',6'-tetra-0-
isobutyry)-3-D-ga1actofuranoside 269 
'H Proton NMR Spectrum of 3-O-Pivalovinzorphine-6-(2 '.3.4 '.6 '-tetra-O-isthutvrvl)-,B-D- 
galactofuranoside 269. 
Figure A.11. 
oH (250 MHz: CDC1 1 ) ( COSY) 1.10-1.19 (24H, m, 8x CHCH), 1.30 (9H. s. 
C(CH3 ) 1 ), 1.95-1.97 (2H, m, "CH.., 5CH ax ), 2.34 (1H, dd. 2gefli  19, ' °CH). 2.42 (3H. 
S, We), 2.44-2.64 (7H, m, 4x CHCH 1 ), 16CHeq 16  CH,,,,. 14CH), 3.05 (1H, d, 2jc,1  19, 
' °CHeq ) 3.35 (1H 9 q, 3 J914 3, 9CH). 4.12-4.22 (3H. 
M. 6CH,  6'  CH,), 4.36 (1 H. dd. J5f  
12, 5 CH), 4.99 (2H, m, 3 'CH , 5 CH). 5.08 (1H, d, 2 CH). 5.28-5.40 (3H, rn. 3 J-.., 10. 
7CH, CH, 4 'Ci-i), 5.63 (IH, bd, 3J87 10, 8CH), 6.53 (1H, d, 3J2 8, 'CH). 6.70 (1 H. d. 
3J2 , 1 8, 2 CH). 
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